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The multidrug resistance protein 4 (MRP4) is a member of the MRP subfamily, which 
in turn belongs to the ATP-binding cassette (ABC) transporter superfamily. MRP4 
has specific tissue distribution, substrate and inhibitor specificity. MRP4 is capable of 
transporting physiological and endogenous compounds, as well as anticancer agents. 
As a MRP4 substrate, topotecan belongs to a group of compounds known as 
camptothecins (CPTs) which have shown substantial anticancer activity by inhibiting 
DNA topoisomerase I, but the success of CPT-related treatment is often limited by 
tumor resistance. Some ABC transporters, including P-glycoprotein (PgP), breast 
cancer resistance protein (BCRP), MRP1 and MRP2, have been implicated in 
resistance to various CPT analogs. Emerging evidence has also shown that MRP4 
may be involved with CPTs. Our interest is thus to elucidate more clearly the role of 
MRP4 in CPTs resistance. The overall hypothesis tested is that CPTs act as substrates 
of MRP4 and interact with MRP4 on cellular levels to mediate multidrug resistance in 
cancer. In this thesis, we aimed to investigate the interaction between MRP4 and 
CPTs by identifying whether CPTs were substrates for MRP4 and exploring their 
effects on MRP4 function. We examined the cytotoxicity profiles of a panel of CPTs 
including CPT, CPT-11, SN-38, topotecan, rubitecan and 10-OH-CPT in HepG2 cells 
overexpressing human MRP4 (MRP4/HepG2) and empty vector (V/HepG2). We 
found that the cytotoxicity of CPTs in V/HepG2 was much higher than that in 
MRP4/HepG2 cells, suggesting that MRP4 overexpression conferred significant 
resistance to CPTs. The resistance to CPTs by MRP4 was significantly reversed by 
the glutathione (GSH) synthesis inhibitor buthionine sulfoximine (BSO), and the 
MRP4 inhibitors including MK571, celecoxib, and diclofenac. However, MRP4 did 
not display resistance to selected anticancer drugs in cytotoxicity assays, except 
 ix 
 
cyclophosphamide. The intracellular accumulations of CPT analogs were further 
investigated. The intracellular concentrations of CPT analogs (except 10-OH-CPT) 
tested in MRP4/HepG2 were significantly lower than in V/HepG2 in both time-
dependent and concentration-dependent accumulation assays, and these 
concentrations could be effectively increased by inhibitors that reversed drug 
resistance in our cytotoxicity assays. In addition, various single amino acid changes 
were introduced into MRP4 and examined for their influence in the intracellular 
accumulation of CPT-11 and SN-38. Our findings strongly suggested that MRP4 
overexpression is involved in the resistance to CPTs by significantly decreasing the 
cellular accumulation. Since MRP4 transports a number of its substrates in a GSH-
dependent manner, effects of CPT analogs on GSH efflux were investigated. Among 
CPT analogs tested, only CPT-11 at a high concentration of 10 µM significantly 
inhibited GSH efflux in MRP4/HepG2. Moreover, BSO showed a specific inhibitory 
effect on the MRP4-mediated GSH efflux. The possible involvement of some related 
ABC transporters (PgP, MRP1, MRP2, MRP3, MRP5 and BCRP) in GSH efflux and 
resistance to CPTs was excluded by their undetectable expression level in western 
blot assays. The resistance to CPTs in cytotoxicity assays, differences in drug uptake 
and GSH efflux can be mainly attributed to a high expression level of MRP4. Our 
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CHAPTER 1  INTRODUCTION 
Cancer remains the main cause of death for both men and women worldwide. To date, 
the major modalities for treating cancer include surgery, radiation, chemotherapy and 
immunotherapy (Gibbs, 2000). More often than not, these therapies provide a cure 
only when the cancer is detected at an early stage, or applied to certain types of cancer 
(e.g. leukemia). The target of chemotherapy is to kill or disable tumor cells by direct 
or indirect mechanisms, while preserving the normal cells (Fidler and Ellis, 2000). 
However, chemotherapeutic agents generally have a narrow margin of safety, and are 
usually given at a maximum tolerated dose (MTD) to achieve maximum cancer cell 
killing. Their mechanisms of actions vary and may include direct cytotoxicity,  
activation of host immune responses, inhibition of the proliferation processes of tumor 
cells, and/or induction of apoptosis (Gibbs, 2000).  
Unfortunately, the success of chemotherapy is often impeded by multidrug resistance 
(MDR). Tumor cells can acquire MDR via a number of factors associated with the 
tumor, host and drug. Host factors include sanctuary sites for tumors, lack of 
bioactivation and/or dose-limiting normal tissue toxicity, leading to inadequate tumor 
cell exposure to chemotherapeutic agents. Specific conditions may produce sanctuary 
sites, which are areas where the tumor is inaccessible to anticancer drugs and/or the 
drug accumulation over time is insufficient to kill cells (Tan et al., 2000). Tumor-
related (cellular) factors, on the other hand, include defective drug transport (reduced 
drug transport or increased drug efflux), altered drug activation or inactivation, and/or 
enhanced repair or tolerance to DNA damage (Gottesman et al., 2002). In this respect, 
it has been well-established that ATP-binding cassette (ABC) transporters play an 
important part in mediating MDR by decreasing intracellular drug concentrations 
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through transporting substrates across cell membranes using the energy of ATP-
binding/hydrolysis (Haimeur et al., 2004). Their increased expression in tumor cells 
has been well associated with resistance to a wide number of important 
chemotherapeutic agents. Besides, these transporters play an important role in the 
absorption, disposition and elimination of chemotherapeutic agents in the body by 
affecting the penetration and transmembrane transport of endogenous compounds and 
their metabolites. The P-glycoprotein (PgP), which is a 170 kDa plasma glycoprotein 
encoded by theP Phuman MDR1 gene (Ambudkar et al., 1999; Borst and Elferink, 2002; 
Schinkel and Jonker, 2003; Marzolini et al., 2004), was the first of such transporters 
to be discovered. PgP can cause considerable resistance to a number of anticancer 
drugs, including paclitaxel, anthracyclines (e.g. daunorubicin and doxorubicin), 
camptothecins, and vinca alkaloids (vincristine and vinblastine) (Zaman et al., 1994; 
Zhu et al., 1997; Loe et al., 1998). With an increased understanding of the function of 
efflux transporters, the multidrug resistance protein (MRP) family was next identified 
(Haimeur et al., 2004), with the breast cancer resistance protein (BCRP) being the 
most recently identified (Allikmets et al., 1998). The focus of this thesis is, however, 
on the fourth member of the MRP family, MRP4, which has specific tissue 
distribution and substrate selectivity, and we will describe this transporter in detail in 
the following section.    
1.1. MULTIDRUG RESISTANCE PROTEIN 4 
The multidrug resistance proteins (MRPs) are important members of the superfamily 
of ABC transporters  (Borst and Elferink, 2002). The ABC transporters are able to 
transport drugs at the cost of ATP hydrolysis. The ABC superfamily of transporters 
consists of a large number of functionally diverse transmembrane proteins which have 
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been subdivided into seven families designated A through G (Borst and Elferink, 
2002). They are capable of transporting a structurally diverse array of endo- and 
xenobiotics and their metabolites across cell membranes. They facilitate 
unidirectional translocation of chemically diverse substrates including amino acids, 
lipids, inorganic ions, peptides, saccharides, metals, drugs, and proteins. Energy 
derived from the hydrolysis of ATP is used to transport the substrate across the 
membrane against a concentration gradient (Jones and George, 2004). These 
transporters are present in almost all tissues and cell types in different amounts. A 
typical ABC transporter is characterized by the presence of three peptide motifs: 
Walker A and B sequences and the so-called ABC-signature sequence (“ALSGGQ”, 
or ‘C’ motif) (Klein et al., 1999; Locher, 2004). Most ABC proteins P Pfrom eukaryotes 
encode full transporters, consisting of two ATP-binding P Pdomains and 12 membrane-
spanning regions or half transporters,P Pwhich are presumed to dimerize (Borst et al., 
2000).  
As the C subfamily of ABC-transporters, MRP family contains at least nine members 
(MRP1-9) with sizes ranging from 1325 to 1545 aminoP Pacids. All MRP members have 
membrane spanning domains (MSDs; transmembrane domains, TMDs) and 
cytoplasmic ATP-binding domains (or nucleotide binding domains, NBDs) (Higgins, 
1992). The NBDs are responsible for the ATP-binding/hydrolysis that drives drug 
transport, and their structure is conserved independently of the degree of primary-
sequence homology (Altenberg, 2004). The MSDs contain the drug-binding sites that 
are likely located in a flexible internal chamber that is sufficiently large to 
accommodate different drugs. Each MSD typically includes six hydrophobic 
transmembrane (TM) helices, but may range from 5 to 10 (Higgins, 1992). The 
critical functional unit of these transporters consists of two MSDs and two NBDs 
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(Figure 1-1). In addition, theP PMRPs can be divided into two different subgroups based 
on theirP Pmembrane topologies: MRP1-3 and MRP6-7 contain three MSDs and two 
NBDs (Bera et al., 2001; Hopper et al., 2001; Tammur et al., 2001; Yabuuchi et al., 
2001); MRP4-5 and MRP8-9 containP Ponly two MSDs and two NBDs. MRPs with the 
third NH B2 B-terminal MSD (MRP1-3 and MRP6-7) have the ability to transport 
conjugates, while MRPs without it are able to transport cyclic nucleotides (Belinsky 
et al., 1998; Borst et al., 1999; Dean et al., 2001; Kruh and Belinsky, 2003; Deeley et 
al., 2006). Not surprisingly, the various MRPs show considerable differencesP Pin their 
tissue distribution, substrate specificities, and proposedP Pphysiological and 
pharmacological functions. MRP4 (ABCC4) has particular tissue expression profile, 
drug resistance selectivity, and substrate and inhibitor specificity, in comparison with 
other MRPs.  
 
Figure 1-1. Topology of short and long MRP family members. “Short” MRPs, such as MRP4-
5 and 8-9, have 12 TM helices and two ATP-binding sites. “Long” MRPs, MRP 1-3 and 6-7, 
are similar in that they contain two ATP-binding regions. They also contain an additional 
domain with a length of five TM segments at the N-terminal end, giving them a total of 17 
TM helices (Gottesman et al., 2002; Deeley et al., 2006).   
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1.1.1. Structure and tissue distribution of MRP4 
MRP4, encoded by the gene ABCC4, was first identified as a homolog of MRP1 
(ABCC1) by the screening of databases of human expressed sequence tags (Kool et 
al., 1997). MRP4 was found overexpressed by gene duplication in the human T-
lymphoid CEM cells which were resistant to nucleoside monophosphate analogs 
(Schuetz et al., 1999). Increased MRP4 expression in these cells was responsible for 
the increased efflux of 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir) and 
azidiothymidine (AZT), leading to the low cytotoxicity of these drugs and other 
nucleoside analogs, such as lamivudine (Schuetz et al., 1999). The MRP4 gene is 
located on the long arm of chromosome 13 at 13q32 (Kool et al., 1997; Lee et al., 
1998; Schuetz et al., 1999), while the MRP4 protein has a length of 1,325 amino 
acids, and resembles the secondary structure of MRP5 (Borst et al., 2000). In 
comparison with MRP5, MRP8 and MRP9, the N-terminus of MRP4 is 87-225 amino 
acids shorter, but its C-terminus is 40 amino acids longer and has a PDZ domain 
(conserved 80-90 amino acid sequence elements found in UPUSD95, the UDUlg-A, and the 
UZUO-1 proteins) (Kocher et al., 1999; Adachi et al., 2002a; Nies et al., 2002). The gap 
of about 50 amino acids shortly after TM6 might be the most special, which is absent 
in the long MRPs (MRP1-3 and MRP6-7) (Deeley et al., 2006). The amino acids in 
TM6 of MRP4 are conserved among different species, but not among other MRPs. 
Two phenylalanines at position 368 and 369 in MRP4 are specific and absent in other 
MRPs. MRP4 also contains a positively charged residue in TM8 (Arg782) that is 
absent in long MRPs (Deeley et al., 2006). 
MRP4 mRNA expression has been found in several tissues, including prostate (Lee et 
al., 1998; Lee et al., 2000), liver (Lee et al., 1998), testis (Lee et al., 1998), ovary (Lee 
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et al., 1998), kidney (Lee et al., 1998; van Aubel et al., 2002; Langmann et al., 2003; 
Nishimura and Naito, 2005), lung (Nishimura and Naito, 2005), pancreas (Konig et 
al., 2005), adrenal gland (Chen et al., 2001; Zelcer et al., 2003), and brain (Nies et al., 
2004). Although MRP4 mRNA is present in most normal tissues, the expression 
levels are highly variable (Nishimura and Naito, 2005). It is highly expressed in 
prostate (Lee et al., 2000), kidney (van Aubel et al., 2002), and lung (Nishimura and 
Naito, 2005); while being present in very low or having no expression in liver, and 
placenta (Lee et al., 1998; Nishimura and Naito, 2005). MRP4 mRNA was found in 
the human brain by quantitative RT-PCR analysis (Nies et al., 2004), while it was not 
detected earlier in human brain by the RNase protection assay (Kool et al., 1997). 
Similar to normal organs, human MRP4 expression in tumors is also highly variable 
(Szakacs et al., 2004). MRP4 is highly expressed in normal lung tissue (Nishimura 
and Naito, 2005), whereas some lung cancer cell lines, such as HCI-H460, have very 
low levels of MRP4 (Szakacs et al., 2004). In rats and mice, Mrp4 mRNA was also 
present in many tissues with highest levels in kidney (Chen and Klaassen, 2004; 
Maher et al., 2005). Mrp4 was found in rat glial cells, and in bovine brain microvessel 
endothelial cells by RT-PCR (Zhang et al., 2000c). It has been reported that the 
activation of the constitutive androsterone receptor was capable of increasing Mrp4 
expression in the mice kidney (Assem et al., 2004). Similarly, Mrp4 expression was 
also found to be increased in the kidney when mice were fed with ursodeoxycholate 
(Zollner et al., 2006).   
MRP4 protein, on the other hand, is mainly detected in the kidneys (Kool et al., 1997; 
Maher et al., 2005; Nishimura and Naito, 2005), and is highly expressed in the 
prostate (Jedlitschky et al., 2004), pancreas (Konig et al., 2005), hematopoietic stem 
cells and blood cells (Su et al., 2004). Unique to this member in the family, MRP4 
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protein displays dual membrane localization in polarized cell types. It is localized in 
the basolateral membrane of tubuloacinar cells in prostate tissues (Lee et al., 2000), 
and the basolateral hepatocyte membrane by immunofluorescence staining of rat liver 
sections (Rius et al., 2003), whereas it is expressed at the apical-membrane of the 
proximal tubules in human and rat kidney (van Aubel et al., 2002), and the luminal 
side of brain capillary endothelium (Leggas et al., 2004). The MRP transporters 
expression levels in cancer cells are basically unpredictable. It is important to identify 
whether the cells have the ability to respond to a xenobiotic stimulus via the 
overexpression of specific MRP transporters. Clinical studies suggest that cancer cells 
are able to rapidly adjust their MRP transporters expression in response to multiple 
stimuli (Zhou et al., 1995; Kruh, 2003). 
Factors governing the substrate specificity of the MRP transporters are complex, as 
these are large membrane proteins that recognize a diverse variety of substrates.  
Studies have only recently begun to identify domains and individual amino acid 
residues in MRP transporters that are involved in determining substrate specificity. At 
least 25 non-synonymous single nucleotide polymorphisms (SNPs) have been 
identified for the MRP4 gene (Gradhand et al., 2008). Trp residues in different region 
of MRP1 (position 1246, 459 and 553) have been shown to affect substrate specificity 
and transport efficiency (Ito et al., 2001; Koike et al., 2002; Deeley et al., 2006; 
Zhang et al., 2006). Despite differences in the topologies of MRP1-3 and MRP4, Trp 
residues are present at position 230 and 995 of MRP4 (analogous to Trp 459, and Trp 
1246 in MRP1) and Phe is present at position 324 (analogous to Trp 553 in MRP1). It 
remains to be determined whether variances in polymorphisms of gene or amino acids 




1.1.2. Substrates of MRP4 
MRP4 is a lipophilic anion pump capable of transporting a variety of compounds with 
diverse chemical structures (Table 1-1 & Figure 1-2). For example, MRP4 has been 
reported to mediate the transport of endogenous molecules (Chen et al., 2002; van 
Aubel et al., 2002; Reid et al., 2003b; Zelcer et al., 2003; Denk et al., 2004), 
nucleoside/nucleotide analogs (Schuetz et al., 1999; Adachi et al., 2002b; Anderson et 
al., 2006; Imaoka et al., 2007), and anticancer drugs (Lee et al., 2000; Chen et al., 
2002; Wielinga et al., 2002; Leggas et al., 2004).  
The physiological and endogenous compounds that could be transported by MRP4 
include prostaglandins, steroids, bile acids, cyclic nucleotides, folate and urate (Chen 
et al., 2001; Chen et al., 2002; van Aubel et al., 2002; Reid et al., 2003b; Zelcer et al., 
2003; Denk et al., 2004; Van Aubel et al., 2005). The cyclic nucleotides, cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) 
were among the first endogenous substrates identified for MRP4 (Chen et al., 2001; 
van Aubel et al., 2002; Wielinga et al., 2002; Van Aubel et al., 2005). cAMP and 
cGMP are intracellular second messengers that mediate a wide range of cellular 
responses to extracellular signals by activating the protein kinase (PK) A and PKG 
signaling pathways (Hofer and Lefkimmiatis, 2007). cGMP has a higher affinity to 
MRP4 than cAMP (Chen et al., 2001), but MRP4-mediated cGMP transport is 
inhibited by cAMP (van Aubel et al., 2002). Increased cGMP efflux was also 
observed in MRP4-transfected HEK293 cells, compared with the parental cells 
(Wielinga et al., 2003), providing evidence that MRP4 might be able to partially 
influence the intracellular concentrations of cGMP and cAMP by controlling their 
efflux. Besides, MRP4 has shown modulating effect on levels of cGMP and cAMP in 
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a microdomain underneath the surface membrane, but not the whole cell 
concentrations (Li et al., 2007).  
The endogenous organic anions and steroid conjugates whose transport can be 
mediated by MRP4 include estradiol 17-β-glucuronide (EB2 B17βG) (Jedlitschky et al., 
1996; Loe et al., 1996a; Zeng et al., 2000; Chen et al., 2001), and 
dehydroepiandrosterone-3-sulfate (DHEAS) which is the major circulating steroid 
made in the adrenal gland in humans (Zelcer et al., 2003). Although MRP5 is a high-
affinity transporter of cGMP and cAMP as MRP4 (Jedlitschky et al., 2000; Chen et 
al., 2001), MRP5 is not able to transport EB2 B17βG. The affinity of MRP4 for EB2 B17βG is 
similar to that of MRP3, while lower than that of MRP1 and MRP2 (Jedlitschky et al., 
1996; Loe et al., 1996a; Zeng et al., 2000). On the other hand, DHEAS shows a higher 
affinity to MRP4 than EB2 B17βG (Zelcer et al., 2003). MRP4-mediated transport of  
EB2 B17βG and DHEAS is inhibited by several steroid derivatives with a cholesterol 
backbone structure in a competitive manner, suggesting they are MRP4 substrates 
(Zelcer et al., 2003). Similar, bile acids have also been identified as MRP4 substrates 
(Zelcer et al., 2003; Rius et al., 2006). Increased MRP4 expression in the liver of 
human and rats with obstructive cholestasis could stimulate the elimination of excess 
bile salts (Denk et al., 2004).  
Prostaglandins (PGEs) are critical mediators in the regulation of many physiological 
processes (Funk, 2001). Specifically, MRP4 is able to mediate the uptake of PGEs, 
PGEB1 B and PGEB2 B, unlike MRP1-3 and MRP5 (Reid et al., 2003b). MRP4 has high 
affinity for PGEB1 B and PGEB2 B, and is capable of reducing their steady state accumulation 
in MRP4-transfected HEK293 cells (Reid et al., 2003b). Some PGEs, including 
PGFB1α B, PGFB2α,B PGAB1 B, and thromboxane B2 (TXBB2 B), are identified as high affinity 
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inhibitors of MRP4, and therefore presumably substrates of MRP4 (Reid et al., 
2003b). 
 MRP4 is also an efflux pump for urate, the purine end metabolite (Van Aubel et al., 
2005) and thioxanthosine monophosphate and thioinosine monophosphate (both 
thiopurine metabolites) (Wielinga et al., 2002). Urate is bidirectionally transported in 
the kidney proximal tubule (Enomoto et al., 2002) and overexpression of MRP4 is 
found to greatly increase urate efflux in HEK293 cells (Van Aubel et al., 2005).  
Although there is interaction between MRP4-mediated transport of cGMP and cAMP 
(van Aubel et al., 2002), MRP4 is able to simultaneously transport urate, cGMP and 
cAMP (Van Aubel et al., 2005). In addition, physiological folates, folic acid (FA) and 
NP5 P-formyltetrahydrofolic acid (leucovorin) are susceptible to be transported by 
MRP4, but not by MRP5 (Chen et al., 2001; Chen et al., 2002; van Aubel et al., 
2002). 
Apart from the above-mentioned physiological substrates, a variety of nucleoside 
(purine and pyrimidine) analogues has been found to be substrates for MRP4. These 
include 9-(1,3-dihydroxy-2-propoxymethyl)guanine (ganciclovir, GCV) (Adachi et 
al., 2002b), azidiothymidine monophosphate (AZT-MP) (Sampath et al., 2002), 
PMEA (Lee et al., 2000; Sampath et al., 2002), bis-POM-PMEA (adefovir dipivoxil, a 
lipophilic ester prodrug of adefovir) (Dallas et al., 2004), 6-mercaptopurine (6-MP), 
and 6-thioguanine (6-TG) (Chen et al., 2001; Wielinga et al., 2002). PMEA is an 
acyclic nucleotide derivative with a broad-spectrum antiviral activity and acts as a 
viral DNA polymerase-mediated chain terminator by inhibiting the replication of both 
hepadna- and herpetoviruses (De Clercq et al., 1986; De Clercq, 1993). Due to the 
low oral bioavailability in animals (Cundy et al., 1994b) and humans (Cundy et al., 
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1995) of PMEA, prodrugs of PMEA have been designed to increase the lipophilicity 
of this compound. The use of bis-POM-PMEA is able to increase the transport of total 
PMEA across Caco-2 monolayers (Annaert et al., 1997). It has been demonstrated that 
bis-POM-PMEA has better permeability than PMEA across human intestinal cell 
membranes in vitro (Starrett et al., 1992; Annaert et al., 1997), and the oral 
bioavailability of PMEA from bis-POM-PMEA was 22-25% in monkeys, which was 
not limited by the dissolution rate of the prodrug (Cundy et al., 1994a).  Bis-POM-
PMEA is only metabolized to PMEA after oral administration to rats (Shaw et al., 
1997). Amplification of both MRP4 gene and MRP4 protein is detected in CEM-r1, a 
selected human T-lymphoid cell line which confers high-level resistance to PMEA by 
250-fold (Schuetz et al., 1999). In agreement with this report, NIH3T3 cells 
transfected with MRP4 displays an average of 2.3-fold resistance to PMEA in a 3-day 
continuous exposure growth assay (Lee et al., 2000). However, the great difference in 
the resistance capacity between the two reports is probably attributed to low 
expression of MRP4 in NIH3T3 transfectants or low sensitivity of NIH3T3 fibroblasts 
to PMEA (Lee et al., 2000). As a prodrug, bis-POM-PMEA has the advantage of 
faster uptake than the parent compound PMEA, and is metabolized to PMEA 
intracellularly before efflux (Gallant et al., 1994; Adachi et al., 2002b). It has been 
shown that the uptake of bis-POM-PMEA was decreased in MCF-7 cells with 
transfection of MRP4, and this decrease was inversely proportional to the quantity of 
MRP4 expression level (Adachi et al., 2002b). In mice, Mrp4 was able to protect the 
bone marrow, spleen, thymus and intestine from PMEA-induced injury, and inhibit 
the penetration of PMEA into the brain (Belinsky et al., 2007).  CEM-r1 cells with 
overexpression of MRP4 showed lower sensitivity to GCV and have lower 
accumulation of the drug, compared with the parental CEM cells. GCV is first 
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converted to its monophosphate form by the herpes simplex virus thymidine kinase 
(HSV-TK) and then in turn metabolized by cellular kinases. Moreover, CEM-r1 cells 
still preserved a lower sensitivity to GCV than CEM cells, when drug activation was 
enhanced by increasing HSV-TK expression in both cell lines. This indicates MRP4 
can transport both GCV and its phosphorylated metabolites, and MRP4 may reduce 
the antiviral efficacy of GCV therapy by changing its cellular retention and 
accumulation (Adachi et al., 2002b).  
Last but not least, a limited number of anticancer agents, such as topotecan (Leggas et 
al., 2004) and methotrexate (MTX) (Kool et al., 1999; Lee et al., 2000; Chen et al., 
2002), have also been reported as MRP4 substrates. Clearly, the importance of MRP4 
as a xenobiotic pump cannot be overlooked as this has bearing on its role in drug 
efficacy. Notably, the substrate specificity of MRP4 is distinguished from that of 
MRP5 by the ability of MRP4 to transport EB2 B17βG (Chen et al., 2002). MRP4-
transfected NIH3T3 cells were able to increase resistance to MTX by 5.5-fold in 4 h 
drug exposure assays, and decrease intracellular MTX concentration at both 4 h and 
24 h. However, MRP4 did not confer significant resistance to MTX in long exposure 
assays (Lee et al., 2000). In membrane vesicles prepared from insect cells with 
transfection of MRP4, it has also been shown that MRP4 is a potent MTX transporter 
(Chen et al., 2002). However, MTX is not specific and has also been identified as the 
substrate of MRP 1-3 and MRP5 (Masuda et al., 1997; Hooijberg et al., 1999; Kool et 
al., 1999; Zeng et al., 1999; Wielinga et al., 2005). As for topotecan, increased 
accumulation has been observed in brain tissue and cerebrospinal fluid of Mrp4-
knockout mice (Leggas et al., 2004). Overexpression of MRP4 in Saos-2 cells was 
able to reduce the sensitivity of cells to topotecan and decrease intracellular drug 
accumulation, suggesting Mrp4 confers resistance to topotecan (Leggas et al., 2004). 
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Given the diversity of substrate specificity, the role of MRP4 in affecting both endo- 
and xenobiotic efflux cannot be undermined.   
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Figure 1-2. Chemical structures of selected MRP4 substrates, illustrating the endogenous and 
xenobiotic molecules with diverse structures that can interact with the transporter.  
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1.1.3. Inhibition of MRP4 activity 
Since MRP4 can transport a number of important chemotherapeutic agents (Schuetz et 
al., 1999; Adachi et al., 2002b; Borst and Elferink, 2002; Sampath et al., 2002; van 
Aubel et al., 2002; Wielinga et al., 2002), the inhibition of MRP4-mediated transport 
might help to improve the efficacy of therapeutic substrate drugs in cancer treatment.  
A variety of inhibitors for MRP4 has been identified (Figure 1-3). Like MRP1 and 
MRP2, MRP4 is inhibited by the leukotriene antagonist (E)-3-((3-(2-(7-
chloroquinolin-2-yl)vinyl)phenyl)(3-(dimethylamino)-3-oxopropylthio)methylthio) 
propanoic acid (MK571) (Chen et al., 2001; van Aubel et al., 2002). MRP4-mediated 
transport of PGE1 and PGE2 is inhibited by rofecoxib and celecoxib (both COX-2-
specific inhibitors), and diclofenac (Reid et al., 2003b). Both probenecid and 
dipyridamol strongly inhibit MRP4-mediated cAMP and cGMP transport  (van Aubel 
et al., 2002). MRP4-mediated PMEA transport is inhibited by benzbromarone, 
nitrobenzylmercaptopurine ribonucleoside (NBMPR), and dilazep (Reid et al., 
2003b). The γ-glutamylcysteine synthetase inhibitor, DL-buthionine-(S,R)-
sulfoximine (BSO), was able to reverse MRP4 resistance to PMEA and 6-TG by the 
regulation of GSH-related mechanism (Lai and Tan, 2002).  
For the substrate bimane-GS, MRP4-mediated transport is totally inhibited in the 
presence of carbonylcyanide m-chlorophenylhydrasone (an uncoupler of oxidative 
phosphorylation) and 1-chloro-2,4-dinitrobenzene (CDNB) which is metabolized to 
the GSH conjugate after entry into cells. Significant inhibition is also observed with 
other known inhibitors of MRP transporters including benzbromarone, verapamil, 
indomethacin, MTX, and 6-TG (Bai et al., 2004). The intracellular accumulation of 
PMEA, on the other hand, could be increased over 600% in Saos-2 cells transfected 
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with MRP4 by the treatment of 100 µM indomethacin (Adachi et al., 2002b). 
Although 4-(2-aminoethyl)benzenesulfonylfluoride (AEBSF)  is not a strong inhibitor 
for MRP4, it seems to have relatively higher specificity for MRP4 than most of other 
inhibitors (de Wolf et al., 2007). Of interest, the transport of some MRP4 substrates 
can exert influence on each other. For instance, theP Pcellular efflux of cGMP by MRP4 
was inhibitedP Pby PGAB1 B and PGEB1 B, the steroid progesterone and the anticancer drug 
estramustine ( Ta combination of estrogen and mechlorethamine), all of which are 
MRP4 substrates (Wielinga et al., 2003)T. PGAB1 B also inhibited the ATP-dependentP 
Pefflux of MTX by MRP4 (Assaraf et al., 1999; Chen et al., 2002). PGEs, including 
PGEB1 B, PGEB2 B, PGFB1α B, PGFB2α,B PGAB1 B, and TXBB2 B, strongly inhibited EB2B17βG transport by 
MRP4, but showed no effect on transport by MRP1 and MRP3 (Reid et al., 2003b). 
Sulfinpyrazone is a potent inhibitor (ICB50B = 420 µM) of PMEA effluxP Pin MRP4-
overexpressing P PHEK293 cells (Reid et al., 2003a), while MTX can  inhibit the 
MRP4-mediated transport of EB2B17βG (Chen et al., 2001). Glucuronide and GSH 
conjugates can also inhibit MRP4-mediated transport of MTX (Chen et al., 2002; van 
Aubel et al., 2002). Last but not least, the MRP4-mediated transport of EB2 B17βG is 
blocked in the presence of estradiol 3,17-disulphate, taurolithocholate 3-sulphate 
(Zelcer et al., 2003), or topotecan (Leggas et al., 2004). 
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Table 1-2. Reported inhibitors for MRP4. 
 
Inhibitors References 
MK571 (Chen et al., 2001; van Aubel et al., 2002) 
Rofecoxib (Reid et al., 2003b) 
Celecoxib (Reid et al., 2003b) 
Diclofenac (Reid et al., 2003b) 
Probenecid (van Aubel et al., 2002) 
Dipyridamol (van Aubel et al., 2002; Reid et al., 2003b) 
Benzbromarone (Reid et al., 2003b) 
Dilazep (Reid et al., 2003b) 
BSO (Lai and Tan, 2002) 
CDNB (Bai et al., 2004) 
Indomethacin (Adachi et al., 2002b) 
Verapamil (Bai et al., 2004) 
MTX (Bai et al., 2004) 
6-TG (Bai et al., 2004) 










1.1.4. GSH and MRP4-mediated transport 
The tripeptide GSH is required for various physiological functions such as proper 
DNA and protein synthesis, cell cycle regulation, storage and transport of cysteine, 
maintenance of the thiol redox status of the cell, protection against oxidative damage, 
and detoxification of endogenous and exogenous reactive metals and electrophiles 
(Meister and Anderson, 1983; Meister, 1984; DeLeve and Kaplowitz, 1990; Wang 
and Ballatori, 1998). GSH also plays a role in the regulation of gene expression, 
apoptosis, and membrane transport of both endogenous and exogenous compounds 
(Hammond et al., 2001). Of more relevance, the reducing capacity of intracellular 
thiols such as GSH has been shown to contribute to the mechanism of action or 
activity of many anticancer agents by interrupting pharmacological functions of 
corresponding transporters for drugs (Lai et al., 1989; Schneider et al., 1995; Sawyer 
and Bonner, 1996; Renes et al., 1999). 
Hepatic GSH is predominantly transported across the basolateral membrane of 
hepatocytes into the blood circulation as the major source of GSH in plasma (DeLeve 
and Kaplowitz, 1990; Loe et al., 1996a). As a physiological antioxidant involved in 
many biochemical processes and as the major transport form of cysteine, GSH needs 
to be transported across the sinusoidal membrane of the hepatocytes to enable GSH 
delivery to other tissues (Ballatori et al., 2005). Several members of MRP family have 
been identified as GSH pumps, including MRP1 (Loe et al., 1996b; Loe et al., 2000), 
MRP2 (Paulusma et al., 1999), MRP4 (Rius et al., 2003) and MRP5 (Wijnholds et al., 
2000). Moreover, efficient transportP Pof some substrates by these transporters requires 
physiological concentrations of the antioxidantP PGSH (Paulusma et al., 1999; Renes et 
al., 1999; Evers et al., 2000; Mao et al., 2000; Wijnholds et al., 2000; Lai and Tan, 
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2002). In the co-transport by MRP1 and MRP4, GSH can be replaced by GSH 
analogs, including S-methyl-glutathione and ophthalmate (Loe et al., 2000; Rius et al., 
2003). Specifically for MRP4, GSH plays a crucial role with MRP4 transporting 
many of its substrates in a GSH-dependent manner. MRP4 can mediate the efflux of 
GSH from hypatocytes into blood by co-transport with bile acids (glucocholate, 
taurocholate and cholate) (Rius et al., 2003). BSO, the GSH synthesis inhibitor, 
significantly decreased the intracellular GSH level in HepG2 cells at a high 
concentration (500 µM) (Zhang et al., 2001). Overexpression of MRP4 in HepG2 
cells is associated with a greater increase in GSH export (Lai and Tan, 2002). BSO is 
able to decrease MRP4-mediated export of cAMP and increase cAMP intracellular 
accumulation. BSO could also abolish  resistance to PMEA and 6-TG by MRP4 (Lai 
and Tan, 2002).    
It has also been shown that MRP4-mediated ATP-dependent co-transport of GSH or 
S-methyl-GSH together with substrates such as cholyltaurine, cholylglycine, or 
cholate, and MRP4-mediated uptake of taurocholate could be stimulated by co-
transport of reduced GSH or its S-methyl derivative (Rius et al., 2003). The 
locatization of MRP4 in human hepatocytes, together with the identification of co-
substrates, cholytaurine and GSH, of MRP4, provide an alternative pathway to 
transport GSH and bile salts into the systemic circulation. Thus, MRP4 may play 
important role in the physiology and pathophysiology of the liver (Rius et al., 2003). 
In the presence of physiological concentrations of GSH, MRP4 has a high affinity for 
the taurine and glycine conjugates of the natural bile acids as well as the unconjugated 
bile acid cholate by using inside-out membrane vesicles (Rius et al., 2006). 
Chenodeoxycholyltaurine and chenodeoxycholylglycine were the GSH co-substrates 
with the highest affinities for MRP4. It is proposed that after GSH binds with MRP4 
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as an anionic moiety, the conformational change of MRP4 may allow the binding of 
bile acids to the other binding site, leading to the co-transport (Rius et al., 2006). 
However, GSH was considered to have no involvement in the transport of cAMP and 
cGMP in HEK293 cells (Wielinga et al., 2003), and did not appearP Pto have a 
significant effect on PMEA efflux mediated by MRP4-5 in rat microglial MLS-8 cells 
(Dallas et al., 2004). The transport of DHEAS or EB2 B17βG mediated by MRP4 was 
found to be independent of GSH, while MRP1-mediated DHEAS transported required 
the presence of GSH (Zelcer et al., 2003). The reasons for such discrepancy in effects 
ofP PGSH are unclear, although the differences in cell lines used, intracellular GSH 
levels, and levels of MRP4 and other transporters may have been causes (Zelcer et al., 
2003).  
To examine the influence of GSH, fluorescent probes have recently been widely used 
to detect intracellular GSH levels (Hedley and Chow, 1994; Coates and Tripp, 1995; 
Kosower and Kosower, 1995). Among them, monochlorobimane (MCB) is reported 
to be the most specific probe (Cook et al., 1991; Ublacker et al., 1991). MCB is cell-
permeant and does not fluoresce. Within the cell, MCB is conjugated to GSH by 
glutathione S-transferase (GST) to form a cell impermeant and fluorescent bimane-
glutathione (bimane-GS) conjugate. It has been shown that MRP4 was able to 
transport both GSH and bimane-GS (Lai and Tan, 2002; Bai et al., 2004). MRP4-
mediated bimane-GS transport was inhibited by known inhibitors for MRP family 
members, including benzbromarone, verapamil and indomethacin. Known substrates 
for MRP4, MTX and 6-TG, reduced MRP4-mediated bimane-GS efflux by 40% at a 
high concentration of 100 µM (Bai et al., 2004). At present, there are no specific GSH 
transport regulators reported. The examination of newly discovered MRP4 substrates 
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on the function of GSH efflux may thus be useful for further clarifying the mechanism 
of substrate-substrate interactions in the corresponding transporters. 
1.2. CAMPTOTHECINS 
The camptothecins (CPTs), a relatively new group of compounds, have shown 
capability against a variety of tumors (Redinbo et al., 1998; Stewart et al., 1998; Jung 
and Zamboni, 2001; Pizzolato and Saltz, 2003). The parent compound, camptothecin 
(CPT), is a natural alkaloid isolated from the Chinese tree, Camptotheca acuminata, 
during a screen of plant extracts for anticancer agents (Wall et al., 1966). Initial 
studies on the mechanism of action of CPT suggested that its activity might be 
attributed to its inhibition of DNA and RNA synthesis (Horwitz et al., 1971; Kessel, 
1971; Kessel et al., 1972), as well as cytotoxic selectivity to S-phase cells, GB2B phase 
cell cycle arrest and induction of chromosomal DNA fragmentation (Horwitz et al., 
1971; Kessel et al., 1972). Over the past few years, intensive efforts in medicinal 
chemistry have led to the generation of a large number of derivatives of CPT, many of 
which showed improved water solubility and potent anticancer activity. The chemical 





Name RB1B RB2B RB3B 
CPT H H H 
CPT-11 CB2BHB5B H 
 
SN-38 CB2BHB5B H OH 
Topotecan H CH B2BN(CHB3B) B2B OH 
9-Rubitecan H NO B2B H 
9-NH B2B-CPT H NH B2B H 
10-OH-CPT H H OH 
 
Figure 1-4. Chemical structures of CPT and its analogs.  
 
It is noted that CPTs have a dynamic equilibrium between the closed ring lactone 
form and open-ring carboxylate form, which is dependent on the pH of the 
environment, interaction with blood components and possible other factors. Under 
neutral or alkaline conditions, CPTs with a closed α-hydroxy-δ-lactone ring, undergo 
reversible, pH-dependent hydrolysis to yield the corresponding open-ring hydroxyl 
acid, namely, the more soluble carboxylate form (Fassberg and Stella, 1992). It has 
been shown that the lactone and carboxylate forms of CPT displayed obviously 
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different interaction with human serum albumin (HSA), which is abundant in human 
plasma (Mi and Burke, 1994a; Sriram et al., 2005). The lactone form binds HSA with 
moderate affinity, while the carboxylate form shows strong binding affinity to HSA, 
becomes stable and will not convert back to lactone form. After incubation in human 
plasma or HSA solution for 2 h, the active lactone form of CPT is almost totally 
converted to its inactive carboxylate form (Burke and Mi, 1994; Mi and Burke, 
1994b).  The percentage of various CPTs, including CPT, 9-aminocamptothecin (9-
AC, IDEC-132) (Burke et al., 1995), topotecan, CPT-11 (irinotecan) and SN-38, 
present in their active lactone form was 13% -19% at 37°C in phosphate buffered 
saline (PBS) (Burke et al., 1995). In the presence of 40 mg/ml HSA, only about 1% of 
CPT and 9-AC are present in the lactone form at equilibrium (Burke et al., 1995; Loos 
et al., 1999). On the contrary, HSA is able to stabilize the lactone form of CPT-11 and 
SN-38, with 30% and 39% of the concentration, respectively, present as the lactone 
form, but shows little effect on the balance of topotecan (Burke et al., 1995; Mi et al., 
1995; Loos et al., 1999). These findings suggest that various substitutions at the C7, 
C9 and C10 position of parental structure CPT are related to the prevention of their 
carboxylate form binding with HSA by stereo-hindrance. The differences in the 
lactone/carboxylate ratio of CPTs may greatly influence their pharmacological 
activity and therapeutic efficacy.   
The cytotoxicity of CPTs depends on their effect on DNA synthesis. The lactone ring 
structure is essential for topoisomerase I (Top 1) binding, antitumor activity and the 
toxicity of CPTs (Chabner, 1992; Slichenmyer et al., 1993; Redinbo et al., 1998; 
Stewart et al., 1998), while the carboxylate form is biologically inactive for inhibiting  
Top 1 and only shows weak cytotoxicity (Hertzberg et al., 1990). This is evident in 
early clinical studies where the carboxylate form of CPT showed much lower 
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antitumor activity in comparison with the lactone form of CPT (Gottlieb et al., 1970; 
Moertel et al., 1972; Muggia et al., 1972). The 20(S) form of CPT and its derivatives 
has also been found to be more active than the corresponding 20(R) form in tumor cell 
models (Wani et al., 1987).  Among the list of CPT derivatives, two have already 
been approved by the US Food and Drug Administration (FDA) for clinical treatment 
(CPT-11 and topotecan) (Figure 1-4). Topotecan was the first CPT derivative to 
receive US FDA approval for the treatment of advanced ovarian cancer in 1996 
(Takimoto and Arbuck, 1997; ten Bokkel Huinink et al., 1997). In 2000, CPT-11 was 
approved by FDA as first-line treatment for advanced colorectal carcinoma (2000). 
With good aqueous solubility, CPT-11 and topotecan have shown broad-spectrum 
anticancer capability in preclinical tumor models, and are currently undergoing wide 
clinical trials. Additionally, other CPT derivatives are being tested in clinical trials, 
including 9-AC, rubitecan (9-nitrocamptothecin, 9-NC, RFS2000), 10-
hydroxycamptothecin (10-OH-CPT, HCPT), silatecan (DB-67, 7-tert-
butyldimethylsilyl-10-hydroxycamptothecin), and exatecan (DX-8951f, a hexacyclic 
analog of CPT) (Ulukan and Swaan, 2002; Pizzolato and Saltz, 2003). All these 
derivatives have been shown to induce tumor cell death by the stabilization of Top 1 
complex and the generation of permanent DNA strand breaks, like CPT with similar 
or higher potency (Goldwasser et al., 1996; Ulukan and Swaan, 2002).  
1.2.1. Mechanism of action 
DNA topoisomerases are a group of enzymes that alter the topology of DNA and are 
present in all organisms including bacteria, viruses, yeast, and humans (Wang, 1996). 
There are two general types of topoisomerases, Type I and Type II. Type I cleaves 
and separates a single strand of DNA and alter the linkage quantity of DNA, whereas 
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Type II cleaves both strands of DNA and changes the linking number of DNA by two 
(Wang, 1996). Mammalian Top 1 is particularly important in supporting replication 
fork movement during DNA replication and to relax supercoils formed during 
transcription (Wang, 1996). There is an increased interest in topoisomerases since 
they were found to be targets for naturally occurring anticancer drugs. Human Top 2 
isozymes are targets in tumor cells for anthracyclines (e.g. doxorubicin) and 
epipodophyllotoxins (e.g. etoposide) (Hande, 2003).  
CPTs inhibit the relegation reaction of Top 1 (Hsiang et al., 1985; Hsiang and Liu, 
1988; Svejstrup et al., 1991). The action mechanism of CPTs was explained by the 
replication collision model, whereby CPTs were considered to stabilize the transient 
cleavable DNA-Top 1 complex and produce an enzyme-drug-DNA cleavable 
complex, leading to the inhibition of cleavage reaction and relegation steps (Figure 
1-5) (Svejstrup et al., 1991; Kjeldsen et al., 1992). The reversible stabilization can 
cause an irreversible arrest of replication fork and double-strand DNA breakage when 
a replication fork collides with a cleavable complex (Hsiang et al., 1989). The 
frequency of cleavable complexes and the number of DNA breakage were increased 
in correlation with the Top 1 level (Pommier, 1996). DNA breakage may eventually 
result in cell cycle arrest in the S/GB2 B-phase, activation of apoptosis pathways, and cell 
death  (Hsiang et al., 1989). In comparison with GB1 B- or GB2 B/M cells, S-phased cells 
displayed higher sensitivity to Top 1 inhibitors, suggesting that CPTs have an S-phase 
specific cytotoxicity (Drewinko et al., 1974; D'Arpa et al., 1990; Takimoto et al., 
2000). However, CPT has some other cellular effects independent from replication, 
including inhibition of RNA synthesis, multi-ubiquitination and degradation of Top 1, 
chromatin reorganization and activation of transcription factors (Kharbanda et al., 
1991; Beidler and Cheng, 1995; Piret and Piette, 1996; Desai et al., 1997; Wu and 
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Liu, 1997). The cellular effects of CPT independent from S-phase were explained by 
the proposed transcription collision model, which suggested that the collision between 
the Top 1-cleavable complexes located on the template strand and the elongating 
RNA polymerase led to transcription arrest and conversion of Top 1-cleavable 
complexes into 'irreversible' strand breakage. As a result, the RNA transcript was 
terminated at the arrested site, resulting in double strand DNA damage and cell killing 
(Wu and Liu, 1997). Thus, Top 1 inhibitors may show cytotoxicity only in the 
presence of ongoing DNA replication or RNA transcription (Horwitz et al., 1971; 




Figure 1-5. Mechanism of DNA damage mediated by Top 1. (A) Cleavage reaction of Top 1; 





1.2.2. Pharmacokinetics and metabolism of CPT-11 and SN-38 
CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin) was the 
first water-soluble, semisynthetic CPT derivative to be used in clinical tests (Negoro 
et al., 1991; Ohe et al., 1992). Similar to CPT, the biological activity of CPT-11 
results from its capacity to bind to the transient cleavable complex formed between 
DNA and Top 1, preventing dissociation of the DNA-Top 1 complex and thereby 
inhibiting enzyme activity (Jaxel et al., 1989; Vassal et al., 1996). CPT-11 has shown 
activity against a broad spectrum of cancer, including non-small cell lung cancer 
(Negoro et al., 1991), ovarian cancer (Takeuchi et al., 1991), non-Hodgkin’s 
lymphoma (Tsuda et al., 1994), refractory leukemia and lymphoma (Ohno et al., 
1990).  
CPT-11 undergoes several metabolic pathways (Figure 1-6) to generate conjugated 
and unconjugated derivatives that could be excreted from the body. As a prodrug, 
CPT-11 is transformed to its active metabolite, SN-38 (7-ethyl-10-
hydroxycampotothecin), by carboxylesterases (CEs). SN-38 exhibits at least a 1000-
fold more potent anticancer effect compared to the parent drug (Kawato et al., 1991). 
SN-38 is further conjugated by uridine diphosphate glucuronosyltransferanse (UGT) 
to generate inactive SN-38G (the β-glucuronide conjugate of SN-38), which is 
considered as a detoxifying route for SN-38 (Iyer et al., 1998). CPT-11 is also 
oxidized by cytochrome P450 isoform 3A (CYP3A), yielding several 
pharmacologically inactive products such as APC (7-ethyl-10-[4-N-(5-aminopentanoic 
acid)-1-piperidino]carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-amino-1-
piperidino]carbonyloxycamptothecin) (Santos et al., 2000). Both CPT-11 and SN-38 
have a labile α-hydroxy-δ-lactone ring that undergoes pH-dependent reversible 
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hydrolysis. Both compounds exist in equilibrium depending on the pH and the 
presence of binding proteins (Burke and Mi, 1994; Rivory et al., 1994). At 
physiological pH and higher, equilibrium favors the less toxic carboxylate form, 
whereas at acidic pH, the more potent lactone form is favored. SN-38G may undergo 
β-glucuronidase-mediated hydrolysis in the intestine, releasing SN-38 (Takasuna et 
al., 1998). Evidence has indicated that the biliary excretion of both CPT-11 and SN-
38 depends on the presence of drug-transporting proteins, notably PgP and MRP2, 
present on the hepatocyte canalicular membrane (Chu et al., 1997a). The major 
toxicities of CPT-11 are myelosuppression and gastrointestinal toxicity, in particular 
unpredictable severe diarrhea (Gupta et al., 1994).  
 






CE enzymes, members of a group of serine esterases, play a critical role in the 
metabolism of numerous drugs. CPT-11 must be transformed in vivo to SN-38 by 
hydrolysis of the bulk di-piperidino side chain at C-10 of CPT-11 to exert its 
antitumor activity. The conversion of CPT-11 to SN-38 mediated by CEs has been 
studied extensively recently. Two similar human isozymes of liver CE, hCE-1 and 
hCE-2, have been characterized to be responsible for the activation of CPT-11 (Slatter 
et al., 1997; Humerickhouse et al., 2000). hCE-2 has a 12.5-fold higher affinity for 
CPT-11 and 5-fold higher maximal rate of CPT-11 hydrolysis than hCE-1. The 
catalytic efficiency of hCE-2 is 60-fold higher than that of hCE-1. This is evident in 
cytotoxicity assay using human head and neck squamous carcinoma cells SQ20b. 
When SQ20b cells were incubated with 1 µM CPT-11, the cell survival was only 38% 
in the presence of hCE-2, but increased to 88% in the presence of hCE-1 
(Humerickhouse et al., 2000). Therefore, hCE-2 is likely to be a key enzyme in CPT-
11 activation in human liver. Apart from hCE-1 and hCE-2, it has been suggested that 
two other human enzymes, hiCE (Khanna et al., 2000) and the butyrylcholinesterase 
(Morton et al., 1999), have the ability to activate CPT-11. The conversion from CPT-
11 to SN-38 may result from any combination of these CEs, and possibly others yet to 
be identified. Looking at pharmacokinetic parameters, phase I studies of CPT-11 has 
shown that there was a linear increase of SN-38 with CPT-11 dose over the dose 
range studied (100-750 mg/mP2 P) (Chabot et al., 1995). The terminal disposition half 
lives of SN-38 lactone and total drug are significantly longer than those of CPT-11 
(Kehrer et al., 2000). In a study of kinetics of transformation from CPT-11 to SN-38, 
twice as much SN-38 was generated when CPT-11 was added to human liver 
microsomes in its lactone form, compared with CPT-11 in its carboxylate form. 
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Because CPT-11 lactone is easier to change to SN-38 lactone,  this phenomenon 
might in part contribute to the predominance of SN-38 in its lactone form in plasma 
(Haaz et al., 1997).  
CYP3A-Mediated Oxidation 
The involvement of CYP3A has been identified in the formation of diverse oxidative 
metabolites of CPT-11. The most abundant derivative is APC, resulting from a double 
oxidation of the terminal piperidine ring and generated by CYP3A4 (Haaz et al., 
1998b). NPC, produced by cleavage of the distal piperidine ring of CPT-11 by 
CYP3A4, is another major metabolite which has been identified in the plasma of 
patients receiving CPT-11 (Dodds et al., 1998). In the study of the kinetic formation 
from CPT-11 to NPC with pooled human microsomes, the lactone form of CPT-11 
was converted more rapidly than the corresponding carboxylate form because the 
former has a higher enzyme affinity than the latter (Haaz et al., 1998a). Both APC and 
NPC showed little cytotoxicity. Like CPT-11, APC and NPC were found to be a poor 
inhibitor of cell growth and a weak inducer of Top 1 DNA-cleavable complexes (100-
fold less potent than SN-38) (Rivory et al., 1996b; Dodds et al., 1998). In comparison 
with CPT-11, APC was not hydrolyzed to SN-38 by human liver microsomes and 
purified human liver carboxylesterase. Moreover, APC did not inhibit the 
transformation from CPT-11 to SN-38. Therefore, APC probably does not play a 
direct role on the activity and toxicity of CPT-11 in vivo (Rivory et al., 1996b). 
However, unlike APC, NPC appeared to be functionally important because it can be a 
substrate of hCE and be transformed into SN-38, though to a lesser extent than CPT-
11. It seems that NPC might contribute to the activity and toxicity profile of CPT-11 
in vivo (Dodds et al., 1998). It has been reported recently that the subtype CYP3A5 
 34 
 
was also capable of metabolizing CPT-11. However, the metabolism of CPT-11 by 
CYP3A5 was markedly different because neither APC nor NPC was produced, 
whereas a new (unidentified) metabolite was generated by de-ethylation of the CPT 
moiety (Santos et al., 2000). Kinetic studies, however, indicated that CPT-11 is 
preferentially metabolized by CYP3A4 and suggested the affinity of CPT-11 for 
CYP3A5 is lower than for CYP3A4. The catalytic activity of CYP3A5 was generally 
weaker than that of CYP3A4 (Santos et al., 2000). Furthermore, CYP3A5 has been 
demonstrated to be polymorphically expressed, because only 25-30% of human livers 
have been found to contain detectable levels of CYP3A5 (Shou et al., 1998). The 
recognition that CPT-11 is a substrate of CYP3A is an important finding, with the 
consequence of CPT-11 being subjected to a host of enzyme-mediated drug 
interactions. The conversion of CPT-11 to APC and NPC could be mostly abolished 
by the prototypical CYP3A inhibitors, ketoconazole and troleandomycine (Haaz et al., 
1998a; Santos et al., 2000).  
UGT-Mediated Detoxification 
The main detoxifying pathway for CPT-11 is the formation of inactive SN-38G. It has 
been suggested that the accumulation of SN-38 in the intestine is responsible for the 
severe diarrhea, one of the major side effects of CPT-11 (Wiseman and Markham, 
1996). Recently, the metabolism of CPT-11 via glucuronidation has been indicated to 
protect against CPT-11 induced gastrointestinal toxicity. An inverse relationship was 
observed between SN-38 glucuronidation rates and severity of diarrhea incidences in 
patients treated with CPT-11(Gupta et al., 1994). Therefore, the conversion of SN-38 
to SN-38G by hepatic UGTs is a critical step in the sequential metabolic pathway of 
CPT-11. Hepatic glucuronidation results from the activities of a multigene family of 
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UGT enzymes, the members of which exhibit specificity for a variety of endogenous 
substrates and xenobiotics (Tephly et al., 1988; Burchell and Coughtrie, 1989). The 
UGT enzymes are broadly classified into two distinct families of protein termed 
UGT1 and UGT2 on the basis of amino acid sequences (Burchell et al., 1995; 
Burchell et al., 1998). UGT1A1 isoenzyme has been suggested to be the predominant 
human UGT involved in the formation of SN-38G. The lactone functionality of SN-
38 could also be hydrolyzed after a pH-dependent equilibrium (Iyer et al., 1998; 
Gagne et al., 2002). In the reaction with SN-38, a UDP-activated glucuronic acid 
moiety is transferred at the C-10 O-aryl-hydroxy of SN-38. This not only inactivates 
the drug but also serves as an integral step in transforming the lipophilic SN-38 
substrate into hydrophilic glucuronide, facilitating its subsequent biliary or renal 
elimination. Other UGT1A isoforms, UGT1A3 and UGT1A6 have also been shown 
to contribute to SN-38 glucuronidation in human liver (Hanioka et al., 2001). 
Recently, another major hepatic UGT, UGT1A9, and the extrahepatic UGT1A7, have 
been reported to be involved in SN-38 glucuronide formation (Gagne et al., 2002). 
Genetic polymorphism has been reported in the TATA box sequences of UGT1A1 
(Ando et al., 1998). Normally, the box contains (TA)B6BTAA in its promoter region, and 
sometimes a box contains an extra TA repeat (Ando et al., 1998; Iyer et al., 1999). 
SN-38 glucuronidation rates were significantly lower in homozygotes (TA) B7 B/(TA)B7 B 
and heterozygotes (TA) B6B/(TA) B7B when compared with the wild type genotype 
(TA) B6B/(TA) B6 B(Iyer et al., 2002). UGT1A1 activity is inversely related to the number of 
TA repeats, since the transcriptional activity of the promoter decreases with the 




Several bacteria including Escherichia coli, Bacteroides species, and Clostridium 
perfringens can convert SN-38G in bile and intestine back to the active compound 
SN-38 by producing the enzyme β-glucuronidase (Skar et al., 1988; Sperker et al., 
1997). Several studies have described (microflora-derived) β-glucuronidase activity in 
non-human (Takasuna et al., 1996; Takasuna et al., 1998) and human intestines 
(Fujisawa and Mori, 1997; Van Huyen et al., 1998). In rats, it has been suggested that 
SN-38, which results from the hydrolysis of SN-38 glucuronide by β-glucuronidase in 
the intestinal microflora, contributes considerably to the distribution of SN-38 in the 
large intestine tissue, and that inhibition of the β-glucuronidase activity by antibiotics 
results in decreased accumulation of SN-38 in the large intestine (Takasuna et al., 
1998). Histopathological changes of rats in the descending colon, cecum, and ileum 
were observed after the daily administration of CPT-11 (Takasuna et al., 1996). 
Recently, these mucosal abnormalities were confirmed in human colon (Kehrer et al., 
2001). It has been noticed that this histological damage showed a good correlation 
with β-glucuronidase activity in the intestinal lumen, but not with the intestinal tissue 
CE activity (Takasuna et al., 1996). The lesser damage found in small intestines 
compared with damage in the colon could be explained by a lower exposure of this 
tissue to SN-38. This may be attributable to a smaller amount of β-glucuronidase in 
small intestinal lumen (Takasuna et al., 1998).  
Because many drugs could affect the functioning of the intestinal bacteria, co-
medication may influence the chemotherapeutic treatment of patients with CPT-11 
(Mallett et al., 1989). Because bacteria producing β-glucuronidase activity will be 
killed by antibiotics, it is anticipated that this will lead to a reduction in acute and 
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delayed diarrhea and cecal damage (Takasuna et al., 1996). It has been demonstrated 
that antibiotics had no effects on the plasma concentrations of CPT-11, SN-38, or SN-
38G in mice (penicillin/streptomycin) (Takasuna et al., 1998) and in humans 
(neomycin) (Kehrer et al., 2001). This combined treatment also resulted in reduced 
SN-38 concentrations in the intestinal contents with concomitantly increased SN-38G 
levels (Takasuna et al., 1998; Kehrer et al., 2001). The decrease of bacterial β-
glucuronidase-mediated deconjugation of SN-38 may be a potential approach for 
modulating CPT-11-induced intestinal toxicity.  
1.2.3. Pharmacokinetics and metabolism of topotecan 
Topotecan (TPT, Hycamtin, 9-dimethylaminomethyl-10-hydroxycamptothecin) is 
synthesized by the combination of 10-OH-CPT with a positively charged dimethyl-
aminomethyl group at position 9, which can increase the aqueous solubility of the 
compound (Figure 1-7) (Hsiang et al., 1989; Kingsbury et al., 1991). As a potent Top 
1 inhibitor, topotecan induces tumor cell death by stabilization of Top 1 complex and 
generation of permanent DNA strand breaks (Grochow et al., 1992; Wall et al., 1992; 
Tanizawa et al., 1994; Kollmannsberger et al., 1999). However, the molecular 
mechanisms by which topotecan treatment inhibits cancer cell proliferation and 
induces cancer cell apoptosis are not fully elucidated. In addition to the approval for 
the treatment of metastatic ovarian cancer (Pizzolato and Saltz, 2003), topotecan is 
used in the treatment of many other tumors including small cell lung cancer (Perez-
Soler et al., 1996; von Pawel et al., 1999; Takeda et al., 2003; Ardizzoni, 2004), non-
small cell lung cancer (Weitz et al., 2000; White et al., 2000), breast cancer (Levine et 
al., 1999), neuroblastoma (Santana et al., 2005), uterine carcinoma (Miller et al., 
2002), refractory glioblastoma multiforme (Pipas et al., 2005), carcinoma of the 
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uterine cervix (Long et al., 2005; Monk et al., 2005), and chronic myelomonocytic 
leukemia (Beran et al., 2003) in clinical practice. 
Topotecan is irreversibly converted by hepatic CYP3A to form a less active 
metabolite, N-desmethyl topotecan (Figure 1-7) (Rosing et al., 1997), which is 
detected at low level in plasma and excreta (Herben et al., 2002), indicating that 
topotecan is only metabolized to a minor extent. A total of 71.3% topotecan and 5.1% 
N-desmethyl topotecan was traced in excretion products of patients within 9 days after 
topotecan infusion, and  both compounds were present in active lactone form and 
inactive carboxylate form (Rosing et al., 1999). Both topotecan and N-desmethyl 
topotecan can undergo UGT-mediated glucuronidation to generate corresponding O-
glucuronides (TPT-G) which can be reconverted to the respectively parent compounds 
by β-glucuronidase (Figure 1-7) (Rosing et al., 1998).  In rat liver and human prostate 
carcinoma cell lines, topotecan might be transformed to a new metabolite by CYP450, 
whose structure and clinical importance remains unclear presently (Platzer et al., 




Figure 1-7. Metabolic pathways of topotecan (TPT), showing known involved important 
metabolites and enzymes. 
 
Topotecan is widely distributed into the peripheral space including cerebrospinal 
fluid, with a mean volume of distribution at steady-state of 75 L/mP2 P(Herben et al., 
1996). There is a large interindividual variability in the exposure and clearance of 
topotecan in cancer patients, with a mean total body clearance of the lactone of 30 
L/h/mP2 P and a mean elimination half-life of 3 h when administered intravenously 
(Grochow et al., 1992; Wall et al., 1992; Loos et al., 2000a; Daw et al., 2004). 
Topotecan is mainly excreted into the urine accounting for 40-70% of the 
administered dose and to a lesser extent into the feces (18-33% of the total dose) in 
cancer patients (Loos et al., 2000a; Loos et al., 2000b; Herben et al., 2002). There is 
an increased interest in the oral administration of topotecan in cancer patients in 
recent years as it can provide a more convenient way of achieving P Pprolonged 
exposure. However, the oral bioavailability of topotecan is moderate (30-44%) with a 
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substantially increased interpatient variability in its systemicP Pexposure (Schellens et 
al., 1996; Zamboni et al., 1999).  
1.2.4. Pharmacokinetics and metabolism of rubitecan 
Rubitecan (RBT), an aqueous-insoluble derivative of CPT, has a wide anticancer 
potency in vitro and in vivo (Figure 1-8) (Verschraegen et al., 1998; Amorino et al., 
2000; Sands et al., 2002). In pharmacological studies, rubitecan conferred higher anti-
tumor activity than CPT in human tumors xenografted in nude mice (Giovanella et al., 
1991). Rubitecan conferred obvious antitumor effect against various cancers in 
preclinical evaluation, such as lung, colorectal, breast, pancreatic, ovarian, prostate, 
stomach, melanoma and leukemia (Giovanella et al., 2002). In addition, rubitecan 
showed inhibitory effect on human immunodeficiency virus type 1 (HIV-1) 
replication in primary human lymphocytes, suggesting potential clinical utility for 
treatment of HIV-infection AIDS (acquired immune deficiency syndrome) (Hung et 
al., 2001). Rubitecan is safe and efficacious as first-line therapy for the treatment of 
advanced pancreatic cancer. It has also displayed some modest success as second-line 
therapy in treating gemcitabine failures (Stehlin et al., 1999). It has also been shown 
with H460 human lung carcinoma in vitro cell culture and in vivo xenografts that 
rubitecan could enhance the effects of radiation in human lung cancer. The sublethal 
damage recovery (SLDR) was found to be inhibited by rubitecan in vitro, suggesting 
that radiation therapy efficacy increased by rubitecan may possibly be related with the 
block of SLDR  (Amorino et al., 2000).   
Rubitecan is partially metabolized to 9-AC in vitro and in vivo (Pantazis et al., 1994; 
Schoemaker et al., 2002). It has been verified that rubitecan was converted to 9-AC in 
humans, dogs, and mice by oral administration (Hinz et al., 1994). Incubation of 
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mouse liver, spleen, kidney, brain, and muscle tissue with rubitecan all showed 
conversion to 9-AC, but no conversion was detected in cell-free plasma from human 
or mouse blood (Hinz et al., 1994). Seven metabolites (M1-M7) were identified in rats 
administered with rubitecan (Figure 1-8) (Li et al., 2003).  The metabolites in the bile 
were parent drug, 9-AC (M3), 9-acetamino-CPT (M4), and the glucuronide of 9-OH-
CPT (M1, 9-OH-CPT-G). Two other metabolites (M2 and M5) were found in the bile. 
M5 possibly was the GSH conjugate of 10-OH-CPT, and M2 may be produced by the 
loss of glutamic acid from M5. Metabolites M1 and M3 were also present in the urine 
and M4 in the feces. Fecal metabolite M7 was 9-OH-CPT. The mercapturic acid 
conjugate of 10-OH-CPT (M6) was found in the urine and feces (Li et al., 2003). 
However, 9-OH-CPT was found to be the main biliary metabolite in the feces, which 
might result from the hydrolysis of the glucuronide conjugate of 9-OH-CPT  (Li et al., 
2003).  
In Caco-2 cells, the absorptive transport of rubitecan was found to be pH dependent 
and the transport was increased at weakly acidic pH on the apical side. No 
concentration dependence and saturation were observed for the absorptive transport of 
rubitecan at concentrations up to 250 µM (Sha and Fang, 2004). In the everted gut 
sacs, the absorption of rubitecan occurred via passive diffusion and had little 
difference in different gut regions.  pH and efflux transporters were able to mediate 
the absorption and efflux of rubitecan, and they may contribute to the low oral 
absorption of rubitecan (Sha and Fang, 2004). The uptake of rubitecan is positively 
correlated to uptake time, and negatively correlated to pH and temperature. PgP had 
significant efflux effects on the uptake and transepithelial transport of rubitecan. The 
PgP inhibitors, cyclosporin A and verapamil, significantly increased the uptake 
amount of rubitecan (Sha et al., 2004).  
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Rubitecan may be tolerated for continuous periods of time, but has the potential for 
significant hematologic, gastrointestinal and urinary bladder toxicity (Verschraegen et 
al., 1998). The MTD of rubitecan given orally has been estimated at 1.5 mg/mP2 P/day 
for five consecutive days weekly (Verschraegen et al., 1998). Primary dose-limiting 
toxicities of rubitecan were myelosuppression and interstitial cystitis (Stehlin et al., 
1999). In a phase I clinical and pharmacological studies of patients with refractory 
cancers, rubitecan showed substantial dose limiting toxicities, including 
myelosuppression and hemorrhagic cystitis (Natelson et al., 1996). For a phase II 
clinical study, no complete or partial responses were observed for patients with 
metastatic cutaneous and uveal melanoma, who orally administered rubitecan. 
Hematologic toxicity was moderate. Gastrointestinal side effects were diarrhea and 
vomiting. In this trial, no patients developed chemical cystitis with gross hematuria. 
Although preclinical studies have shown potent activity of rubitecan for melanoma, 
rubitecan, used at a starting dose of 1.5 mg/mP2 P/day for 5 consecutive days of each 
week in this trial, is significantly toxic and is not active for metastatic melanoma of 
cutaneous or uveal origin (Ellerhorst et al., 2002). Another phase II study was 
performed in patients with heavily refractory ovarian, tubal or peritoneal cancer. Side 
effects were hematologic toxicity (including anemia neutropenia and 
thrombocytopenia) and non-hematologic toxic effects (including nausea and vomiting, 
diarrhea, weight loss, chemical cystitis and neutropenic sepsis) (Verschraegen et al., 
1999). Rubitecan administered orally to patients with advanced pancreatic cancer 
gave promising results, while the toxicity of the therapy was mild and readily 





Figure 1-8. Metabolic pathways of rubitecan (RBT), showing known involved important 
metabolites and enzymes. 
 
1.2.5. Pharmacokinetics and metabolism of 10-OH-CPT 
10-OH-CPT, a natural derivative of CPT, is a potent anticancer agent in preclinical 
stage. In addition to be a Top 1 inhibitor, 10-OH-CPT can induce human hepatoma 
HepG2 cell differentiation and apoptosis (Zhang et al., 1999; Zhang et al., 2000a; 
Zhang et al., 2000b; Platzer et al., 2001). The differentiation of HepG2 cells induced 
by 10-OH-CPT is related to specific GB2B/M cell cycle arrest, down-regulation of the 
proliferating cell nuclear antigen (PCNA) and up-regulation of wild-type protein p53 
(Zhang et al., 2000b). 10-OH-CPT could arrest cells in GB2 B/M phase at low 
concentration or in S phase at high concentration in HepG2 cells (Zhang et al., 1999). 
It was found that in HepG2 cells, 0.1 µg/ml 10-OH-CPT could increase the level of 
p53, c-Myc and Bax proteins, and decrease the level of Bcl-2 protein and α-
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fetoprotein (AFP). The activation of caspase-1 and caspase-3 induced by 10-OH-CPT 
may contribute most to the apoptosis of cells (Zhang and Xu, 2000). In the human 
breast cancer cell lines MCF-7 and MDA-MB-468, the apoptosis induced by 10-OH-
CPT and CPT was shown to be dose- and time-dependent. 10-OH-CPT and CPT may 
increase the expression of p21WAF1/CIP1 protein and mRNA, and induce apoptosis 
in human breast cancer cells through both p53-dependent and -independent manners 
(Liu and Zhang, 1998).  
10-OH-CPT is more active and less toxic than CPT (Wani et al., 1986; Ling et al., 
1993; Ling and Xu, 1993; Han, 1994). 10-OH-CPT showed definite anticancer 
activity on murine leukemia L1210 cells (Wani et al., 1986), murine bladder 
carcinoma MBT-2 cells (Ling et al., 1993), and rodent tumors (Han, 1994). In murine 
bladder carcinoma MBT-2 cells, 50 µM 10-OH-CPT decreased protein formation in 
the matrix and other nuclear subfractions. 10-OH-CPT-induced ultrastructural 
changes in nuclei and nuclear matrix were specifically related with DNA replication 
or RNA transcription (Ling et al., 1993). In murine ascites hepatoma cells, 10-OH-
CPT decreased DNA syntheses and inhibited phosphorylation in histone time-
dependently. Moreover, 10-OH-CPT preferably inhibited phosphorylation of histone 
H1 and H3. In vivo, 10-OH-CPT also had inhibitory effect on histone H1 and H3 
phosphorylation. Cell death induced by 10-OH-CPT may be related with the 
inhibition of histone H1 and H3 phosphorylation (Ling and Xu, 1993).  
In liver model of male Wistar rats, 10-OH-CPT mainly has three metabolites, which 
are 10-OH-CPT glucuronide, hydroxyl-10-OH-CPT glucuronide and hydroxyl-10-
OH-CPT (Figure 1-9). 10-OH-CPT preferred a non-biliary secretion, and conjugated 
10-OH-CPT metabolites preferred biliary elimination (Platzer et al., 2001). After i.v. 
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administration to rats, lactone form of 10-OH-CPT was changed to its carboxylate 
form in the blood, and at the same time distributed to other organs widely, including 
liver, kidney and bone marrow. Urinary excretion was the main elimination pathway 
of 10-OH-CPT in the first 3 h, and major metabolites in the urine were the 
carboxylate form and glucuronides. Thereafter, fecal excretion was the major 
elimination pathway. Less active carboxylate form of 10-OH-CPT had a longer 
elimination half-time than its active lactone form. 10-OH-CPT is mainly 
biotransformed to its carboxylate form and glucuronide conjugates in vivo. 10-OH-
CPT glucuronides were found in plasma, urine, feces and various organs. Thus the 
elimination time of 10-OH-CPT is increased by its carboxylate form.  With i.v. 
administration, the toxicity of 10-OH-CPT is increased in accordance with dose 
(Zhang et al., 1998).  
 






1.3. RESISTANCE TO CPTS  
Both severe and unpredictable dose-limiting toxicity and tumor resistance are major 
reasons for the failure of CPT analogs-based chemotherapy (Rasheed and Rubin, 
2003). For example, CPT-11 could only give an objective response in about 20% 
treated patients with advanced colorectal or lung cancer (Gupta et al., 1997; Kudoh et 
al., 1998). Topotecan could give 35−38% response rates in recurrent ovarian 
carcinoma (ten Bokkel Huinink et al., 1997) and ∼10% in breast cancer (Levine et al., 
1999). The mechanisms for tumor resistance to CPTs are complicated and a number 
of tumor-, drug- and host-related factors have been implicated (Rasheed and Rubin, 
2003; Beretta et al., 2006). These include: a) inadequate accumulation of drug in the 
tumor; b) alterations in the target (Top 1); c) alterations in the cellular response to the 
Top 1-CPT interaction. Intracellular accumulation of the active form of CPTs is the 
final outcome of processes such as cellular influx, metabolism and efflux. Both 
passive diffusion and transporter-mediated transport are involved in intestinal uptake 
of CPT (Gupta et al., 2000). In addition, cellular metabolism may be a significant 
factor to determine the intracellular concentrations of drugs. For instance, lack or low 
activity of bioactivating enzymes will result in insufficient conversion of drugs to its 
active forms and lower activity than expected. The toxicity of CPTs will also become 
lower when the formation of the cleavable complexes is decreased by alteration in 
Top 1 protein levels or gene mutations (Larsen and Skladanowski, 1998; Staker et al., 
2002; Tsurutani et al., 2002). Finally, the increased efflux of CPTs by several drug 
transporters greatly contributes to tumor resistance. The action of several ABC drug 
transporters in this respect will be described below. 
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1.3.1. PgP-mediated resistance 
Overexpression of PgP has been linked to the clinical multidrug resistance phenotype 
andP Ppoor prognosis for a number of cancers (Ambudkar et al., 1999; Borst and 
Elferink, 2002; Gottesman et al., 2002; Schinkel and Jonker, 2003; Marzolini et al., 
2004). PgP conferred minor to moderate resistance to topotecan and diminished 
topotecan accumulation (Chen et al., 1991), but the effects were substantially smaller 
than the effects of PgP overexpression on the accumulation and cytotoxicity of 
daunorubicin and etoposide (Hendricks et al., 1992). Cells with overexpression of PgP 
conferred little resistant ability to CPT, whose cytotoxic levels were similar to the 
drug-sensitive parental cell line, KB 3-1, and its multidrug-resistant derivative, KB 
V1. Other uncharged CPT derivatives, including 9-AC and 10,11-methylenedioxy-
camptothecin, had similar results compared with CPT. However, topotecan, the 
charged CPT derivative, showed reduced cytotoxicity against PgP-overexpressing KB 
V1 cells. For KB V1 cells, the resistance to topotecan was due to the overexpression 
of PgP. These results suggest that the charge on CPT may influence the drug 
resistance of PgP (Chen et al., 1991). CHRC5 (colchicine-resistant) and AuxB1 
(parental) Chinese hamster ovary cells were also used to examine the effect of PgP 
overexpression on topotecan cytotoxicity. CHRC5 cells conferred 15-fold resistance 
to topotecan after a 1 h exposure and 3.2-fold resistance in continuous exposure in the 
examination of ICB50B values by colony forming assays (Hendricks et al., 1992). Similar 
effects were detected in PgP-expressing human cells, MCF-7/Adriar Pr P(doxorubicin-
resistant derivative of MCF-7 cell line) breast cancer cells and KG1a human acute 
myelogenous leukemia cells (Hendricks et al., 1992). Quinidine or verapamil 
increased intracellular topotecan levels in both of these cell lines but had no effect in 
parental MCF-7 cells or a variety of human leukemia cell lines without 
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overexpression of PgP. Quinidine also increased cytotoxicity for topotecan in the 
PgP-overexpressing cell lines, but not in the parental lines. These results suggest that 
PgP overexpression lowered topotecan accumulation and topotecan cytotoxicity in 
both hamster and human cells (Hendricks et al., 1992). In another study using the two 
kinds of Chinese hamster ovary cell lines, CHRC5 cells with overexpression of PgP 
conferred significant resistance only to topotecan, SN-38 and 9-AC, in comparison 
with the control cell line AuxB1. There was no significant cytotoxicity difference 
between the two cell lines when they were exposed to CPT, 10-OH-CPT, and 10,11-
methylenedioxycamptothecin (Mattern et al., 1993). Hoki et al examined the 
relationship between PgP and resistance to CPT analogs by using two cell models, 
which were MDR KB-V1 cells selected by vinblastine resistance, and NIH3T3 cells 
with transfection of PgP (NIH-MDR-G185). Both KB-V1 and NIH-MDR-G185 cells 
were resistant to topotecan, and topotecan-induced cleavable complexes were reduced 
in KB-V1 cells, consistent with PgP-mediated resistance to topotecan. However, NIH-
MDR-G185 cells did not show obvious resistance to CPT, 9-AC, 10, 11-
methylenedioxycamptothecin, or SN-38. Although KB-V1 cells were cross-resistant 
to these compounds, the cleavable complexes level was similar to that of parental KB-
3-1 cells. These data indicated that PgP only conferred resistance to topotecan in this 
assay. The resistance to other CPT derivatives observed in KB-V1 cells can probably 
be attributable to additional resistance factors besides PgP (Hoki et al., 1997). Human 
malignant cell lines (BRO/mdr1 and 2780AD) with overexpression of PgP showed a 
low cross-resistance to CPT-11 and SN-38, which was obvious in human tumor 
xenografts only with high-expression PgP in vivo (Jansen et al., 1998; Van Hattum et 
al., 2000). However, PgP showed no resistance to karenitecin ((7-[(2-
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trimethylsilyl)ethyl]-20(S)camptothecin), BNP1350), a CPT derivative (Van Hattum 
et al., 2000). 
As a known substrate and inhibitor of PgP, cyclosporin A increases the area under the 
plasma concentration-time curve (AUC) of CPT-11 and its metabolites in rats. Both 
renal and nonrenal clearances of  CPT-11 are decreased in rats with pretreatment of 
cyclosporin A  (Gupta et al., 1996). CPT-11 and its metabolites were also found to 
interact with PgP with the use of a photoaffinity analogue of verapamil (Gupta et al., 
1996). In vivo, it was found that PgP may be involved in the biliary excretion of CPT-
11 (Sugiyama et al., 1998). The ATP-dependent uptake of the carboxylate form of 
CPT-11 (5 µM) was found in membrane vesicles isolated from KB-C2 cells, a human 
epidermoid carcinoma KB-derived cell line with overexpression of PgP (Chu et al., 
1999b). Moreover, PgP is considered as the high-affinity component in the biliary 
excretion of the carboxylate form of CPT-11 (Chu et al., 1999a). In isolated rat 
canalicular membrane vesicles (cMVs), both cyclosporin A and verapamil could 
inhibit the ATP-dependent uptake of the carboxylate form of CPT-11 at 5 µM, at 
which the high-affinity component is responsible for CPT-11 transport (Chu et al., 
1997b; Chu et al., 1999a). On the contrary, when the concentration of CPT-11 
carboxylate form was increased to 250 µM, at which the low-affinity component was 
the main factor for drug transport, the inhibitory effect of cyclosporin A and 
verapamil was greatly reduced (Chu et al., 1999a). It was found that the efflux of 
CPT-11 was decreased by PgP inhibitors, GF120918 (elacridar) and verapamil, in 
MDCKII cells with overexpression of PgP, indicating that PgP was involved in  the 
efflux of CPT-11 in vitro (Luo et al., 2002).  
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1.3.2. MRPs-mediated resistance 
The first member of MRP family, MRP1 (ABCC1), was found in 1992 in a lung 
cancer cell line conferring resistance to doxorubicin which was not related to PgP 
(Cole et al., 1992). MRP1 is nearly present in all major tissues and in all peripheral 
blood cell types (Zaman et al., 1993; Burger et al., 1994). In human epidermoid KB-
3-1-derived cell lines with overexpression of MRP1, cytotoxicity of CPT-11 and SN-
38 was significantly decreased, which indicated that MRP1 may contribute the active 
efflux of CPT-11 and SN-38 (Chu et al., 1999a). C-A120 cells and KB/MRP cells 
with overexpression of MRP1 were efficiently more resistant to CPT-11 and SN-38 
than parental KB-3-1 cells (Chen et al., 1999).  2-[4-(diphenylmethyl)-1-
piperazinyl]ethyl-5-(trans-4,6-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-2,6- dimethyl-
4-(3-nitrophenyl)-3-pyridinecarboxylate P-oxide (PAK-104P) and MK571 could 
increase the accumulation of CPT-11 and SN-38 in C-A120 and KB/MRP cells, and 
inhibit the drug resistance. However PAK-104P and MK571 had little effect on the 
drug sensitivity and accumulation in parental KB-3-1 cells (Chen et al., 1999). 
Furthermore, the metabolism of CPT-11 to SN-38 in C-A120 and parental KB-3-1 
cell lines was similar. These data suggested that MRP1 may be related to the transport 
of CPT-11 and SN-38 and contribute to drug resistance (Chen et al., 1999). However, 
MRP1 expressed in human malignant cells (BRO/mdr1 and 2780AD) only showed 
resistance to SN-38, while no cross-resistance was observed for CPT-11 (Jansen et al., 
1998). Resistance to topotecan in the tumor cell lines was also associated with the 
expression of the MRP1 (Jonsson et al., 1997).  
MRP2 (ABCC2) was previously known as the canalicular multispecific organic anion 
transporter (cMOAT). The amino acids of MRP2 have 49% identity with MRP1 
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(Evers et al., 1998). The location of MRP2 is unique, as it is present on the apical 
plasma membranes of polarized cells such as hepatocytes, pneumocytes, kidney 
proximal tubules, and specialized cells in the intestine and brain (Keppler et al., 1997; 
Masuda et al., 1997), while other MRPs are in general located on the basolateral 
membrane of polarized cells. Based on its localization and substrate specificity, it is 
proposed that the primary physiological function of MRP2 is to export amphiphilic 
organic anions and xenobiotics into bile and into the lumen of excretory organs 
(Keppler and Kartenbeck, 1996). MRP2 has been shown to affect the biliary excretion 
of CPT-11 and SN-38 (Chu et al., 1997b). In Mrp2-deficientrats, MTX, CPT-11 and 
SN-38 showed decreased biliary clearance (Masuda et al., 1997; Chu et al., 1998; 
Sugiyama et al., 1998). In another report, MRP2 was also identified to mediate the 
biliary excretion of CPT-11 and its metabolites, by using isolated liver bile cMVs 
(Sugiyama et al., 1998). The carboxylate forms of SN-38G and SN-38 significantly 
inhibit the uptake of leukotriene C4 mediated by MRP2, while inhibition by the 
carboxylate form of CPT-11 is moderate (Chu et al., 1998). The efflux of CPT-11 was 
much greater in MDCKII cells overexpressing MRP2 than in wild-type MDCKII 
cells, and this phenomenon could be efficiently reduced by MRP2 inhibitors. It is 
suggested that MRP2 is partly responsible for the efflux of CPT-11 in vitro (Luo et 
al., 2002). More recently, it was found that the brain concentration of topotecan in 
Mrp4 knockout mice was significantly increased compared to the wild type, 
indicating that topotecan is a potential substrate for mouse Mrp4 (Leggas et al., 2004). 
Topotecan was able to inhibit MRP4-mediated transport of EB2 B17βG. Overexpression 
of MRP4 in Saos-2 cells decreased the intracellular accumulation of topotecan, 
suggesting that topotecan is a new substrate for MRP4 (Leggas et al., 2004). 
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However, it is not clear whether MRP4 is invovled in resistance to other CPT analogs 
which have been identified as the substrates for PgP, MRP1-2.  
1.3.3. BCRP-mediated resistance 
BCRP is a 655-amino acid protein of about 72 kDa. It is the second member of the G 
family of ABC transporters (ABCG2) (Allikmets et al., 1998) and also named as 
ABCP or mitoxantrone (MX) resistance gene, MXR (Mao and Unadkat, 2005). BCRP 
was first identified in a highly doxorubicin-resistant MCF-7 breast cancer cell subline 
(MCF-1/AdrVp) (Doyle et al., 1998). Overexpression of BCRP was also detected in 
multidrug-resistant cell lines selected with mitoxantrone (Ross et al., 1999). The 
transfection of BCRP cDNA in MCF-7 breast cancer cells caused the resistance to 
mitoxantrone, doxorubicin and daunorubicin, the decreased daunorubicin 
accumulation and retention in cells, and the increased efflux of rhodamine 123 (Doyle 
et al., 1998). In multidrug resistant cell lines, the expression of BCRP was correlated 
with great reduction in the intracellular content of mitoxantrone, daunorubicin, 
bisantrene, topotecan, prazosin, and rhodamine 123 (Litman et al., 2000).  
BCRP confers resistance to SN-38 and topotecan (Lage and Dietel, 2000). Moreover, 
two sublines of multidrug-resistant human colon (S1) and breast (MCF-7) cancer cell 
lines with high BCRP expression, S1-M1-80 and MCF-7 AdVp3000, showed more 
higher resistance ability to topotecan than cells with PgP-mediated drug resistance 
(Litman et al., 2000). Topotecan-selected T8 and mitoxantrone-selected MX3 cell 
lines, derived from the human IGROV1 ovarian cancer cells, were resistant to 
topotecan and SN-38. The expression levels of BCRP protein in both cell lines were 
in proportion to the resistance ability to topotecan and SN-38, which suggested that 
BCRP may increase the transport of drugs out of cells. In vitro, 70% of topotecan in 
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T8 or MX3 cells was effluxed out in 30 sec. Thus, BCRP mRNA levels in the human 
IGROV1 ovarian cancer cells may be modulated by topotecan (Maliepaard et al., 
1999). Mouse Bcrp1 was found to be overexpressed in topotecan-resistant mouse 
fibroblast cell lines, which lacked functional Mdr1a, Mdr1b, and Mrp1 genes. In 
resistant cells, the intracellular drug levels were significantly reduced and GF120918 
inhibited resistance function of cells. Thus, mouse Bcrp1 may act as a multidrug 
transporter like the human BCRP (Allen et al., 1999). Similarly, GF120918 increased 
the intracellular concentration of topotecan in the human ovarian tumor cell lines T8 
and MX3 to the drug level in the parental IGROV1 cells. GF120918 could almost 
totally inhibit BCRP-mediated drug-resistance to CPT analogs (Maliepaard et al., 
2001). In vivo, mouse Bcrp1 is found to be responsible for the transport of topotecan, 
to reduce drug bioavailability and avoid drug harm to fetuses. The established BCRP 
inhibitor GF120918 could greatly reduce the resistance of topotecan in mice (Jonker 
et al., 2000). It is also reported that GF120918 efficiently increased oral 
bioavailability of topotecan in patients, possibly by increasing absorption and 
decreasing clearance of topotecan.  (Kruijtzer et al., 2002).   
A mitoxantrone-resistant human MCF-7 breast cancer subline (MCF/MX) conferred 
cross-resistance to topotecan, CPT-11 and SN-38, which was not clearly related to 
PgP or MRP1-mediated drug resistance (Nakagawa et al., 1992; Yang et al., 1995). A 
topotecan-resistant subline MCF-7/TPT300, derived from MCF-7 wild-type cells, 
showed an increase of topotecan efflux compared with the parental cells. The 
expression levels of PgP and MRP1 were similar in topotecan-resistant and parental 
cells, while the BCRP was overexpressed in MCF-7/TPT300 cells. Therefore, the 
topotecan-resistant activity of MCF-7/TPT300 cells may be caused by the increased 
topotecan efflux which possibly was mediated by BCRP (Yang et al., 2000). A 
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mitoxantrone-resistant HT29 colon carcinoma cell line (HT29/MIT) showed great 
resistance to topotecan and SN-38, which was not related with PgP or other MRPs. 
Overexpression of BCRP in HT29/MIT contributed to the reduction of intracellular 
levels of topotecan (Perego et al., 2001). CPT seems to be a poor substrate for BCRP, 
while its derivatives with potential for glucuronidation, such as SN-38, topotecan, 9-
AC, are better BCRP substrates than CPT itself (Brangi et al., 1999; Mao and 
Unadkat, 2005).  PgP, MRP1 and MRP2 showed little resistance to rubitecan and 9-
AC, expression of both wild-type BCRP and R482T BCRP mutant displayed 
resistance to 9-AC, while not to rubitecan (Rajendra et al., 2003). Moreover, other 
CPT analogs, such as lurtotecan (NX211), exatecan mesylate (DX8951f), karenitecin 
(BNP1350) and gimatecan (ST1481), seem to be poor BCRP substrates (Mathijssen et 
al., 2001; Perego et al., 2001). The relationship between substrate selectivity of these 
transporters and compound structure still remain unclear. Studies aimed at identifying 
the specific regions responsible for the recognition of the different CPTs by 
transporters are expected to contribute to the development of new derivatives of 
overcoming specific mechanisms of drug resistance (Nakagawa et al., 2006).  
1.3.4. GSH-mediated resistance 
Intracellular GSH is a known determinant of sensitivity to alkyating agents and is 
involved in a general mechanism for drug detoxification (Gamcsik et al., 1999). GSH 
plays an important role in the resistance to alkylating CPT analogs by a series of 
processes including inhibition by formation of drug-GSH conjugates in spontaneous 
or enzyme-dependent reactions (Colvin et al., 1993). As such, GSH is proposed to be 
a determinant of cellular response to CPTs, by affecting the redox state of the tumor 
cells (Adams et al., 2000). GSH also showed influence on the sensitivity to other 
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nonalkylating CPT analogs. The relationship of CPTs sensitivity to GSH metabolism 
across cell lines is complicated, indicating that parameters such as GSH turnover rate 
or GSH utilization by MRPs, glutaredoxin or thioredoxin play a key role in the 
cellular sensitivity to CPTs (Adams et al., 2000). Several reports have found that 
reduction of intracellular GSH synthesis by treatment with BSO increases the cell 
sensitivity to CPT analogs, suggesting that GSH and its metabolism play a crucial role 
in the cytotoxicity of CPTs (Niimi et al., 1992; Matsumoto et al., 1995; Sawyer and 
Bonner, 1996; Gamcsik et al., 2001). Consistently, the intracellular GSH level was 
significantly increased in glioma cell lines (T98G/CPT-11, C6/CPT-11) with acquired 
resistance to CPT-11. In contrast, it was found that neither the difference of 
intracellular accumulation of CPT-11 nor the change in the total activity of Top 1 was 
involved in the CPT-11 resistance, implicating GSH might be partly responsible for 
the resistance to CPT-11 (Matsumoto et al., 1995). Furtherover, GSH is one crucial 
component in MRP4-mediated transport, being co-transported with MRP4 substrates 
(Rius et al., 2003; Rius et al., 2006). It seems that GSH may be involved in drug 
resistance in several ways and the study of the relationship between GSH and newly 
identified MRP4 substrates will be helpful in providing a clearer understanding of 




CHAPTER 2 HYPOTHESIS & AIMS  
CPTs are among the most promising antitumor agents endowed with a unique 
mechanism of action, because they act through inhibition of DNA Top 1, an enzyme 
involved in regulating critical cellular functions including DNA replication, 
transcription and recombination. On the premise of its pharmacological potential in 
cancer chemotherapy, medicinal chemistry has played a crucial role in the 
development of novel analogs, and recently some compounds have emerged as 
promising agents for clinical evaluation. A major limitation, however, to the clinical 
efficacy of CPT-containing therapies is represented by drug resistance. Although drug 
resistance is a multifactorial phenomenon involving both pharmacological and tumor-
related factors, recent reports have pointed towards ABC transporters as important 
mediators of drug resistance in the context of CPTs. Specifically, transporters such as 
PgP, MRP1, MRP2 and BCRP have been implicated (Beretta et al., 2006; Ozben, 
2006; Beretta and Zunino, 2007). Emerging evidence has also shown that MRP4 may 
be involved with limited members of this class of compounds (Stewart et al., 2004; 
Norris et al., 2005). Our interest is thus to elucidate more clearly the role of MRP4 in 
CPT resistance using an extensive panel of its analogs. The overall hypothesis tested 
is that CPT and its analogs act as substrates of MRP4 and interact with MRP4 on 
cellular levels to mediate multidrug resistance in cancer. The following aims were 
proposed to test this hypothesis: 
 (1) Determine the resistance profiles of CPT and its analogs in cancer cells 
overexpressing human MRP4 in vitro;  
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 (2) Characterize MRP4-mediated uptake, accumulation, and transport of CPT 
and its analogs; and 
 (3) Examine the effect of CPT and its analogs on MRP4-mediated efflux of 
GSH. 
Achieving the aims above will greatly enable us to better understand CPT resistance 
in cancer and hopefully devise new strategies to overcome drug resistance either 
through the molecular design of novel non-cross-resistant analogs or utilization of 





CHAPTER 3 MATERIALS & METHODS 
3.1. GENERAL  
3.1.1. Chemicals 
CPT analogs (all in lactone form), including CPT, CPT-11, SN-38, topotecan, 
rubitecan, and 10-OH-CPT were purchased from SinoChem Ningbo Co. (Ningbo, 
China). All CPT analogs have a purity of > 99%. Vincristine, vinblastine, MTX, bis-
POM-PMEA, celecoxib, and diclofenac sodium salt (all compounds with a purity > 
99%) were also purchased from SinoChem Ningbo Co. (Ningbo, China). The GSH 
biosynthesis inhibitor, BSO, was from Sigma Chemical Co (St. Louis, MO, USA). 
The leukotriene antagonist, MK571, was a gift from Dr Ford-Hutchinson (Merck 
Frosst Canada, Inc., Kirkland, Quebec, Canada) (Laskey et al., 1989).  Norcantharidin 
(with a purity of 99.5%), a protein phosphatase I inhibitor for cancer therapy, was a 
gift from Professor Andy Lee (Putuo District People’s Hospital, Shanghai University 
of Traditional Chinese Medicine, Department of Oncology, China). Other anticancer 
drugs used such as etoposide (VP-16), 5-fluorouracil, cyclosporin A, carboplatin, 
paclitaxel, and mitoxantrone were obtained from Sigma Chemical Co (St. Louis, MO, 
USA).  
3.1.2. Cell culture 
The human hepatocellular carcinoma cells, V/HepG2 and MRP4/HepG2, were 
established by the stable transfection of empty vector and full length cDNA of the 
human MRP4, respectively, and were kindly provided by Dr Theresa Tan (National 
University of Singapore, Department of Biochemistry, Singapore) (Lai and Tan, 
2002; Bai et al., 2004). Briefly, full-length MRP4 cDNA was cloned into the 
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pcDNA6/V5-His vector and then transfected into HepG2 cells using Lipofectamine™ 
reagent. Blasticidin (0.25 µg/ml) was added to the medium for selection 48 h after the 
start of transfection. Parent cells and cells with stably transfected MRP4 
(MRP4/HepG2) or insertion of vector alone (V/HepG2) were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma Chemical Co, St. Louis, MO, 
USA) in the presence of 0.25 mg/ml blasticidin. The sequence of human MRP4 was 
analyzed and confirmed, its mRNA determined by RT-PCR assay, and the protein 
expression analyzed using western blotting assay (Lai and Tan, 2002). The 
established HepG2 cells with stable expression of MRP4 demonstrated significant 
resistance to PMEA and 6-TG (Lai and Tan, 2002). These cells are capable of 
transporting GSH (Lai and Tan, 2002) and bimane-GS conjugate (Bai et al., 2004). 
Seven point mutations (F324A, F324W, W230A, W230F, W216A, W995C, and 
W995F) were also made to the human MRP4 and the respective plasmids were stably 
transfected into HepG2 cells. All cells were cultured in DMEM containing 100 
units/ml penicillin (Sigma Chemical Co, St. Louis, MO, USA), 100 µg/ml 
streptomycin (Sigma Chemical Co, St. Louis, MO, USA) and 10% fetal bovine serum 
(Life Technologies, Carlsbad, CA, USA), in the presence of 0.25 µg/ml blasticidin 
(Invitrogen, Carlsbad, CA, USA).  
A series of Madin-Darby canine kidney (MDCKII) cell lines with the overexpression 
of PgP (MDCKII-PgP) , MRP1 (MDCKII-MRP1), MRP2 (MDCKII-MRP2), MRP3 
(MDCKII-MRP3) and MRP5 (MDCKII-MRP5) were provided by Professor Piet 
Borst (Netherlands Cancer Institute, Amsterdam, Netherlands) (Bakos et al., 1998; 
Evers et al., 1998; Kool et al., 1999; Scheffer et al., 2000; Wijnholds et al., 2000). 




The breast carcinoma MCF/MX cells were obtained from A/P Go Mei Lin (National 
University of Singapore, Department of Pharmacy, Singapore) and cultured in RPMI 
medium (Invitrogen, Carlsbad, CA, USA) containing 100 units/ml penicillin, 100 
µg/ml streptomycin and 10% fetal bovine serum, in the presence of 250 nM 
mitoxantrone.  
All cell lines were grown at 37Po PC in a humidified atmosphere of 95% air and 5% COB2 B.  
Experiments were performed on cells within 10 passages. Viable cells were counted 
using the trypan blue exclusion method. 
3.1.3. Statistical analysis 
Data are presented as mean ± SD. Statistical analysis was performed using the 
GraphPad PrismP®P program Version 3.0 (GraphPad Software, San Diego, CA). The 
statistical analysis to evaluate the differences of continuous variables among the 
different groups was performed by one-way or two-way analysis of variance 
(ANOVA) followed with a post-hoc test (Dunnett’s multiple comparison test). 
Student's unpaired t test was conducted for comparisons between two groups. P < 
0.05 was regarded as significant.  
3.2. MRP4-MEDIATED RESISTANCE TO CPTS 
3.2.1. Cytotoxicity assays 
Drug effects on exponentially growing tumor cells were determined using MTT assay 
as described previously (Carmichael et al., 1987). V/HepG2 and MRP4/HepG2 cells 
were seeded at a density of 5,000 cells/100 µl per well in 96-well plates and allowed 
to attach for 24 h at 37°C under 5% COB2 B. After the attachment period, tumor cells 
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were exposed to drugs at different concentrations in culture medium for 4 h or 48 h. 
Bis-POM-PMEA and MTX were freshly prepared by dissolving in dimethylsulfoxide 
(DMSO) and diluted with DMSO to a series of different concentrations. All CPTs 
(CPT, CPT-11, SN-38, topotecan, rubitecan and 10-OH-CPT) in lactone forms were 
freshly prepared by dissolving in DMSO. CPT analogs were protected from light 
exposure to avoid degradation. The carboxylate forms of CPT, CPT-11 and SN-38 
were freshly obtained from their lactone forms respectively by incubation in PBS 
buffer at pH 9.0 overnight and at room temperature. These CPTs were 99% in lactone 
form at pH 3.0 and 98% in carboxylate form at pH 9.0 (Chu et al., 1997a; Chu et al., 
1997b).  Other anticancer drugs used in this study were prepared by dissolving in 
DMSO with the exception of cyclophosphamide which was dissolved in water. The 
final concentration of DMSO in cell culture medium was 1% (v/v) and such 
concentration showed little cytotoxicity to both strains of cells when incubated for 4 h 
or 48 h. For short drug exposure, the medium with drug at different concentrations 
was removed by aspiration 4 h after drug addition. The cells were washed twice with 
PBS, and fresh drug-free medium was added and the cells were incubated for a further 
44 h. At 48 h after drug addition for both long and short drug exposures, 100 µl MTT 
reagent (0.5 mg/ml) (Duchefa Biochemie E.V., Haarlem, Netherlands) was added to 
each well after removal of medium, and cells were incubated for a further 4 h at 37°C. 
Thereafter, the MTT reagent was discarded, and the purple precipitate was dissolved 
in 100 µl DMSO. The absorbance of formazan, a metabolite of MTT, in the resulting 
solution was photometrically measured at a wavelength of 595 nm using a microplate 
reader (Tecan Instruments Inc., Research Triangle Park, NC, USA). Experiments were 
performed in eight replicate wells for each drug concentration and carried out 
independently at least three times. Cytotoxicity was evaluated with reference to the 
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ICB50B value which was defined as the concentration needed for a 50% reduction of 
survival based on the survival curves. ICB50 B values were calculated from dose-response 
curves (i.e., cell survival vs. drug concentration) obtained in replicate experiments. 
3.2.2. In vitro cytotoxicity inhibition assays 
BSO, MK571, celecoxib and diclofenac are all known inhibitors of MRP4 (Borst and 
Elferink, 2002; Tian et al., 2005). To check for the effects of BSO, celecoxib, 
diclofenac, and MK571 on drug resistance, cells were preincubated with or without 
BSO (200 µM) for 24 h, celecoxib (50 µM), diclofenac (200 µM), or MK571 (100 
µM) for 2 h. All inhibitors were prepared by dissolving in DMSO, with the exception 
of BSO which was dissolved in water. The final concentration of DMSO or water was 
1% (v/v). All inhibitors at the concentrations used did not show any significant 
cytotoxicity when incubated with BSO for 24 h or with other inhibitors for 2 h. Before 
the cells were exposed to the model substrates for MRP4 or the CPT analogs, the 
medium with these inhibitors was removed, and the cells were washed twice with 
PBS. Then bis-POM-PMEA, MTX and CPT analogs were added and MTT assay 
performed as described previously in section 3.2.1.  
3.2.3. Western blot analysis 
For the western blot analysis of related ABC proteins in V/HepG2 and MRP4/HepG2 
cell lines, the following procedures were followed. Logarithmic growth phase 
adherent cells were scraped and subsequently lysed in PBS buffer with 1% Triton, 
supplemented with protease inhibitors (Roche Diagnostics Asia Pacific Pte Ltd, 
Singapore). The cell mixture was centrifuged at 13,000 rpm at 4P°PC for 20 min. After 
that, the supernatant was taken out as the samples. The protein samples were stored at 
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-80°C. To ensure that the same amount of protein from different samples was applied, 
protein levels were determined by the Bradford method (Sigma Chemical Co, St. 
Louis, MO, USA) with bovine serum albumin (Sigma Chemical Co, St. Louis, MO, 
USA) as the standard. Briefly, protein samples were thawed, and then diluted 
appropriately with Milli-Q water to ensure that the concentrations are within 
measurable ranges of the calibration curve. Bovine serum albumin was dissolved in 
PBS buffer to prepare the standards in the concentration range of 0-1.4 mg/ml. The 
standards and protein samples were added in duplicates to a 96-well plate. The 
Bradford reagent (250 µl) was then added to each well and mixed on a shaker for 30 
sec. The absorbance was read at 595 nm using a microplate reader (Tecan Instruments 
Inc., Research Triangle Park, NC, USA). Standard curves were obtained by plotting 
the net absorbance versus the protein concentration of standards. The protein 
concentration of the unknown samples was calculated using the standard curves. 
Proteins were separated on a 7.5% polyacrylamide gel, and subsequently transferred 
electrophoretically to PVDF membrane.  After blocking overnight, the membrane was 
incubated with primary antibody for 2 h, and then with the appropriate secondary 
antibody for 1 h in appropriate dilution (Table 3-1). The related transporters including 
PgP, MRP1, MRP2, MRP3, MRP5 and BCRP, were incubated with primary 
monoclonal antibodies of C219, MRPr1, M B2BIII-6, MB3 BII9, M B5BII-54 and BXP-21, 
respectively (Signet Laboratories, Dedham, MA). MRP4 was incubated with primary 
monoclonal antibody of MB4BI (Alexis Biochemicals, Lausen, Switzerland). β-actin was 
detected by primary monoclonal antibody of AC-74 (Sigma Chemical Co, St. Louis, 
MO, USA). Either HRP-conjugated anti-mouse (Bio-Rad Laboratories, Hercules, CA; 
Amersham Biosciences, Piscataway, USA) or anti-rat IgG (Sigma Chemical Co, St. 
Louis, MO, USA) was used as the secondary antibody (Table 3-1). Proteins were 
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detected using an enhanced chemiluminescence system (SuperSignal West Femto, 
Pierce, Rockford, IL). The images were acquired by Charged Coupling Device 
(CCD)-based detector of Alpha Innotech’s FluorChem™ (Alpha Innotech 
Corporation, San Leandro). The expression of β-actin was used as internal standard.  
 
Table 3-1. List of antibodies for transporter proteins. 
Transporter 
proteins Primary antibody (dilution) Secondary antibody (dilution ) 
β-actin Anti-β-actin (1:2000, Sigma) Anti-mouse (1:3000, Biorad) 
PgP C219 (1:1000, Signet) Anti-mouse (1:3000, Biorad) 
MRP1 MRPr1 (1:1000, Signet) Anti-rat (1:20,000, Sigma) 
MRP2 M B2BIII-6 (1:1000, Signet) Anti-mouse (1:10,000, Amersham) 
MRP3 M B3BII9 (1:1000, Signet) Anti-mouse (1:10,000, Amersham) 
MRP4 M B4BI  (1:2000, Alexis) Anti-rat (1:20,000, Sigma) 
MRP5 M B5BII-54 (1:1000, Signet) Anti-rat (1:20,000, Sigma) 
BCRP BXP-21 (1:1000, Signet) Anti-mouse (1:10,000, Amersham) 
 
3.3. UPTAKE & TRANSPORT ASSAYS  
3.3.1. Intracellular accumulation of CPT analogs 
The accumulation of CPT analogs (CPT-11, SN-38, topotecan, rubitecan and 10-OH-
CPT) in V/HepG2 and MRP4/HepG2 cells was examined in confluent cell cultures 
grown in BD FalconPTM Pcell culture dishes (BD Biosciences, San Jose, CA USA). 
Briefly, exponentially growing cells were exposed to CPT analogs lactone form (5 
µM CPT-11 or rubitecan lactone, 1 µM SN-38, topotecan, or 10-OH-CPT lactone) 
over 120 min at 37Po PC. The medium was aspirated off at the indicated times, and the 
dishes were rapidly rinsed 6 times with 5 ml of ice-cold PBS. The reverse-phase high-
performance liquid chromatography (HPLC) analysis of final washes ensured that 
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they contained no residual CPT analogs. After washing with ice-cold PBS, the cells 
were harvested and each cell pellet was suspended in 100-200 µl extraction solution 
(acetonitrile:methanol = 1:1, v/v, with 0.01 N hydrochloric acid) with the addition of 
5-10 µl internal standard correspondingly. The extraction solution volume for CPT-
11, SN-38 topotecan, and 10-OH-CPT was 200 µl, and for rubitecan was 100 µl. CPT 
(2.0 µg/ml) was the internal standard for CPT-11, SN-38, and rubitecan. SN-38 (0.5 
µg/ml) was internal standard for topotecan and 10-OH-CPT. The acidity of the 
extraction solution ensures the conversion of the compounds to their lactone form. 
Subsequently, the mixture was sonicated, vortexed and centrifuged. The supernatant 
was then injected into HPLC for drug concentration determination. Viable cells were 
monitored using the trypan blue exclusion method and the accumulation of CPT 
analogs in time-dependent assays was expressed as ng/10P6 P cells. The concentration 
effect of CPT analogs (0.1-10 µM CPT-11 for 30 min; 0.05-5 µM SN-38 or 10-OH-
CPT for 5 min; 0.05-5 µM topotecan for 10 min; 1-25 µM rubitecan for 5 min) on the 
cellular accumulation in the two cell lines was also investigated using the above 
described method. The intracellular accumulation rate of CPT analogs in 
concentration-dependent assays was expressed as ng/min/10P6 Pcells. Similar procedures 
were followed for the determination of intracellular accumulation of CPT-11 and SN-
38 in the MRP4 mutant cell lines, with MRP4/HepG2 cells being used as the control 
group. CPT-11 and SN-38 lactone form were used in these concentrations: 1 µM or 5 
µM CPT-11; 0.2 µM or 1 µM SN-38 lactone, with fixed time points of 5 min and 30 
min.  The intracellular accumulation of CPT-11 and SN-38 in mutant cell lines was 
expressed as percentage relative to that in MRP4/HepG2. 
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3.3.2. Inhibition of intracellular uptake of CPT analogs 
In addition, the effect of celecoxib (50 µM), BSO (200 µM) and MK-571 (100 µM) 
on CPT analogs accumulation was investigated. Both celecoxib and MK-571 were 
prepared by dissolving in DMSO, while BSO was dissolved in sterile Milli-Q water. 
The final concentration of DMSO was 1% (v/v). The three inhibitors at indicated 
concentrations showed little cytotoxicity (<5%) when incubated for 2 h for 50 µM 
celecoxib and 100 µM MK-571 or 200 µM BSO was preincubated for 24 h. 
Thereafter, cells were washed with warm PBS buffer for 4 times. Exponentially 
growing cells were then exposed to CPT analogs lactone form (5 µM CPT-11 or 
rubitecan lactone, 1 µM SN-38, topotecan, or 10-OH-CPT lactone) at 37Po PC. After 
continued incubation for the fixed time (30 min for CPT-11-treated cells, and 5 min 
for SN-38, rubitecan and 10-OH-CPT-treated cells, 10 min for topotecan-treated 
cells), cells were washed 6 times with ice-cold PBS. The cells were then harvested, 
lysed by sonication and extracted using ice-cold acetonitrile:methanol mixture (1:1, 
v/v, with 0.01 N hydrochloric acid). The supernatant was injected into HPLC for the 
determination of CPT analogs. 
3.3.3. Determination of CPT analogs by HPLC 
The HPLC system (Shimadzu, Nakagyo-ku, Kyoto, Japan) consisted of a LC-10AT 
pump, a FCV-10AL low-pressure gradient flow control valve, a DGU-14A on-line 
solvent degasser, a RF-10AXL fluorescence detector, a SPD-M10A UV detector and 
a SIL-10AD sample injector. Shimadzu Class-LC10 workstation was used for system 
control and data were monitored and analyzed using Shimadzu CLASS VP software. 
Quantitative HPLC analysis of samples was performed at room temperature using a 
CB18 B reverse-phase column (Phenomenex, 5 µm, 4.6×200 mm) preceded by a C B18 B   
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guard column (Phenomenex, 4×3.0 mm) (Phenomenex Co., Torrance, CA). The 
mobile phase was a mixture of acetonitrile with aqueous buffer containing 50 mM 
sodium hydrogen phosphate and 10 mM sodium heptane sulfonate (pH=3.0). The 
flow rate was maintained at 1 ml/min. CPT-11, SN-38, topotecan, and 10-OH-CPT 
were detected by a fluorescence detector (Shimadzu Scientific instrument) with an 
excitation wavelength at 380 nm and an emission wavelength at 540 nm, respectively. 
Rubitecan was determined by UV detector (Shimadzu Scientific Instrument) at the 
wavelength of 365-366 nm. 
CPT-11 and SN-38 
The mobile phase for CPT-11 and SN-38 was a mixture of 27% (v/v) acetonitrile with 
73% (v/v) aqueous buffer containing 50 mM sodium hydrogen phosphate and 10 mM 
sodium heptane sulfonate  (pH=3.0). The limit of quantification for CPT-11 and SN-
38 were 0.20 ng and 0.01 ng respectively, when the injection volume was 100 µl.   
Topotecan 
The mobile phase for topotecan was a mixture of 22.5% (v/v) acetonitrile with 77.5% 
(v/v) aqueous buffer containing 50 mM sodium hydrogen phosphate and 10 mM 
sodium heptane sulfonate (pH=3.0). The limit of quantification for topotecan was 0.25 
ng, when the injection volume was 100 µl.  
Rubitecan 
The mobile phase for rubitecan was a mixture of 27% (v/v) acetonitrile with 73% 
(v/v) aqueous buffer containing 50 mM sodium hydrogen phosphate and 10 mM 
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sodium heptane sulfonate  (pH=3.0). The limit of quantification for rubitecan was 10 
ng, when the injection volume was 100 µl.  
10-OH-CPT 
The mobile phase for 10-OH-CPT was a mixture of 24% (v/v) acetonitrile with 76% 
(v/v) aqueous buffer containing 50 mM sodium hydrogen phosphate and 10 mM 
sodium heptane sulfonate  (pH=3.0). The limit of quantification for 10-OH-CPT was 
0.1 ng, when the injection volume was 100 µl.  
3.3.4. Determination of efflux kinetic parameters 
The MRP4-mediated efflux of CPT analogs (CPT-11, SN-38, topotecan, and 
rubitecan, all in lactone form) in MRP4/HepG2 cells was estimated by subtracting the 
accumulation of CPT analogs in MRP4/HepG2 cells from that in V/HepG2 cells. 
One-binding site model was found to give the best fit for the resultant data. Kinetic 
parameters for the MRP4-mediated efflux of CPT analogs were obtained by fitting the 








Where v is the initial efflux rate of substrate (pmol/min/10P6P cells), [S] is the substrate 
concentration in the medium (µM), VBmax B is the maximum efflux rate (pmol/min/10P6 P 
cells), and KBmB is the Michaelis-Menten constant.  
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3.4.  GSH EFFLUX ASSAYS 
3.4.1. Export assay of bimane-GS using MCB 
The formation and efflux of bimane-GS was assessed by a previously published 
method (Bai et al., 2004). V/HepG2 and MRP4/HepG2 cells were seeded at a density 
of 6 × 10P6 P cells/2 ml per well in 6-well plates and allowed to attach for 24 h at 37°C 
under 5% COB2 B. The next day, the medium was removed and the cells were incubated 
with 1 ml of cell culture medium DMEM containing 100 µM MCB at 10°C for 1 h. 
After pretreatment with MCB (Invitrogen, Carlsbad, CA, USA), the plates were 
placed on ice and the medium was removed. Then the cells were washed twice with 
cold HBSS (Hanks balanced salt solution, containing 5.8 mM KP+P, 143 mM Na P+P, 1.3 
mM Ca P2+P, 0.8 mM Mg P2+P, 146 mM Cl P− P, 0.8 mM phosphate, 4.2 mM HCOB3 PB− P, and 10 
mM HEPES, pH=7.4) without glucose (1-2 ml). Cells were further incubated with 0.6 
ml HBSS/with glucose (5.6 mM) at 37°C. At the designated times (0, 5, 10, 15 min), 
the plate was placed on ice and 200 µl aliquots of incubation buffer were collected 
and placed into a black 96-well plate. The cells were then lysed with 0.6 ml of 0.2% 
sodium dodecyl sulfate (SDS), and the cells were detached with a rubber policeman. 
200 µl aliquots of cell lysate were collected and placed into a black 96-well plate. The 
bimane-GS content in the sample was measured by determining the fluorescence 
intensity at an excitation wavelength of 385 nm and an emission wavelength of 478 
nm in a Tecan Infinite® 200 series microplate reader (Tecan Instruments Inc., 
Research Triangle Park, NC, USA).  
To quantify the amount of bimane-GS, a series of bimane-GS standards were 
generated based on previously described procedure (Bai et al., 2004). 0-48 µM of 
GSH, 1 unit/ml equine liver GST in HBSS buffer (or in HBSS buffer containing 0.2% 
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SDS for cell lysate) were mixed and incubated until no increase in fluorescence was 
observed. After 30 min of incubation at 37°C, the fluorescence of the standards was 
read using an excitation wavelength of 385 nm and an emission wavelength of 478 
nm in a Tecan Infinite® 200 series microplate reader (Tecan Instruments Inc., 
Research Triangle Park, NC, USA). A calibration curve was obtained and the 
fluorescence of the samples was then correlated with the calibration curve.  
To examine the effect of CPT analogs (CPT-11, SN-38, topotecan, rubitecan, and 10-
OH-CPT) on the transport of bimane-GS, cells were incubated in 1 ml DMEM 
containing 100 µM MCB at 10°C for 1 h together with CPT analogs. The medium 
was removed and cells were washed with cold HBSS. For time-dependent effects, the 
efflux was carried out with 0.6 ml HBSS/with glucose (5.6 mM) in the presence of 
CPT analogs at 37°C for designated times (0. 5, 10, 15 min). For concentration-
dependent effects, the efflux was carried out in HBSS/5.6 mM glucose containing 
CPT analogs at 37°C for 10 min at which the difference of GSH efflux between two 
cell lines reached the peak. The CPT analogs used were replaced by 1% DMSO in the 
control group. 
3.4.2. Effect of BSO on bimane-GS export assay 
To determine the effect of BSO on the bimane-GS export, cells were seeded at a 
density of 6 × 10P6 P cells/2 ml per well in 6-well plates with the presence of 200 µM 
BSO and allowed to attach for 24 h at 37°C under 5% COB2 B. For control group, cells 
were seeded with the presence of 1% water. After the attachment period, the cells 
were incubated in 1 ml of DMEM containing 100 µM MCB and 200 µM BSO at 
10°C for 1 h. The medium was then removed and efflux was carried out in HBSS/5.6 
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mM glucose containing 200 µM BSO at 37°C. The BSO was replaced by 1% water in 






CHAPTER 4 RESULTS 
4.1. MRP4-MEDIATED RESISTANCE TO CPTS 
The aim of the first part of the study was to determine the resistance profiles of CPT 
and its analogs in cancer cells overexpressing human MRP4 in vitro. The strategy 
chosen was to first validate the functionality of MRP4 in our cell model system using 
established MRP4 substrates such as bis-POM-PMEA and MTX and then screen 
time- and concentration-dependent cytotoxicity effects of CPTs in vitro.  The effect of 
known inhibitors on MRP4-mediated resistance of CPTs was also examined. 
4.1.1. Functionality of MRP4 in cell model system 
HepG2 cells were stably transfected with empty vector and full-length cDNA of 
human MRP4 and were kindly provided by Dr Theresa Tan (National University of 
Singapore, Department of Biochemistry). This cell model was chosen based on the 
following reasons: (1)  MRP4 mRNA is highly expressed in kidney, lung and prostate, 
but absent or present in low levels in liver, placenta, and adrenal gland (Nishimura 
and Naito, 2005). This low MRP4 expression background in liver cells enabled us to 
associate cell response to our manipulations to the involvement of exogenous MRP4; 
and (2) liver is the main tissue responsible for the metabolism of CPTs and the liver 
system and its enzymes are ideal used for the study of CPTs and metabolisms (Haaz 
et al., 1998b; Platzer et al., 2000). To validate the functionality of this cell model 
system, we assessed the cytotoxicity of both bis-POM-PMEA and MTX in these cells. 
As shown in Table 4-1 and Figure 4-1, the forced expression of MRP4 in HepG2 
cells conferred 3.9- and 10.4-fold resistance to bis-POM-PMEA when the cells were 
exposed to the drug for 4 h and 48 h, respectively. MRP4-transfected HepG2 cells 
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exposed to MTX for 4 h were 4.7-fold more resistant compared with V/HepG2 cells, 
whereas there was no significantly increased resistance when cells were exposed to 
MTX for 48 h. These results for MTX were consistent with that in MRP4-transfected 
NIH3T3 cells as reported by Lee et al (Lee et al., 2000). Comparing MTX and bis-
POM-PMEA, MTX was 3-fold more potent than bis-POM-PMEA in V/HepG2 cells 
when the cells were exposed to the drugs for 48 h (ICB50B: 0.372 ± 0.027 vs. 0.110 ± 
0.017 µM). However, at 4 h of drug exposure, the toxicities of bis-POM-PMEA and 
MTX in V/HepG2 cells were close to each other (ICB50B: 2.40 ± 0.20 vs. 2.59 ± 0.51 
µM). We then analyzed the statistical significance of the cytotoxic effects of bis-
POM-PMEA and MTX in both V/HepG2 and MRP4/HepG2 cells using a two-way 
ANOVA analysis with “Drug concentration” and “Cell line” as within- and between-
sample factors, respectively. Results showed that the “Drug concentration” effect was 
significant with variation (P < 0.05) for both bis-POM-PMEA and MTX in V/HepG2 
and MRP4/HepG2 cells, indicating that the cytotoxicity of these two compounds to 
V/HepG2 and MRP4/HepG2 cells was drug concentration-dependent. The “Cell line” 
effect was also significant with variation (P < 0.05) for both bis-POM-PMEA and 
MTX except for MTX at drug exposure time of 48 h, indicating that MRP4/HepG2 
cells had different cytotoxic profiles when incubated with bis-POM-PMEA or MTX 
compared to V/HepG2 cells.  
Statistical significance was only observed for MTX in MRP4/HepG2 when MTX 
exposure was limited to the first 4 h and not 48 h of the cytotoxicity assay (Table 
4-1). This may be attributed to increased polyglutamylation of MTX in the continuous 
drug exposure. In long-term exposure to MTX, cells can accumulate long-chain 
polyglutamylated metabolites of MTX to high enough levels causing cell death 
(Hooijberg et al., 1999; Kool et al., 1999). For short-term drug exposure, however, 
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there may not have been enough time for the conversion to the long-chain 
polyglutamylated forms to take place, resulting in MTX being present in free drug 
form. It has also been demonstrated that MRP4 is not able to transport MTX 
polyglutamates out of cells (Chen et al., 2002). Thus, MRP4 could not display 
resistance to MTX in long-term exposure due to its inability to efflux MTX in long-
chain polyglutamylated form, but show resistance in short-term exposure by 
transporting MTX present mainly in free drug form. 
The effects of BSO on the cytotoxicity of bis-POM-PMEA and MTX in V/HepG2 
and MRP4/HepG2 cells were also examined. This was performed because BSO was 
found to be able to modulate MRP4 function by decreasing the intracellular GSH 
level (Lai and Tan, 2002). Cells were preincubated with 200 µM BSO for 24 h before 
they were exposed to bis-POM-PMEA and MTX. In MRP4/HepG2 cells, the addition 
of BSO significantly increased the cytotoxicity of bis-POM-PMEA by 4.0- and 3.6-
fold when the cells were exposed to bis-POM-PMEA for 48 h and 4 h, respectively 
(Table 4-1 & Figure 4-2). BSO also significantly reversed the MRP4-mediated 
resistance to MTX with drug exposure time of 4 h, with the ICB50 B reduced from 12.1 ± 
1.3 to 5.06 ± 0.96 µM (P < 0.05). Interestingly, the presence of BSO significantly 
decreased the cytotoxicity of bis-POM-PMEA in V/HepG2 cells by 2.6- and 1.3-fold 
when the cells were exposed to bis-POM-PMEA for 48 h and 4 h, respectively (Table 
4-1 & Figure 4-2). BSO also decreased the cytotoxicity of MTX by 1.5-fold in 
V/HepG2 cells for the 4 h exposure assay. In contrast, BSO had little effect on the 
cytotoxicity of MTX for both V/HepG2 and MRP4/HepG2 cells in 48 h drug 
exposure assay (Table 4-1 & Figure 4-2). Since MRP4 did not display any effect 
with long-term drug exposure, it is expected that BSO will not have any inhibitory 
effect on MRP4-mediated transport. Overall, we have shown that the MRP4-
 75 
 
overexpressing HepG2 cells conferred significant resistance to established MRP4 
substrates such as bis-POM-PMEA and MTX and that such resistance was effectively 
reversed by the addition of the GSH biosynthesis inhibitor, BSO. These results 
indicate that there is proper functionality of MRP4 in cell models used in our study. 
 
Table 4-1.  Drug sensitivity of MRP4-overexpressing HepG2 cells to bis-POM-PMEA and 
MTX. 
ICB50 B(µM) Drugs Drug exposure time (h) V/HepG2 MRP4/HepG2 
Fold 
resistance 
Bis-POM-PMEA 48 0.372 ± 0.027 3.86 ± 0.35Pa P 10.4 
+ BSO 48 0.98 ± 0.13PbP 0.96 ± 0.16PbP 0.98 
Bis-POM-PMEA 4 2.40 ± 0.20 9.40 ± 0.37Pa P 3.9 
+ BSO 4 3.05 ± 0.77PbP 2.60 ± 0.10Pa,bP 0.85 
MTX 48 0.110 ± 0.017 0.130 ± 0.024 1.2 
+ BSO 48 0.105 ±  0.029 0.128 ± 0.017 1.2 
MTX 4 2.59 ± 0.51 12.1 ± 1.3Pa P 4.7 
+ BSO 4  3.82 ± 0.74Pb P  5.06 ± 0.96PbP 1.3 
 
Data are reported as means ± SD. Fold resistance is calculated as ICB50B in MRP4/HepG2 cells 
divided by that in V/HepG2 cells. Each experiment was performed independently at least 3 
times. Two-way ANOVA test was used.  
P
a
P  < 0.05, MRP4/HepG2 vs. V/HepG2; PbP  < 0.05, test drug vs. test drug + BSO.  
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Figure 4-1. Representative cytotoxicity profiles of bis-POM-PMEA and MTX when the cells 
were treated with the drug for 48 h (A & C) or 4 h (B & D) in V/HepG2 (▲) and 
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Figure 4-2. Representative cytotoxicity profiles of bis-POM-PMEA and MTX when the cells 
were preincubated with 200 µM BSO for 24 h and then treated with the drug for 48 h (A & C) 
or 4 h (B & D) in V/HepG2 (▲) and MRP4/HepG2 (■) cells.  
 
4.1.2. Human MRP4 conferred resistance CPTs 
The cytotoxicities of CPT, CPT-11 and SN-38 in lactone and carboxylate forms in 
both MRP4/HepG2 and V/HepG2 are shown in Table 4-2. We first examined their 
effects in V/HepG2 cells. Compared with CPT-11 lactone, CPT lactone showed 16.0- 
and 75.6-fold higher cytotoxicity while SN-38 lactone exhibited 13.7- and 29.2- fold 
higher cytotoxicity at drug exposure times of 4 h and 48 h, respectively.  The lactone 
of CPT and SN-38 displayed similar cytotoxicity to V/HepG2 cells in 4 h drug 
exporsure assay, whereas CPT lactone had 2.6-fold higher cytotocixity to V/HepG2 
than SN-38 latone in 48 h drug exposure assay (Table 4-2 & Figure 4-3). Prolonged 
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drug exposure time from 4 h to 48 h significantly decreased the ICB50 B of CPT, CPT-11, 
and SN-38 in lactone form in V/HepG2 cells by 25.3-, 5.4-, and 11.4-fold, 
respectively.  
CPT-11, CPT, and SN-38 in carboxylate form exhibited lesser but comparable 
cytotoxicity in both MRP4/HepG2 and V/HepG2 cells compared to their respective 
lactone (Table 4-2 & Figure 4-4). This indicated that part of CPTs in carboxylate 
form at pH 7.4 medium was rapidly converted to active lactone form, whereas 
conversion to less active carboxylate occurred only when CPTs in lactone were 
loaded, resulting in a stable lactone percentages. The pH-dependent interconversion of 
lactone and carboxylate forms of CPT analogs has been widely reported; CPT in its 
lactone form was 11.7% at pH 7.6 (Fassberg and Stella, 1992), and 17% at pH 7.4 
(Burke and Mi, 1994), while both CPT-11 and SN-38 existed in lactone form for 
about 13% at pH 7.4 (Burke and Mi, 1994). In V/HepG2 cells, CPT and SN-38 
carboxylate displayed similar cytotoxicity. Compared with CPT-11 carboxylate, CPT 
carboxylate showed 24.2- and 54.3-fold higher cytotoxicity, whereas SN-38 
carboxylate exhibited 30.1- and 49.5- fold greater toxicity in V/HepG2 cells at drug 
exposure times of 4 h and 48 h respectively (Table 4-2 & Figure 4-4). It is noted that 
as the active metabolite of CPT-11, SN-38 in either lactone or carboxylate form 
showed much higher toxicity to cells than its parent drug. When the drug exposure 
time was changed from 4 h to 48 h, the ICB50 B of CPT, CPT-11, and SN-38 in 
carboxylate form in V/HepG2 cells decreased 11.7-, 5.2- and 8.5-fold respectively. 
The cytotoxicities of topotecan, rubitecan, and 10-OH-CPT in lactone form in both 
MRP4/HepG2 and V/HepG2 cells are shown in Table 4-3 and Figure 4-5. Topotecan 
lactone showed 24.1- and 14.3-fold higher cytotoxicity in V/HepG2 cells at drug 
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exposure times of 4 h and 48 h, respectively, compared with CPT-11 lactone. 
Rubitecan and SN-38 had similar cytotoxicity in V/HepG2 and MRP4/HepG2 cells 
(Table 4-2 & Table 4-3).  Rubitecan lactone exhibited 14.3- and 28.5-fold greater 
toxicity in V/HepG2 cells when the cells were exposed to rubitecan lactone for 4 h 
and 48 h respectively, compared with CPT-11 lactone. With a similar cytotoxicity of 
topotecan lactone, 10-OH-CPT displayed 19.9- and 17.8-fold higher cytotoxicity in 
V/HepG2 when the cells were exposed to 10-OH-CPT lactone for 4 h and 48 h 
respectively, compared with CPT-11 lactone (Table 4-2 & Table 4-3). Prolonged 
drug exposure time from 4 h to 48 h significantly decreased the ICB50B of topotecan, 
rubitecan, and 10-OH-CPT 3.2-, 10.6- and 4.8-fold in V/HepG2 cells respectively. 
For MRP4/HepG2 cells, the ICB50B of topotecan, rubitecan, and 10-OH-CPT decreased 
5.6-, 8.7- and 4.0-fold, respectively, when the drug exposure time was changed from 4 
h to 48 h (Table 4-3).  
MRP4 overexpression, on the other hand, conferred significant resistance to CPT, 
CPT-11, SN-38, topotecan, rubitecan and 10-OH-CPT in lactone form (7.2-, 5.6-,  
8.9-, 6.9-, 9.1- , and 14.2-fold, respectively) when the exposure time of the cells for 
the test drugs was 48 h (Figure 4-3 & Figure 4-5). At a shorter exposure time of 4 h, 
MRP4/HepG2 cells showed lower levels of resistance to CPT, CPT-11, SN-38, 
topotecan, rubitecan and 10-OH-CPT in lactone form  (5.0-, 3.5-, 8.1-, 12.0-, 7.4-, and 
11.9-fold, respectively) (Figure 4-3 & Figure 4-5). Furthermore, MRP4 rendered 1.8- 
to 9.7-fold resistance to CPT, CPT-11 and SN-38 in carboxylate form when the cells 
were exposed to the tested CPT analog for 4 h and 48 h (Figure 4-4). Based on the 
resistance folds from the MTT assays with 48 h exposure time of the test drugs, 
MRP4 conferred resistance to CPTs tested in an order of from 10-OH-CPT lactone 
(14.2) > SN-38 carboxylate (9.7) > rubitecan lactone (9.1) > SN-38 lactone (8.9) > 
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CPT lactone (7.2) > topotecan lactone (6.9) > CPT-11 lactone (5.6) > CPT 
carboxylate (4.3) > CPT-11 carboxylate (2.7). MRP4 showed the highest resistance to 
10-OH-CPT lactone, whereas CPT-11 carboxylate had the lowest resistance by MRP4 
(Table 4-2 & Table 4-3).  
The cytotoxicity effects of various CPTs tested in both V/HepG2 and MRP4/HepG2 
cells were statistically analyzed by conducting 2-way ANOVA analysis using “CPT 
analog concentration” and “Cell line” as within- and between-sample factors, 
respectively. Generally, the “CPT analog concentration” effect was significant with 
variation (P < 0.05) for all CPTs tested in this study in V/HepG2 and MRP4/HepG2 
cells, indicating that the cytotoxicity of these CPT analogs to V/HepG2 and 
MRP4/HepG2 cells was drug concentration-dependent. In addition, the “Cell line” 
effect was significant with variation (P < 0.05) for all CPTs tested with 4 h and 48 h 
drug exposure time, indicating that there were significantly different cytotoxicity 
profiles between MRP4/HepG2 and V/HepG2 cells when incubated with either of the 
test CPTs.  
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Table 4-2. Resistance profiles of CPT, CPT-11 and SN-38 in HepG2 cells overexpressing 
MRP4 or empty vector. 
 
Data are the means ± SD. Fold resistance is calculated as IC B50 B in MRP4/HepG2 cells over that 
in V/HepG2 cells. Each experiment was carried out independently at least 3 times. Two-way 









time (h) V/HepG2 MRP4/HepG2 
Fold 
resistance 
CPT-11 (lactone) 48 2.420 ± 0.053 13.6 ± 1.3PaP 5.6 
   + Celecoxib 48 2.834 ± 0.053 3.15  ± 0.50PbP 1.1 
   + Diclofenac  48 4.4 ± 1.4PbP 8.10 ± 0.82Pa,bP 1.8 
   + MK-571 48 3.09 ± 0.13PbP 6.39 ± 0.65Pa,bP 2.1 
   + BSO 48 5.39 ± 0.55 4.908 ± 0.045PbP 0.91 
CPT-11 (lactone) 4 12.9 ± 1.3 44.9 ± 8.0PaP 3.5 
   + Celecoxib 4 10.6 ± 1.1 9.9  ± 1.7Pb P 0.93 
   + Diclofenac 4 10.81 ± 0.85 12.66 ± 0.23PbP 1.2 
   + MK-571  4 12.9 ± 1.7 11.9 ± 1.9Pb P 0.92 
   + BSO 4 11.8 ± 2.0 14.4 ± 3.8Pb P 1.2 
CPT-11 (carboxylate) 48 3.91 ± 0.23 10.49 ± 0.48PbP 2.7 
 4 20.3 ± 1.2Pb P 36.1 ± 5.5Pa,b P 1.8 
SN-38 (lactone) 48 0.083 ± 0.005 0.741 ± 0.004PaP 8.9 
   + Celecoxib 48 0.086 ± 0.001 0.349  ± 0.016Pa,bP 4.1 
   + Diclofenac 48 0.091 ± 0.014 0.366 ± 0.003Pa,bP 4.0 
   + MK-571  48 0.091 ± 0.002 0.367 ± 0.003Pa,bP 4.0 
   + BSO 48 0.194 ± 0.007PbP 0.207 ± 0.010Pa,bP 1.1 
SN-38 (lactone) 4 0.948 ± 0.009 7.70 ± 0.65 8.1 
   + Celecoxib 4 0.970 ± 0.029 3.17  ± 0.13 3.3 
   + Diclofenac 4 0.97 ± 0.21 3.37 ± 0.48 3.5 
   + MK-571  4 0.938 ± 0.032 3.19 ± 0.20 3.4 
   + BSO 4 0.95 ± 0.13 1.882 ± 0.089 2.0 
SN-38 (carboxylate) 48 0.079 ± 0.007 0.766 ± 0.091PaP 9.7 
 4 0.674 ± 0.061PbP 5.53 ± 0.63Pa,bP 8.2 
CPT (lactone) 48 0.032 ± 0.001 0.231 ± 0.050PaP 7.2 
   + BSO 48 0.083 ± 0.005PbP 0.110  ± 0.013 Pa,bP 1.3 
CPT (lactone) 4 0.808 ± 0.130 4.054 ± 0.221PaP 5.0 
   + BSO   4 1.879 ± 0.017PbP 1.515 ± 0.030Pa,bP 0.81 
CPT (carboxylate) 48 0.072 ± 0.005 0.309  ± 0.021PaP 4.3 
 4 0.840 ± 0.051PbP 2.449 ± 0.294Pa,bP 2.9 
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Table 4-3. Resistance profiles of topotecan, rubitecan and 10-OH-CPT in HepG2 cells 
overexpressing MRP4 or empty vector. 
 
 
Data are the means ± SD. Fold resistance is calculated as IC B50 B in MRP4/HepG2 cells over that 
in V/HepG2 cells. Each experiment was performed carried out independently at least 3 times. 




P  < 0.05, MRP4/HepG2 vs. V/HepG2; PbP  < 0.05, test drug vs. test drug + inhibitor. 
 
 
ICB50B (µM) Drug Drug 
exposure 
time (h) V/HepG2 MRP4/HepG2 
Fold 
resistance 
Topotecan (lactone) 48 0.169 ± 0.011 1.16 ± 0.16PaP 6.9 
   + BSO 48 0.192 ± 0.016 0.403  ± 0.047 Pa,bP 2.1 
Topotecan (lactone) 4 0.537 ± 0.022 6.46 ± 0.21PaP 12.0 
   + BSO   4 0.522 ± 0.067 1.143 ± 0.040Pa,bP 2.2 
Rubitecan (lactone) 48 0.085 ± 0.012 0.77 ± 0.14PaP 9.1 
   + BSO 48 0.072 ± 0.002 0.153 ± 0.008Pa,bP 2.1 
Rubitecan (lactone) 4 0.904 ± 0.006 6.69 ± 0.36PaP 7.4 
   + BSO   4 1.036 ± 0.096 1.91 ± 0.14Pa,bP 1.8 
10-OH-CPT (lactone) 48 0.136 ± 0.005 1.929 ± 0.021PaP 14.2 
   + BSO   48 0.154 ± 0.002 0.809 ± 0.019Pa,bP 5.3 
10-OH-CPT (lactone) 4 0.651 ± 0.002 7.74 ± 0.78PaP 11.9 
   + BSO   4 0.715 ± 0.016 1.822 ± 0.037Pa,bP 2.6 
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Figure 4-3. Representative cytotoxicity profiles of lactone form of CPT, CPT-11 and SN-38 
when the cells were treated with the drug for 48 h (A, C & E) or 4 h (B, D & F) in V/HepG2 
























































































































Figure 4-4. Representative cytotoxicity profiles of carboxylate form of CPT, CPT-11 and SN-
38 when the cells were treated with the drug for 48 h (A, C & E) or 4 h (B, D & F) in 
V/HepG2 (▲) and MRP4/HepG2 (■) cells. Student’s t test was used. *P < 0.05. 
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Figure 4-5. Representative cytotoxicity profiles of lactone form of topotecan, rubitecan and 
10-OH-CPT when the cells were treated with the drug for 48 h (A, C & E) or 4 h (B, D & F) 
in V/HepG2 (▲) and MRP4/HepG2 (■) cells. Student’s t test was used. *P < 0.05. 
 
 
4.1.3. Effect of BSO on MRP4-mediated resistance to CPTs  
The observation that MRP4 is able to transport its established substrates (bis-POM-
PMEA and MTX) and CPT derivatives indicates that the substrate range of this pump 
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is quite diverse. The effects of the GSH synthesis inhibitor BSO on the cytotoxicity of 
CPT and its analogs in V/HepG2 and MRP4-expressing cells were investigated 
(Table 4-2 & Table 4-3). The addition of BSO significantly decreased the ICB50B values 
of CPT lactone (by 52.4% and 62.6% when the cells were exposed to CPT lactone for 
48 h and 4 h, respectively, Figure 4-8), CPT-11 lactone (by 64.1% and 68.0% when 
the cells were exposed to CPT-11 lactone for 48 h and 4 h, respectively, Figure 4-6) 
and SN-38 lactone (by 17.2% and 72.06% when the cells were exposed to SN-38 
lactone for 48 h and 4 h, respectively, Figure 4-7) in MRP4/HepG2 cells (Table 4-2). 
BSO also significantly reduced the ICB50B values of topotecan (by 65.2% and 82.3% 
when the cells were exposed to topotecan for 48 h and 4 h, respectively ,  rubitecan 
(by 80.1% and 71.4% when the cells were exposed to rubitecan for 48 h and 4 h, 
respectively), and 10-OH-CPT lactone (by 58.1% and 76.4% when the cells were 
exposed to 10-OH-CPT for 48 h and 4 h, respectively) in HepG2 cell expressing 
MRP4 (Table 4-3 & Figure 4-8). The pretreatment of HepG2 cells expressing MRP4 
with BSO for 24 h resulted in cytotoxicity profiles for CPT, CPT-11, SN-38, 
topotecan, rubitecan and 10-OH-CPT lactone similar to those observed with V/HepG2 
cells.  These results indicate that BSO can partially reverse the MRP4-mediated 
resistance to CPT, CPT-11, SN-38, topotecan, rubitecan, and 10-OH-CPT lactone. 
 In contrast, the presence of BSO significantly reduced the cytotoxicity of CPT and 
SN-38 lactone with respective increase of 133% to 159% in ICB50B values in V/HepG2 
cells when the cells were exposed to CPT and SN-38 for 4 h and 48 h (Table 4-2). 
This is consistent with our results with bis-POM-PMEA and MTX where reduced 
cytotoxicity was observed with the addition of BSO. BSO did not significantly affect 
the ICB50B values of CPT-11, rubitecan and 10-OH-CPT lactone when the cells were 
exposed to the CPT analog for 4 h and 48 h. It appeared that BSO had a confounding 
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effect on the cytotoxicity of CPT and SN-38 lactone in V/HepG2 cells (Table 4-2 & 
Table 4-3). The reduced cytotoxicity may be due to intracellular GSH level depletion 
caused by BSO, leading to functional modification of transporters other than MRP4   
that play an important role in the accumlation of CPTs.  
4.1.4. Effects of other inhibitors on MRP4-mediated resistance to CPT -11 & 
SN-38 
To gain insight into the effects of other known inhibitors including MK571 (Chen et 
al., 2001; van Aubel et al., 2002), celecoxib, diclofenac (Reid et al., 2003b), on 
MRP4-mediated resistance to the CPT analogs, both V/HepG2 and MRP4/HepG2 
cells were  pre-incubated with celecoxib, diclofenac, or MK571 for 2 h before 
treatment with CPT-11 and SN-38. We found that the pretreatment of these inhibitors 
significantly decreased the ICB50 B values of CPT-11 and SN-38 lactone in 
MRP4/HepG2 cells (Table 4-2). Celecoxib significantly decreased the resistance fold 
by 76.6-78.0% for CPT-11 lactone, and 52.9-58.9% for SN-38 lactone (Figure 4-6 & 
Figure 4-7). Addition of diclofenac resulted in significantly decreased ICB50 B of CPT-11 
lactone by 40.7-71.8%, and SN-38 lactone by 50.6-56.3% (Figure 4-6 & Figure 4-7). 
Furthermore, MK-571 significantly reduced the ICB50 B of CPT-11 lactone by 53.2-
73.6% and SN-38 lactone by 50.5-58.6% (Figure 4-6 & Figure 4-7).  In contrast, all 
inhibitors used had little effect on the cytotoxicity of CPT-11, SN-38 in V/HepG2 
cells (Table 4-2). 
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Figure 4-6. Effects of preincubation of cells with BSO at 200 µM, celecoxib at 50 µM, or 
MK571 at 100 µM on the cytotoxicity profiles of CPT-11 lactone when the cells were treated 
with CPT-11 for 48 h (A, C, E & G) or 4 h (B, D, F & H)  in V/HepG2 (▲) and 
MRP4/HepG2 (■) cells.  
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Figure 4-7. Effects of preincubation of cells with BSO at 200 µM, celecoxib at 50 µM, or 
MK571 at 100 µM on the cytotoxicity profiles of SN-38 lactone when the cells were treated 
with SN-38 for  48 h (A, C, E & G) or 4 h (B, D, F & H) in V/HepG2 (▲) and MRP4/HepG2 
(■) cells. Student’s t test was used. *P < 0.05. 
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*P<0.05 (MRP4/HepG2 vs. V/HepG2)
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Figure 4-8. Effects of preincubation of cells with BSO at 200 µM on the cytotoxicity profiles 
of CPT, topotecan, rubitecan, and 10-OH-CPT  lactone when the cells were treated with drugs 
for  48 h (A, C, E & G) or 4 h (B, D, F & H) in V/HepG2 (▲) and MRP4/HepG2 (■) cells. 
Student’s t test was used. *P < 0.05. 
 91 
 
4.1.5. Effect of MRP4 on the cytotoxicity of various anticancer drugs  
To examine the specificity of our cell model system, the cytotoxicity of a panel of 
anticancer agents which are established substrates for various ABC transporters was 
examined in MRP4/HepG2 and V/HepG2 cells. The ICB50B values are listed in Table 
4-4. In summary, MRP4 did not exhibit any significant resistance to vinblastine, 
vincristine, etoposide, carboplatin, norcantharidin, 5-fluorouracil, and paclitaxel, as 
indicated by similar ICB50 B values in both MRP4/HepG2 and V/HepG2 cells (Figure 
4-9 & Figure 4-10 & Figure 4-11), indicating MRP4 has no interaction with these 
drugs. There was also no significant difference in the cytotoxicity of cyclosporin A, a 
known PgP substrate (Augustijns et al., 1993; Gan et al., 1996), in the two strains of 
cells (Table 4-4), suggesting that PgP can be excluded as a transporter for CPT and its 
analogs resistance in this study. Vincristine, vinblastine and etoposide (Table 4-4) are 
typical substrates of PgP and MRP1-3 (Zeng et al., 1999; Borst et al., 2000). In 
NIH3T3 cells transfected with MRP4, no significant resistance is observed to 
etoposide, vincristine, and paclitaxel, which is consistent with our drug screening 
results (Lee et al., 2000). The possibility of other transporters instead of MRP4 
playing a role in the resistance to CPTs may thus be excluded. However, MRP4 
conferred 4.0- and 3.2-fold resistance to cyclophosphamide in cytotoxicity assays 
with 48 h and 4 h drug exposure time, respectively (Figure 4-9). A 2-way ANOVA 
analysis indicated that the cytotoxicity of cyclophosphamide to V/HepG2 and 
MRP4/HepG2 cells was drug concentration-dependent and there was significantly 
different cytotoxic profile between MRP4/HepG2 and V/HepG2 cells when incubated 
with cyclophosphamide. These initial studies indicate that cyclophosphamide may be 





Table 4-4.  Cytotoxicity of various anticancer drugs in HepG2 cells expressing MRP4 and 





time (h) V/HepG2 MRP4/HepG2 
Fold 
resistance 
Etoposide 48 0.81 ± 0.16 0.94 ± 0.18 1.2 
 4 2.50 ± 0.48 2.83 ± 0.14 1.1 
Cylophosphamide 48 10.4 ± 1.1 41.7 ± 7.3PaP 4.0 
 4 38.46 ± 0.39 121.84 ± 0.24PaP 3.2 
5-Fluorouracil 48 1.027 ± 0.056 1.07 ± 0.16 1.1 
 4 6.135 ± 0.044 6.701 ± 0.090 1.1 
Norcantharidin 48 14.9 ± 1.4 15.50 ± 0.42 1.0 
 4 24.4 ± 1.9 24.98 ± 0.48 1.0 
Carboplatin 48 5.79 ± 0.25 6.01 ± 0.56 1.0 
 4 59.5 ± 2.7 58.49 ± 2.44 0.98 
Vincristine 48 0.77 ± 0.14 0.75 ± 0.18 0.97 
 4 1.73 ± 0.40 1.80 ± 0.24 1.0 
Vinblastine 48 0.232 ± 0.025 0.288 ± 0.005 1.2 
 4 2.13 ± 0.28 2.07 ± 0.14 0.97 
Paclitaxel 48 3.548 ± 0.044 3.753 ± 0.091 1.1 
 4 21.8 ± 1.3 21.27 ± 0.56 0.98 
Cyclosporin A** 48 0.699 ± 0.144 0.754 ± 0.037 1.08 
 4 6.99 ± 0.34 7.56 ± 0.55 1.1 
 
Data are the means ± SD. Fold resistance is calculated as IC B50 B in MRP4/HepG2 cells over that 
in V/HepG2 cells. Each experiment was performed independently at least 3 times. 
P
*




P It is not an anticancer agent. 
P
a
P  < 0.05 by Student’s t test, MRP4/HepG2 vs. V/HepG2. 
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Figure 4-9. Representative cytotoxicity profiles of etoposide, cyclophosphamide and 5-
fluorouracil when the cells were treated with the drug for 48 h (A, C & E) or 4 h (B, D & F) 
in V/HepG2 (▲) and MRP4/HepG2 (■) cells. Student’s t test was used. *P < 0.05. 
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Figure 4-10. Representative cytotoxicity profiles of norcantharidin, carboplatin and 
vincristine when the cells were treated with the drug for 48 h (A, C & E) or 4 h (B, D & F) in 
V/HepG2 (▲) and MRP4/HepG2 (■) cells. 
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Figure 4-11. Representative cytotoxicity profiles of vinblastine, paclitaxel and cyclosporin A 
when the cells were treated with the drug for 48 h (A, C & E) or 4 h (B, D & F) in V/HepG2 
(▲) and MRP4/HepG2 (■) cells. 
 
 
4.1.6. Western blot analysis of related ABC transporters expression 
We also verified the protein expression of MRP4 and some related ABC transporters 
using western blot in V/HepG2 and MRP4/HepG2 cells. The protein extracted from a 
series of MDCKII cell lines with overexpression of PgP, MRP1, MRP2, MRP3 and 
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MRP5 was used as the positive control of related transporters respectively (Bakos et 
al., 1998; Evers et al., 1998; Kool et al., 1999; Scheffer et al., 2000; Wijnholds et al., 
2000). The protein from MCF/MX cells was used as the positive control of BCRP 
(Suzuki et al., 2003). The western blot results showed that MRP4 was overexpressed 
in MRP4/HepG2, and was hard to be detected in V/HepG2 (Figure 4-12). No 
detectable protein expression of other related ABC transporters, including PgP, 
MRP1, MRP2, MRP3, MRP5 and BCRP (Figure 4-12), was observed suggesting the 
exclusion of their involvements in the response difference to CPTs in the two cell 
lines. The difference of cytotoxicity of CPTs between V/HepG2 and MRP4/HepG2 is 
mainly due to the high expression level of MRP4.  
 
 
Figure 4-12. MRP4 and some related ABC transporters expression in V/HepG2 and 
MRP4/HepG2 cells. A series of MDCKII cell lines with the overexpression of PgP, MRP1, 
MRP2, MRP3 and MRP5 were used as positive controls of corresponding transporters. Each 
transporter was specifically recognized by its corresponding monoclonal antibody. Blots were 




4.2. UPTAKE AND TRANSPORT OF CPT ANALOGS BY MRP4  
We have shown in the previous section that MRP4 overexpression conferred 
significant resistance to a panel of CPTs (in both lactone and carboxylate forms), 
which could be reversed by known inhibitors using cell proliferation assays. Clearly, 
the resistance magnitude of MRP4 to some CPTs, including CPT, CPT-11, and SN-
38, is different in both the lactone and carboxylate form. This may possibly be due to 
different affinity and transport capacity of MRP4 to both forms. As this may have 
important clinical implications in the transport and disposition of CPTs given that 
CPTs undergo rapid interconversion in vivo, we thus set our second aim to 
characterize MRP4-mediated uptake, accumulation, and transport of CPT analogs.  
4.2.1. Time-dependent intracellular accumulation of CPT analogs 
Cellular Accumulation of CPT-11 and SN-38 
The accumulation of CPT-11 and SN-38 lactone in MRP4/HepG2 and V/HepG2 cells 
was examined. As shown in Figure 4-13 A & B, the intracellular accumulation of 
CPT-11 and SN-38 lactone in MRP4/HepG2 cells over 120 min was significantly 
lower than in V/HepG2 cells for most time points (P < 0.05, by ANOVA). For CPT-
11 lactone, the uptake by both V/HepG2 and MRP4/HepG2 cells achieved the 
maximum within 30 min, and then declined up to 120 min. V/HepG2 cells 
accumulated 1.3- to 2.7-fold more CPT-11 than MRP4/HepG2 cells. Notably, the 
uptake profile of SN-38 lactone was significantly different from that of CPT-11 
lactone. Maximal SN-38 uptake was rapidly achieved within 5 min in MRP4/HepG2 
and V/HepG2 cells; and then declined over the rest of the time. A similar maximum 
cellular concentration profile has been found in other cell lines, including HCT116, 
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HT29 and A2780 ovarian cancer cells, whose peak intracellular drug concentrations 
were detected at the earliest 5 min time point (Cummings et al., 2002b). Overall, 
MRP4/HepG2 cells accumulated 2.5- to 6-fold less SN-38 than V/HepG2 cells.  
Cellular Accumulation of Topotecan 
As shown in Figure 4-13 C, the intracellular accumulation of topotecan in 
MRP4/HepG2 cells over 120 min was significantly lower than in V/HepG2 cells (P < 
0.05). V/HepG2 cells accumulated 1.3- to 3.0-fold more topotecan than MRP4/HepG2 
cells. The uptake of topotecan by V/HepG2 cells achieved the peak concentration by 
10 min (1.46 ± 0.14 ng/10 P6P cells), and then declined up to 120 min. Notably, the 
uptake profile of topotecan in MRP4/HepG2 cells was significantly different from 
that in V/HepG2 cells. Maximal topotecan accumulation was rapidly achieved within 
5-10 min in MRP4/HepG2 cells and remained stable over the rest of the time (0.463 ± 
0.011 - 0.487 ± 0.02 ng/10P6 P cells). 
Cellular Accumulation of Rubitecan 
As shown in Figure 4-13 D, the intracellular accumulation of rubitecan in 
MRP4/HepG2 cells over 120 min was significantly lower than in V/HepG2 cells (P < 
0.05). V/HepG2 cells accumulated 1.3- to 2.7-fold more rubitecan than MRP4/HepG2 
cells. A similar uptake manner of rubitecan was observed in V/HepG2 and 
MRP4/HepG2 cells with the highest intracellular concentration being detected at the 
earlist time point studied (2 min). After 60 min, intracellular concentration stopped 
declining and stabilized at a level that was maintained till 120 min.  
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Cellular Accumulation of 10-OH-CPT  
As shown in Figure 4-13 E, the intracellular accumulation of 10-OH-CPT in 
V/HepG2 cells over 120 min was significantly lower than in MRP4/HepG2 cells (P < 
0.05). This result was not in agreement with the results of other CPTs (CPT-11, SN-
38, topotecan, and rubitecan). In 48 h and 4 h MTT assay, MRP4 conferred 12- to 14-
fold resistance to 10-OH-CPT in MRP4/HepG2 cells (Table 4-3). The time-
dependent cellular accumulation data did not achieve the consistent conclusion with 
the cytotoxicity profile of 10-OH-CPT. Thus, the resistance of MRP4/HepG2 to 10-























































































































































































Figure 4-13. Time-dependent intracellular accumulation of CPT-11 (A), SN-38 (B), topotecan 
(C), rubitecan (D), and 10-OH-CPT (E) lactone over 120 min in V/HepG2 (▲) and 
MRP4/HepG2 (■) cells. About 10P7P cells were exposed to CPT analogs (5 µM CPT-11 or 1 
µM SN-38, or 1 µM topotecan, or 5 µM rubitecan, or 1 µM 10-OH-CPT lactone) at 37°C. At 
indicated time, cells were rinsed with ice-cold PBS. Cells were then harvested, sonicated and 
acidified. The concentration of CPT analogs was determined by validated HPLC with 





4.2.2. Concentration-dependent intracellular accumulation of CPT analogs 
The concentration-dependent uptake of CPT analogs (0.1-10 µM CPT-11 for 30 min; 
0.05-5 µM SN-38 or 10-OH-CPT for 5 min; 0.05-5 µM topotecan for 10 min; 1-25 
µM rubitecan for 5 min) by V/HepG2 and MRP4/HepG2 was examined. The optimal 
time point for each drug was the time with the highest intracellular concentration of 
CPT analogs, which was chosen according to results of the time-dependent uptake 
assay (Figure 4-13). As shown in Figure 4-14, the uptake of CPT analogs in both cell 
lines increased rapidly in a concentration-dependent manner. The intracellular 
accumulation rate of CPT analogs in V/HepG2 increased faster than in MRP4/HepG2, 
with the exception of 10-OH-CPT. Overall, the accumulation rate of CPT-11 and SN-
38 in V/HepG2 cells was 1.2-3.0 folds and 2.1-3.1 folds higher than that in 
MRP4/HepG2 cells, respectively. The accumulation rate of topotecan and rubitecan in 
V/HepG2 cells was 1.5-8.4 folds and 2.7-6.7 folds higher than that in MRP4/HepG2 
cells, respectively. In contrast, the accumulation rate of 10-OH-CPT in V/HepG2 cells 
was lower than that in MRP4/HepG2 cells. 
MRP4-mediated efflux of CPTs was estimated by fitting the data obtained from 
subtracting the accumulation rate of CPT analogs in MRP4/HepG2 cells from that in 
V/HepG2 cells (Figure 4-15).  One-binding site model was found to give the best fit 
for the resultant data. Following the Michaelis-Menten equation, the estimated kinetic 
parameters of CPT-11, SN-38, topotecan, and rubitecan were summarized in Table 
4-5. In contrast, MRP4 exhibited a much higher affinity (or a lower KBmB value) toward 
topotecan than other CPTs examined. The highest VBmax B was observed for CPT-11, 
which was about two times of that of SN-38, and the lowest VBmax B was for topotecan. If 
the efflux activity (VBmax B/KBmB) is considered (Chu et al., 1997b), the contribution of 
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MRP4 to the efflux of CPT-11 was approximately three times higher than that of SN-
38. Topotecan efflux mediated by MRP4 was about two times of that of SN-38. 
MRP4 had lowest efflux activity for rubitecan.  
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Figure 4-14. Concentration-dependent intracellular accumulation of CPT-11 (A), SN-38 (B), 
topotecan (C), rubitecan (D), and 10-OH-CPT (E) lactone in V/HepG2 (▲) and 
MRP4/HepG2 (■) cells. About 10P7P cells were exposed to different concentrations of CPT 
analogs at 37°C. After the fixed incubation time (30 min for CPT-11; 10 min for topotecan; 5 
min for SN-38, rubitecan, and 10-OH-CPT), cells were rinsed with ice-cold PBS. Cells were 
then harvested, sonicated and acidified.  The concentrations of CPT analogs were determined 
by validated HPLC with fluorescence or UV detection. Data represent means ± SD. 
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Figure 4-15. The MRP4-mediated efflux of CPT analogs by fitting the data resulting form 
subtracting the accumulation of CPT analogs (CPT-11 (A), SN-38 (B), topotecan (C), and 
rubitecan (D) lactone) in MRP4/HepG2 cells from that in V/HepG2 cells. Data represent 
means ± SD. 
 
Table 4-5. Estimated kinetic parameters for the concentration-dependent efflux of CPT 
analogs by MRP4. 
 
Substrates K BmB (mM) V max (nmol/min/10P6 P cells ) VBmax B/KBm Bratio 
CPT-11 1166 543.3 0.466 
SN-38 1794 290.7 0.162 
Topotecan 0.0309 0.0101 0.327 





4.2.3. Effects of inhibitors on the intracellular accumulation of CPT analogs 
The effects of inhibitors on the intracellular accumulation of CPT analogs were 
examined. The data for the intracellular accumulation of CPT analogs in lactone form 
in MRP4/HepG2 cells, with the preincubation with 200 µM BSO, 50 µM celecoxib or 
100 µM MK-571, are shown in Figure 4-16. Pretreatment of the MRP4/HepG2 cells 
with 200 µM BSO for 24 h resulted in significantly (P < 0.05) increased accumulation 
of CPT-11 lactone over 30 min by 15%. Preincubation of MRP4/HepG2 cells with 
celecoxib (50 µM) or MK-571 (100 µM) for 2 h also significantly increased the 
accumulation of CPT-11 lactone by 16% and 13% (P < 0.05) over 30 min, 
respectively (Figure 4-16 A). Similarly, preincubation of BSO, celecoxib or MK-571 
significantly (P < 0.05) increased the accumulation of SN-38 lactone over 5 min in 
MRP4/HepG2 cells by 22 %, 47.0% and 86%, respectively (Figure 4-16 B). The 
accumulation of topotecan over 10 min in MRP4/HepG2 was also slightly but 
significantly increased by 11% by the preincubation of BSO. Celecoxib or MK-571 
significantly increased the accumulation of topotecan over 10 min by 72%, and 68% 
(P < 0.05), respectively (Figure 4-16 C). In contrast, BSO, celecoxib and MK-571 
showed insignificant effect on the accumulation of these three CPT analogs in 
V/HepG2 cells (99%-105%, compared with control group), and this may provide 
partial explanation for the negligible effect of inhibitors on the cytotoxicity of CPT-
11, SN-38 and topotecan in V/HepG2 cells. It is also indicated that the possible 
involement of MRP4 or other transporters, such as MRP1-3, in the cellular uptake of 
CPT-11, SN-38 and topotecan might be excluded in V/HepG2 cells. 
For rubitecan and 10-OH-CPT, BSO had no significant effect on their accumulation 
over 5 min in both V/HepG2 and MRP4/HepG2 cells (Figure 4-16 D & E). Celecoxib 
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or MK-571 significantly increased the accumulation of rubitecan over 5 min by 33%, 
and 18% (P < 0.05), respectively (Figure 4-16 D). In contrast, the accumulation of 
10-OH-CPT in MRP4/HepG2 cells was significantly decreased 62% and 47% by 
celecoxib and MK571, respectively (Figure 4-16 E). Interestingly, celecoxib and 
MK571 decreased the accumulation of rubitecan (27-49%), and 10-OH-CPT (44-
52%) in V/HepG2, respectively. There may be a competition between drugs (10-OH-
CPT and rubitecan) and inhibitors for the binding sites on cellular proteins. The fewer 
available binding sites on cellular proteins possibly led to the apparent decreased 





















































































































































Figure 4-16. Effects of of preincubation of MRP4/HepG2 cells with BSO at 200 µM, 
celecoxib at 50 µM, or MK-571 at 100 µM on the accumulation of CPT analogs (CPT-11 (A), 
SN-38 (B), topotecan (C), rubitecan (D), and 10-OH-CPT (E) lactone). Both celecoxib and 
MK-571 were prepared by dissolution in DMSO, while BSO was dissolved in water. 
Celecoxib or MK-571 was preincubated with cells for 2 h, while BSO was preincubated for 
24 h. Thereafter, cells were washed with warm PBS buffer for 4 times. After continued 
incubation for a fixed time point for CPT analogs (30 min for CPT-11; 10 min for topotecan; 
5 min for SN-38, rubitecan, and 10-OH-CPT) treated cells were washed with ice-cold PBS. 
The cells were then harvested, lysed by sonication and extracted. The concentration of CPT 
analogs was determined by validated HPLC with fluorescence or UV detetion. Data represent 
means ± SD. One-way ANOVA test was used. *P < 0.05. 
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4.2.4. Intracellular accumulation of CPT-11 and SN-38 in MRP4 mutants 
Many factors are involved in the substrate specificity of the transporters. It is of great 
interest to examine the relationship between the alterations of amino acid sequences in 
the transporters and their substrate specificity. Only limited information is available to 
date regarding the effect of amino acids position on the function properties of MRP 
family members (Deeley et al., 2006). Moreover, the relationship between amino acid 
structure and the specific transport capability of MRP4 is not clear (Russel et al., 
2008). We collaborated with Dr. Theresa Tan of Department of Biochemistry 
(National University of Singapore, Singapore) to examine the effect of amino acid 
residue change on the MRP4 function. Since MRP1 is the only member in MRPs 
family which is under extensive investigation on the structure-function relationship 
(Deeley et al., 2006), the mutants of MRP4 were designed according to the related 
information obtained from MRP1. Trp residues in different regions of MRP1 (position 
1246, 459 and 553) have been shown to affect substrate specificity and transport 
efficiency (Ito et al., 2001; Koike et al., 2002; Zhang et al., 2006).  Trp residues are 
present at position 230 and 995 of MRP4 (analogous to Trp 459, and Trp 1246 in 
MRP1) and Phe is present at position 324 (analogous to Trp 553 in MRP1). Trp (W) 
residues at position 230, 216 and 995 of MRP4 molecule were replaced by Phe (F), 
Ala (A), and Cys (C), respectively. Phe (F) at position 324 of MRP4 was substituted 
by Ala (A) and Trp (W), respectively. Plasmid constructed encoding specific mutated 
amino acids were stably transfected into HepG2 cells. Seven different HepG2 cell 
lines with tranfection of MRP4 mutants (F324A, F324W, W230A, W230F, W216A, 
W995C, and W995F) were used to detect their intracellular accumulation of CPT-11 
and SN-38, and their cytotoxicity response to CPT-11 and MTX.  
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The results of intracellular accumulation of CPT-11 and SN-38 in lactone form in 
MRP4 mutants were shown in Figure 4-17. Most mutant cell lines displayed little 
effect on intracellular accumulation of CPT-11, with the exception of W995C. 
Cellular accumulation of CPT-11 (5 µM CPT-11 over 5 min and 30 min, 1 µM CPT-
11 for 30 min) was significantly increased by 21-34% in W995C cells, compared with 
that in MRP4/HepG2 cells (Figure 4-17 A & C & E). However, all mutant cell lines 
could increase the intracellular accumulation of SN-38, compared with MRP4/HepG2. 
When cells were exposed to 1 µM SN-38 for 5 min, the intracellular accumulation of 
SN-38 was significantly increased by 85-259% in nearly all mutant cell lines except 
F324W cells (Figure 4-17 B). If the time of incubation with 1 µM SN-38 was 
extended to 30 min, four mutant cell lines, including F324A, W230A, W216A, and 
W995C, showed 111-277% significantly higher accumulation of SN-38 than 
MRP4/HepG2 (Figure 4-17 D). When cells were exposed to 0.2 µM SN-38 for 5 min, 
SN-38 accumulation was significantly increased in most mutant cell lines, excluding 
W995F (Figure 4-17 F). These findings suggest that mutant cell lines display 
different effects on drug cellular accumulation contingent on the chemical structure, 















































































































*P<0.05 (mutants vs. MRP4/HepG2)











































































*P<0.05 (mutants vs. MRP4/HepG2)
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*P<0.05 (mutants vs. MRP4/HepG2)
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Figure 4-17. Relative intracellular accumulation of CPT-11 and SN-38 in MRP4 mutants. The 
concentration of CPT-11 and SN-38 was determined by a validated HPLC method with 
fluorescence detection. Data represent means ± SD. One-way ANOVA test was used. *P < 
0.05. 
 
The relative cytotoxicity results of CPT-11 lactone for 48 h exposure and MTX for 4 
h exposure in MRP4 mutant cells (with exception of W216A cells) were shown in 
Figure 4-18. For cytotoxicity of CPT-11 in 48 h exposure, the ICB50B values in most 
mutant cell lines were significantly decreased by 30-57% compared with that in 
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MRP4/HepG2 cells, suggesting that these MRP4 mutants have significantly lower 
resistance to CPT-11 in comparison to MRP4 (Figure 4-18 A). However, W995C cell 
line had no significant difference in resistance to CPT-11 for 48 h exposure compared 
with MRP4. In MTX 4 h exposure assay, the ICB50B value in W230A cell line was 
significantly decreased by 31% of that in MRP4/HepG2 cells, whereas in F324A cells 
it was not significantly changed (Figure 4-18 B). In other MRP4 mutants, F230W, 
W230F, W995C, and W995F, their MTX ICB50B values were greatly increased to 136-
395% of that in MRP4/HepG2 cells, suggesting these mutants have significantly 
higher resistance ability than MRP4 in 4 h exposure to MTX (Figure 4-18 B). 
Because CPT-11 is converted to the active metabolite, SN-38, under long-term 
exposure, it is more accurate to compare our cytotoxicity results with the 
accumulation data of SN-38 instead of CPT-11. The lower resistance to CPT-11 
displayed in some mutants including F324A, W230A, and W230F, is considered 
consistent with higher intracellular SN-38 concentration in these mutants (Figure 


















































































Figure 4-18. Relative cytotoxicity profiles in MRP4 mutants when the cells were treated with 
CPT-11 for 48 h (A) or MTX for 4 h (B). The relative cytotoxicity percentage was calculated 
by taking the ratio of the IC B50B value of drugs in MRP4/HepG2 to that in MRP4 mutant cell 
lines and multiplying by 100%. Data represent means ± SD. Each experiment was carried out 
independently at least 3 times. One-way ANOVA test was used. *P < 0.05.  
 
4.3. EFFECT OF CPT ANALOGS ON MRP4-MEDIATED EFFLUX OF GSH 
The third aim of our study was to examine the effect of CPT analogs on MRP4-
mediated GSH efflux. CPT analogs have been identified as new substrates for MRP4. 
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GSH is a critical component in MRP4-mediated efflux and its level can greatly 
influence MRP4 transport function. GSH also plays important roles in non-MRPs-
related resistance to CPT analogs. These studies will be useful in clarifying the 
multifunction of GSH in the resistance to CPT analogs.  
4.3.1. Export of bimane-GS by MRP4 
The bimanes are a series of heterocyclic compounds that produce fluorescent adduct 
with thiols. MCB has been shown to form a fluorescent adduct with GSH specifically 
and preferentially over other thiols (Fernandez-Checa and Kaplowitz, 1990). MCB 
enters the cell via passive diffusion but within the cell, MCB is conjugated with GSH 
by cellular GST. The product hydrophilic bimane-GS product can only leave the cell 
through carrier-mediated transport (Ishikawa et al., 1994; Zhang and Wong, 1996; 
Terlouw et al., 2001). In this study, the formation and efflux of fluorescent bimane-
GS adduct was examined in MRP4/HepG2. Cells were first incubated with 100 µM 
MCB at 10°C to ensure that active efflux of the bimane-GS was totally inhibited. The 
MCB-containing medium was then replaced with HBSS containing glucose and upon 
warming to 37°C, cells preincubated with MCB showed a time-dependent efflux of 
bimane-GS. 
The percent of bimane-GS present in the incubation buffer of MRP4/HepG2 increased 
to 85% in 15 min (Figure 4-19). This is accompanied by a corresponding decrease in 
cellular bimane-GS levels. The efflux of bimane-GS from MRP4/HepG2 cells is rapid 
and tapered off after 10 min as intracellular bimane-GS level decreases and becomes 
limiting. Subsequent export assays were thus carried out after 10 min of incubation at 
37°C. In contrast, 57% of bimane-GS was exported from V/HepG2 cells after 15 min, 
which increased more gradually (Figure 4-19). Efflux of bimane-GS from V/HepG2 
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cells may possibly be mediated by other transporter proteins that are endogenously 
expressed in HepG2 cells (Roelofsen et al., 1997; Lee et al., 2000; Lee et al., 2001; 
Norris et al., 2005). Although our western blot analysis in Section 4.1.6 (Figure 4-12) 
showed that the expression level of some related ABC transporters (PgP, MRP1-3, 
MRP5 and BCRP) was undetectable V/HepG2 and MRP4/HepG2 cells, this list of 
transporters is not exhaustive and we may not exclude the presence of other 
transporters not included in this list, such as transporters of the organic anion 
transporting polypeptide (OATP) family (Ballatori et al., 2005). At all time points 
beyond 0 min, efflux of bimane-GS from MRP4/HepG2 cells was significantly higher 
than that from V/HepG2 cells (Figure 4-19).  
 


















*P<0.05 (MRP4/HpeG2 vs. V/HepG2)
 
 
Figure 4-19. Efflux of bimane-GS in V/HepG2 (▲) and MRP4/HepG2 (■). Cells were 
preincubated with medium containing 100 µM MCB. The medium was then removed and 
replaced with HBSS containing 5.6 mM glucose and incubated at 37°C. The percent efflux 
was calculated by taking the ratio of the amount of bimane-GS in the incubation buffer to that 
of the total bimane-GS (sum of bimane-GS in incubation buffer and cell lysate) and 
multiplying by 100%. All points for MRP4/HepG2 cells with the exception of that at 0 min 
were significantly different from that observed for V/HepG2 cels (*P < 0.05). Data shown are 




4.3.2. Time-dependent effects of CPT analogs and BSO on bimane-GS export 
A series of CPT analogs (5 µM of CPT-11, 1 µM of SN-38, topotecan, rubitecan and 
10-OH-CPT) were used to examine their effects on bimane-GS efflux in V/HepG2 
and MRP4/HepG2.  The assay for control group was carried out in the presence with 
1% DMSO (the solvent used for CPT analogs); whose bimane-GS efflux values in 
both cell lines were very close to those corresponding untreated cells (Figure 4-20).  
Compared with the control group (1% DMSO), the presence of CPT analogs 
displayed no significant effect on the bimane-GS efflux in both cell lines during a  
period of 15 min tested and the range was between 90-110% of the control group 
value (Figure 4-21).  
 








































Figure 4-20. Time-dependent effects of 1% DMSO on bimane-GS efflux in V/HepG2 (A) and 
MRP4/HepG2 (B). Cells were incubated in 1 ml DMEM containing 100 µM MCB at 10°C 
for 1 h together with 1% DMSO. The medium was then removed and efflux was carried out in 
HBSS/5.6 mM glucose with 1% DMSO at 37°C. Percent efflux was calculated by taking the 
ratio of the amount of bimane-GS in the incubation buffer to that of the total bimane-GS (sum 
of bimane-GS in incubation buffer and cell lysate) and multiplying by 100%. Data shown are 






























































































































































































































































































Figure 4-21. Time-dependent effects of CPT analogs on bimane-GS efflux in V/HepG2 (A, C, 
& E) and MRP4/HepG2 (B, D, & F). Cells were incubated in 1 ml DMEM containing 100 
µM MCB at 10°C for 1 h together with CPT analogs. The medium was then removed and 
efflux was carried out in HBSS/5.6 mM glucose with CPT analogs at 37°C. The 100% value 
represents bimane-GS efflux in the absence of CPT analogs. The slanting striped bars show 
the values in V/HepG2, and the black bars show the values in the MRP4/HepG2 cells. Values 




As a known GSH synthesis inhibitor, BSO could lead to the decrease of the 
intracellular GSH in HepG2 cells (Zhang et al., 2001). In this study, the effect of BSO 
on the efflux of bimane-GS efflux was also examined. The assay for control group 
was carried out in the presence with 1% water (the solvent used for BSO). The 
presence of BSO led to significant decrease in bimane-GS efflux from MRP4/HepG2 
cells (Figure 4-22). At 5 min, the exported bimane-GS in BSO-treated MRP4/HepG2 
cells was only 52% of that in control group. At 10 min and 15 min, BSO decreased 
bimane-GS efflux in MRP4/HepG2 by about 24% of control group values (Figure 
4-22). However, BSO showed little effect on the bimane-GS efflux in V/HepG2, 
which suggests that BSO might have specific interaction with MRP4. 
Correspondingly, our cytotoxicity assays showed that BSO could increase the 
sensitivity of MRP4/HepG2 cells to known MRP4 substrates (bis-POM-PMEA, 
MTX, Table 4-1), CPT and its analogs (Table 4-2 & Table 4-3).   
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Figure 4-22. Time-dependent effect of BSO on bimane-GS efflux in V/HepG2 and 
MRP4/HepG2.  Cells were seeded with the presence of 200 µM BSO. After 24 h for 
attachment, cells were preincubated with medium containing 100 µM MCB and 200 µM BSO. 
The medium was then removed and efflux was carried out in HBSS/5.6 mM glucose 
containing 200 µM BSO at 37°C. Control group consisted of cells incubated with 1% water 
(solvent used for BSO). The percent efflux was calculated by taking the ratio of the amount of 
bimane-GS in the incubation buffer to that of the total bimane-GS (sum of bimane-GS in 




4.3.3. Concentration-dependent effects of CPT analogs on bimane-GS export 
The concentration-dependent effects of CPT analogs on bimane-GS efflux in 
V/HepG2 and MRP4/HepG2 were examined at time point of 10 min.  Compared with 
the control group (1% DMSO), CPT-11 at high concentration (10 µM) led to 
significant decrease by 20% in bimane-GS in MRP4/HepG2 cells, while no 
significant decrease in bimane-GS efflux was observed in V/HepG2 cells (Figure 
4-23 A & B). SN-38 and topotecan at low concentrations (0.05 and 1 µM) had little 
effect on the bimane-GS efflux in both in V/HepG2 and MRP4/HepG2 cells. With the 
presence of 5 µM SN-38 and topotecan, MRP4/HepG2 cells also displayed no 
significant change of bimane-GS efflux (93% -103% of control group value, Figure 
4-23 D & F). However, V/HepG2 cells showed significant decrease in bimane-GS 
efflux by 15% and 22% with the presence of 5 µM SN-38 and topotecan respectively 
(Figure 4-23 C & E). The presence of 0.01-5 µM rubitecan and 10-OH-CPT had no 
significant effect on bimane-GS efflux in both cell lines at 10 min tested and the range 















































































































Figure 4-23. Concentration-dependent effects of CPT-11 (A & B), SN-38 (C & D) and 
topotecan (E & F) on bimane-GS efflux in V/HepG2 and MRP4/HepG2. Cells were incubated 
in 1 ml DMEM containing 100 µM MCB at 10°C for 1 h together with CPT analogs at 
different concentrations. The medium was then removed and efflux was carried out in 
HBSS/5.6 mM glucose with CPT analogs at 37°C for 10 min. The 100% value represents 
bimane-GS efflux in the absence of CPT analogs. The slanting striped bars show the values in 
V/HepG2, and the black bars show the values in the MRP4/HepG2 cells. Data shown are 










































































Figure 4-24. Concentration-dependent effects of rubitecan (A & B) and 10-OH-CPT (C & D) 
on bimane-GS efflux in V/HepG2 and MRP4/HepG2. Cells were incubated in 1 ml DMEM 
containing 100 µM MCB at 10°C for 1 h together with CPT analogs at different 
concentrations. The medium was then removed and efflux was carried out in HBSS/5.6 mM 
glucose with CPT analogs at 37°C for 10 min. The 100% value represents bimane-GS efflux 
in the absence of CPT analogs. The slanting striped bars show the values in V/HepG2, and the 







CHAPTER 5  DISCUSSION, CONCLUSION & FUTURE WORK 
5.1. DISCUSSION 
5.1.1. Resistance to CPTs by MRP4 
In this study, we first validated the functionality of MRP4 in the stably transfected 
HepG2 cells using bis-POM-PMEA and MTX, which are known substrates for MRP4 
(Lee et al., 2000; Dallas et al., 2004). Bis-POM-PMEA was chosen in this study as it 
first spontaneouslyP Phydrolyzed to mono-POM-PMEA (an intermediate compound 
formed during the conversion of bis-POM-PMEA to PMEA) (Hatse et al., 1998; 
Dallas et al., 2004), which is then rapidly converted to PMEA by cellular esterases 
(Srinivas et al., 1993). PMEA is also a substrate for MRP4 (Dallas et al., 2004). The 
established HepG2 cells expressing human MRP4 conferred significant resistance to 
bis-POM-PMEA when the cells were treated with bis-POM-PMEA for 4 h and 48 h 
and the presence of the GSH synthesis inhibitor BSO partially reversed the resistance 
in the present study (Table 4-1). As reported, intracellular conversionP Pefficiency of 
bis-POM-PMEA in vitro to PMEA is in the orderP Pof 80-90% for initial substrate 
concentrations of 0.125-1.0 µM (Robbins et al., 1995; Wijnholds et al., 2000), and we 
presume that the observed cytotoxicity for bis-POM-PMEA is due to the action of 
PMEA. Since PMEA does not appear to be a substrate for PgP, MRP1 or BCRP (Reid 
et al., 2003a; Dallas et al., 2004), nor does it interact with typical substratesP Pfor 
MRP1-3 (McAleer et al., 1999; Lee et al., 2000), the observed resistance to bis-POM-
PMEA by MRP4/HepG2 cells is thus mediated by MRP4.  
As for MTX, MRP4 displayed resistance which was reversed by BSO when the drug 
exposure time was 4 h only, but not when the drug exposure time was prolonged to 48 
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h (Table 4-1). The resistance level of MRP1-4 to MTX seemed to be strictly time-
dependent, and associated with the schedule of MTX exposure. Various studies have 
shown that MRP1-4 had high resistance capacity to MTX when the drug exposure 
was limited to 1-4 h of a 3-day growth assay, whereas little resistance to MTX was 
conferred in a standard continuous exposure assay (Hooijberg et al., 1999; Kool et al., 
1999; Zeng et al., 1999; Lee et al., 2000; Zeng et al., 2001; Chen et al., 2002). This 
may be explained by the unique metabolic processes that MTX undergoes in the cells. 
MTX is a monoglutamate and enters the cells through the reduced folate carrier (RFC) 
(Dixon et al., 1994). Thereafter, up to six γ-linked glutamate residues is enzymatically 
added by folylpolyglutamate synthetase (FPGS), converting MTX to its 
polyglutamylated forms inside the cells, which results in its therapeutic action of 
inhibiting the enzyme dihydrofolate reductase (DHFR) (Hooijberg et al., 1999; Kool 
et al., 1999). Notably, the polyglutamated forms of MTX are not transported by MTX 
efflux pumps, though monoglutamated forms have been shown to be substrates. For 
instance, MRP1 and MRP3 have been shown to be high capacity, low affinity MTX 
efflux pumps, which have little or no activity to MTX polyglutamates (Zeng et al., 
2001). Similarly, MRP2 and MRP4 are also unable to transport MTX polyglutamates 
out of cells (Chen et al., 2002). Due to the slow polyglutamylation of MTX, cells with 
overexpression of one of these MTX efflux pumps can transport MTX 
monoglutamate out of cells after short-term exposure to MTX. The rest of MTX 
accumulates in cells in its long-chain polyglutamylated forms, whose concentration is 
low because the short-term MTX exposure schedule doses not provide sufficient 
conversion time. However, with longer duration of drug exposure, polyglutamylated 
metabolites of MTX accumulate to concentrations sufficient to kill cells. This 
essentially explains our observations with MTX.  
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Our results with bis-POM-PMEA and MTX in MRP4/HepG2 cells are consistent with 
those reported in other cell systems with the exogenous overexpression of MRP4 
(Schuetz et al., 1999; Lee et al., 2000; Reid et al., 2003a). To name a few examples, 
resistance to PMEA by human T-lymphoid selected cell line CEM-r1 has been 
identified resulting from ATP-dependent PMEA efflux mediated by MRP4 which was 
overexpressed in cells (Schuetz et al., 1999). The time required for the intracellular 
concentration of the PMEA to decrease to half of its initial values (tB1/2B) in CEMss cells 
was about 5.9-fold longer than that in  CEM-r1 cells, after  both cell lines have been 
incubated with 1 µM bis-POM-PMEA for 1 h. Moreover, the rate of PMEA efflux in 
CEM-r1 cells was significantly decreased under ATP-depleting condition, but not in 
CEMss. In cytotoxicity assay, CEM-r1 cells showed 250-fold higher resistance to 
PMEA than CEMss cells (Schuetz et al., 1999). In another report, MRP4-transfected 
NIH3T3 cells displayed a modest higher resistance (2.3-fold) to PMEA than parental 
vector-transfected NIH3T3 cells (Lee et al., 2000). Similarly, MRP4 overexpression 
in HEK293 cells conferred significant resistance to bis-POM-PMEA and PMEA in 
cytotoxicity assay (Reid et al., 2003a). In all these reports, MRP4 was verified to 
transport PMEA in its unchanged form. MRP4 inhibitors, including MK571, 
dipyridamole and dilazep, could inhibit MRP4-mediated PMEA efflux (Reid et al., 
2003a). Similarly for MTX, MRP4-mediated resistance has been studied in a variety 
of cell lines. Transfection of MRP4 increased the resistance of NIH3T3 cells to MTX 
by 5.5-fold in short-term drug exposure assays and decreased intracellular 
accumulation of MTX at 4 h and 24 h (Lee et al., 2000). In general, MTX is subject to 
high capacity and low affinity transport by MRP4 (Chen et al., 2002). 
Besides MRP4, other ABC transporters are also components of bis-POM-PMEA, 
PMEA and MTX efflux system. As another efflux pump for PMEA, MRP5 is able to 
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transport PMEA in an unmodified form (Wijnholds et al., 2000). PgP, MRP1-3 and 
BCRP are all involved in resistance to MTX (Norris et al., 1996; Hooijberg et al., 
1999; Kool et al., 1999; Volk et al., 2000). In contrast to MRP1-4, BCRP is able to 
mediate the transport of MTX polyglutamates (Volk and Schneider, 2003). Both 
MTX-Glu(2) MTX-Glu(3) are substrates for BCRP, although the decreased efflux 
correlates with the increased polyglutamate chain length (Volk and Schneider, 2003). 
The capacity to transport MTX-polyglutamates may account for the high levels (> 
100-fold) of BCRP-mediated resistance to MTX in the long-term assay (7-day)  (Volk 
et al., 2000). Thus, similar MTX cytotoxicity values in V/HepG2 and MRP4/HepG2 
cell at 48 h exposure suggest that BCRP may not be involved in the MTX resistance. 
Moreover, expression levels of these ABC transporters in model cell lines, V/HepG2 
and MRP4/HepG2, are too low to be detected in western blot analysis, which further 
exclude their effects in resistance to bis-POM-PMEA and MTX. On the other hand, 
the expression of MRP4 is very high in MRP4/HepG2 cells, but undetectable in 
V/HepG2 cells, according to our western blot analysis result (Figure 4-12). The 
resistance to bis-POM-PMEA and MTX observed in MRP4/HepG2 can thus be 
attributed to overexpression of MRP4, suggesting MRP4/HepG2 has normal MRP4 
transport function. 
CPTs clearly represent an important group of anticancer drugs developed in the last 
few decades. A wealth of information has become available that has yielded valuable 
insight into their mechanism of action, pharmacokinetics, toxicities, and tumor 
resistance. Resistance to CPTs is a major clinical problem often resulting in 
therapeutic failure. Detailed investigations aimed at identification of resistant proteins 
and approaches circumventing intrinsic drug resistance are thus warranted. Our 
cytotoxicity data is novel evidence that MRP4 conferred significant resistance to 
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various CPTs including both lactone and carboxylate forms of CPT, CPT-11 and SN-
38, and the lactone form of topotecan, rubitecan and 10-OH-CPT (Table 4-2 & Table 
4-3). The addition of BSO, a GSH synthesis inhibitor, significantly reversed MRP4-
mediated resistance to these CPTs. This indicated that GSH played an important role 
in MRP4-mediated efflux of CPTs. Other inhibitors, including celecoxib, diclofenac, 
and MK-571, also significantly reduced the resistance to CPT-11 and SN-38 in 
MRP4/HepG2 cells. Estimated from the resistance folds for the MTT assay with 48 h 
drug exposure time of the test CPTs (Table 4-2 & Table 4-3), the substrate affinity of 
MRP4 appears to decrease from 10-OH-CPT lactone (14.18)>SN-38 carboxylate 
(9.70)>rubitecan lactone (9.05)> SN-38 lactone (8.91)>CPT lactone (7.22)>topotecan 
lactone (6.86)>CPT-11 lactone (5.64)> CPT carboxylate (4.29)>CPT-11 carboxylate 
(2.68). 10-OH-CPT lactone seems to have the highest affinity to MRP4, whereas 
CPT-11 carboxylate might have the lowest affinity. These observations have 
important implications in the clinical setting for drug combination therapy and 
administration route design. At the same time, there should be an awareness of the 
interaction with MRP4 in the further development of CPTs which should gear towards 
the synthesis of new CPT analogs without binding affinity to MRP4. 
The resistance magnitude of MRP4 to CPT, CPT-11 and SN-38 in lactone and 
carboxylate form is different (Table 4-2). Thus, MRP4 is considered to have different 
affinity and transport capacity to their lactone and carboxylate form. This may have 
important implications in the transport and disposition of these CPT analogs given 
that CPTs undergo rapid interconversion in vivo. The half-life of CPT, CPT-11 and 
SN-38 lactone varies from 29-32 min at pH 7.3 and the equilibrium lactone content is 
approximately 15% to 23% (Chourpa et al., 1998). SN-38, both lactone and 
carboxylate forms exist considerably in vivo, with the lactone accounting for 54−64% 
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of the total area under the plasma concentration versus time curve (Rivory et al., 
1994; Sasaki et al., 1995). The lactone and carboxylate of CPTs possess different 
affinities for drug transporters. CPT-11 and SN-38 lactone were both passively 
transported with significantly more being rapidly taken up than their carboxylate 
forms in HT29 cells, whereas their respective carboxylate forms were primarily 
transported via an ATP-dependent mechanism (Kobayashi et al., 1999). Similarly, the 
intestinal uptake of CPT-11 and SN-38 lactone is about 10 times greater than that of 
the carboxylate form (Kobayashi et al., 2001). Active uptake of the CPT-11 
carboxylate instead of lactone was also observed in KB-C2 membrane vesicles (Chu 
et al., 1999b). MRP2 is responsible for theP Pbiliary excretion of the carboxylate form of 
CPT-11 and SN-38 as well as the lactone and carboxylate forms of SN-38 
glucuronide in rats (Chu et al., 1997a; Chu et al., 1997b).  
In our study, the lactone form of CPT, CPT-11 and SN-38 displayed different 
cytotoxicities compared with their corresponding carboxylate form (Table 4-2). 
V/HepG2 cells were more sensitive to CPT lactone form (ICB50B: 0.032 ± 0.001 µM) 
than its carboxylate form (ICB50 B: 0.072 ± 0.005 µM) in 48 h drug exposure (Table 4-2). 
This may be attributed to the fact that CPT in carboxylate form has lower activity than 
in lactone form, and once bound with proteins in the cell culture medium, the 
carboxylate form could not easily convert back to the lactone form. With the 
exception of SN-38 and CPT-11, it has been found that CPT and most CPT analogs 
had a stronger binding ability to HSA in negatively charged carboxylate form than in 
lactone form (Burke and Mi, 1993; Mi and Burke, 1994b; Prijovich et al., 2003).  
Moreover, only the free drug (unbound to protein) is primarily responsible for drug 
activity. The structure of CPT carboxylate bound to protein will be much bigger than 
the free CPT carboxylate, leading to difficulty in transport through cell membrane by 
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passive diffusion. On the other hand, CPT in free lactone form enters cells easily and 
is able to exert higher cytotoxicity than CPT carboxylate, which needs additional 
conversion to the lactone form in cells. In V/HepG2 cells, the cytotoxicity difference 
between CPT lactone and CPT carboxylate in 48 h exposure was 2.3-fold, while the 
difference decreased to 1.0-fold in 4 h exposure. This may be explained by short drug 
exposure time which is not sufficient for the drug to fully exert its toxicity. For 
MRP4/HepG2 cells, CPT lactone displayed significantly lower cytotoxicity than CPT 
carboxylate in 4 h drug exposure, which may be explained by the fact that MRP4 
showed higher resistance to  CPT lactone (7.2) than to CPT carboxylate (4.3) (Table 
4-2). The cytotoxicity difference in 48 h exposure between CPT lactone and 
carboxylate in V/HepG2 cells (2.3-fold) was much higher than that in MRP4/HepG2 
(1.3-fold) (Table 4-2), which may be explained by the higher resistance to CPT 
lactone by MRP4 overexpression in MRP4/HepG2 cells.  
Looking at the effect of SN-38, we noted a similar response to both the lactone form 
and carboxylate form in 48 h exposure assay  in both V/HepG2 (ICB50 B: 0.083 ± 0.005 
µM vs. 0.079 ± 0.007 µM) and MRP4/HepG2 (ICB50B: 0.741 ± 0.004 µM vs. 0.766 ± 
0.091 µM) (Table 4-2). In contrast, SN-38 lactone showed higher ICB50 B value than SN-
38 carboxylate in both V/HepG2 (ICB50 B: 0.948 ± 0.009 µM vs. 0.674 ± 0.061 µM) and 
MRP4/HepG2 (ICB50B: 7.70 ± 0.65 µM vs. 5.53 ± 0.63 µM) for 4 h drug exposure 
(Table 4-2), suggesting that SN-38 carboxylate is more potent than lactone. For 
V/HepG2, the concentration of unchanged SN-38 lactone in cell culture medium may 
have been decreased by its binding to protein, and less SN-38 molecules in lactone 
form are available to enter into cells. Although SN-38 lactone form has higher 
cytotoxicity than SN-38 carboxylate, SN-38 carboxylate in free form may enter cells 
and be transformed to active lactone form and display corresponding cytotoxicity. 
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This provides explanation for short duration of exposure, but for longer duration, the 
action of SN-38 carboxylate may not have been sustained because the equilibrium 
between lactone form and carboxylate form has sufficient time to shift according to 
the environment. This may also have been the case for MRP4/HepG2 cells, whereby a 
similar resistance level to SN-38 lactone (8.9) and SN-38 carboxylate (9.7) (Table 
4-2) has been observed.  
For CPT-11, its lactone form displayed higher cytotoxicity than its carboxylate form 
in V/HepG2 cells at 4 h and 48 h assay. CPT-11 lactone has a stronger binding ability 
to protein than CPT-11 carboxylate. Although CPT-11 carboxylate mainly exists as 
free form, it is still difficult to enter cells very quickly like SN-38 carboxylate, 
because CPT-11 structure is much bigger. Moreover, both lactone and carboxylate 
forms of CPT-11 are able to convert to corresponding lactone and carboxylate forms 
of SN-38.  As the products of CPT-11 metabolism, SN-38 lactone has higher stability 
than SN-38 carboxylate in cell culture medium with the binding to protein. As such, 
the conversion of CPT-11 lactone to SN-38 lactone will be easier to proceed than the 
conversion of CPT-11 carboxylate to SN-38 carboxylate, leading to higher 
concentration of SN-38 lactone than that of SN-38 carboxylate. Besides its own 
activity, the final cytotoxicity of CPT-11 lactone showed in V/HepG2 cells is also 
attributed to SN-38 lactone produced by CPT-11 lactone metabolism. All these factors 
may contribute to the reason why CPT-11 lactone showed higher toxicity than CPT-
11 carboxylate in V/HepG2 cells. As a result of being a more effective substrate, 
MRP4 showed higher fold resistance to CPT-11 lactone (5.6) than CPT-11 
carboxylate (2.7) (Table 4-2). 
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Efficient transportP Pof some substrates by several of the MRP protein family members, 
such as MRP1, MRP2, MRP4 and MRP5 also requires physiological concentrations 
of the antioxidantP PGSH which is co-transported with another substrate (Paulusma et 
al., 1999; Wijnholds et al., 2000; Lai and Tan, 2002). Similarly, P Pin MRP4-
overexpressing HepG2 cells used in the present study, GSH depletion by BSO (200 
µM) significantly reversed the resistance to bis-POM-PMEA, MTX and CPTs (Table 
4-1 & Table 4-2 & Table 4-3). When high concentration of BSO (500 µM) was used, 
MRP4-transfected HepG2 cellsP Pshowed altered drug resistance in the presence of 200-
400 µM P P MEA (Lai and Tan, 2002). However, GSH does not appearP Pto play a 
significant role in PMEA efflux in MRP4-overexpressing HEK293 (Wielinga et al., 
2003) cells or rat microglial MLS-8 cells (Dallas et al., 2004). The reasons for such 
discrepancies in effects ofP PGSH are unclear, but the differences in cell lines used, 
intracellular GSH levels, and MRP4 and other transporter levels may be involved. 
There is a possibility that other transporters instead of MRP4 play a role in the 
resistance to CPTs observed. However, PgP is excluded as a transporter for CPT 
resistance in this study by the fact that there was no difference in the ICB50B of paclitaxel 
(a known PgP substrate) in MRP4/HepG2 and V/HepG2 cells (Table 4-4). This is 
further supported by the similar ICB50B values in the two strains of cells with cyclosporin 
A, a known PgP substrate (Gan et al., 1996). Furthermore, our study did not find 
resistance of MRP4 to vincristine, vinblastine and etoposide (Table 4-4) which are 
typical substrates of PgP and MRP1-3 (Borst et al., 2000; Borst and Elferink, 2002). It 
has been reported that MRP4 does not interact with typical substratesP Pof MRP1-3, 
including vincristine, etoposide, daunorubicin, andP Pcisplatin (McAleer et al., 1999; 
Lee et al., 2000). Moreover, the involvement of some related ABC transporters, 
including PgP, MRP1, MRP2, MRP3, MRP5 and BCRP, could be excluded by their 
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undetectable expression level in both cell lines (Figure 4-12). The overexpression of 
MRP4 in MRP4/HepG2 cells (Figure 4-12) further supports that the resistance to 
CPTs observed in this study is mediated by MRP4 which is functionally distinct from 
other transporter proteins.  
In conclusion, our results in the first part of our study indicate that CPTs are part of 
the MRP4 resistance profile. The findings from MTT assays highly indicate the 
possibility that CPTs used in this study are substrates for MRP4 transporter. This is 
supported by the following: a) MRP4/HepG2 cells had lesser sensitivity to both 
lactone and carboxylate forms of CPT, CPT-11 and SN-38, and the lactone form of 
topotecan, rubitecan and 10-OH-CPT than V/HepG2 cells; b) the resistance to CPTs 
in MRP4/HepG2 cells was inhibited by BSO; c) the resistance to CPT-11 and SN-38 
in MRP4/HepG2 cells was inhibited by celecoxib, diclofenac and MK-571; d) MRP4 
was only highly expressed in MRP4/HepG2 cells; and e) some ABC transporters (PgP, 
MRP1, MRP2, MRP3, MRP5 and BCRP) which showed resistance to CPTs were not 
detected in both V/HepG2 and MRP4/HepG2 cells by western blot analysis.  Our new 
finding that MRP4 may interfere with the therapeutic efficacy of CPTs creates a new 
awareness in the successful management of patients undergoing CPT-related 
anticancer therapies.  
5.1.2. Uptake and transport of CPT analogs 
Targeting Top1 to kill tumor cells requires high enough intracellular accumulation of 
the active lactone form of CPTs. Inadequate accumulation of CPTs in tumor cells is 
considered an important reason for their resistance. The mechanism for the uptake of 
CPTs by HepG2 cells is unknown, but both active and passive transport are 
implicated.  CPT-11 and SN-38 can be readily taken up by human intestinal Caco-2 
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cells through passive diffusion (Gupta et al., 2000), while the influx of topotecan and 
SN-38 by ovarian tumor cells requires active transporters and disrupted influx results 
in drug resistance (Ma et al., 1998). To date, CPTs have been shown to be substrates 
for various transporters including PgP, BCRP, OATP1B1, MRP1 and MRP2 (Yang et 
al., 1995; Chu et al., 1997b; Luo et al., 2002; Nozawa et al., 2005). Its relationship 
with MRP4 has also now been reported herein. The different accumulation of CPT 
analogs in MRP4/HepG2 and V/HepG2 cells (Figure 4-13) provides partial 
explanation for the different cytotoxicities observed and contributes to the acquisition 
of resistance in vitro. The undetectable expression of some related ABC-transporters, 
including PgP, MRP1, MRP2, MRP3, MRP5 and BCRP, excluded their interaction 
with CPT analogs. The different intracellular concentrations of CPT analogs in 
V/HepG2 and MRP4/HepG2 cells can be mainly attributable to the high expression 
level of MRP4 in MRP4/HepG2 cells.   
The differential accumulation cannot be attributed to the damage of the plasma 
membrane, which in turn could lead to increased drug influx, given that the tumor 
cells remained viable during our drug accumulation studies over 120 min as measured 
using trypan blue exclusion. The differential uptake manner of various CPT analogs 
tested in this study are mainly due to differences in their lipophilicity, transport across 
cell membrane, steric hindrance of chemical structures, and binding affinity to MRP4. 
In this study, the detection of intracellular CPT analogs accumulation did not 
distinguish between the active lactone form (the parent drug) and the inactive 
carboxylate form (the chemical hydrolysis product of corresponding lactone form). 
Our time-dependent accumulation studies of CPT analogs in V/HepG2 and 
MRP4/HepG2 led us to conclude that a different set of dynamics operates for the 
compounds in cells. It appears that CPT analogs with small chemical structures (SN-
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38, rubitecan and 10-OH-CPT) reached the peak intracellular level faster (within 5 
min) than the analogs with bigger chemical structures (CPT-11 and topotecan, 10-30 
min). Significant difference in intracellular accumulation was observed at the earliest 
time point studied (2 min) for SN-38, rubitecan and 10-OH-CPT, but not for CPT-11 
and topotecan. The rate of chemical degradation of the parent lactone form to the 
carboxylate form in the extracellular culture medium appears to be one of major 
determinants behind intracellular accumulation, perhaps because only the lactone 
forms are being taken up into cells predominantly by passive diffusion, as previously 
reported for normal intestinal cells (Gupta et al., 2000; Cummings et al., 2002b). At 
physiological pH, the extracellular lactone concentration decreases rapidly over the 
first 30 min of incubation, as chemical equilibrium favours the carboxylate form 
(Fassberg and Stella, 1992; Cummings et al., 2002b). This may partly explain why 
peak intracellular drug concentrations of small CPT analogs (SN-38, rubitecan and 
10-OH-CPT) were detected within the first few minutes of incubation in our cell lines. 
Similar accumulation profiles of SN-38 lactone were also reported in a number of 
cancer cell lines (Gabr et al., 1997; Kobayashi et al., 1999; Cummings et al., 2002b). 
For example, the highest intracellular SN-38 concentrations were observed at the 
earliest time point 5 min in three cell lines, HCT116 and HT29 colon cancer cells and 
A2780 human ovarian cancer cells (Cummings et al., 2002b). On the other hand, the 
observation may be attributable to the following: CPT-11 and topotecan tend to enter 
tumor cells at a moderate rate, and are then distributed within cells and bound by 
subcellular organelles, drug metabolizing enzymes located on endoplasmic reticulum 
and drug target in nucleus (Top 1), which in turn act as a store for the active drug. The 
drug is finally cleared from the cells by metabolism and transporter-mediated efflux. 
In contrast, small CPT analogs (SN-38, rubitecan and 10-OH-CPT) tend to enter cells 
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more rapidly and are also removed from the cells just as rapidly. This may be due to 
the steric hindrance difference between the small functional groups of SN-38, 
rubitecan and 10-OH-CPT and the bigger ones of CPT-11 and topotecan.  
Moreover, differential lipophilicity of CPT analogs can result in different uptake, 
subcellular compartmentation, metabolism and efflux of drugs. For example, 
topotecan is mainly localized in mitochondria when incubated with HT29 cells, while 
gimatecan (ST1481, a water-insoluble CPT analog) is mainly distributed into 
lysosomes (Croce et al., 2004). Furthermore, it has been indicated that the lipid 
bilayer membrane affinities of the CPTs should be important determinants influencing 
cellular uptake and cytotoxic potency of CPTs, because a number of CPTs are 
accumulated in cancer cells by passive diffusion (Gabr et al., 1997). Increased 
lipophilic character of CPTs allows for more extensive membrane transport, thereby 
results in greater levels of accessibility and drug accumulation by cancer cells at the 
tumor site (Gabr et al., 1997). The difference in lipophilicity of CPTs might lead to 
the difference in the degree of penetration of a drug into the lipid bilayer domains of 
MRP4-containing membranes. Such a difference in lipid bilayer location may 
potentially, at least in part, explain the observed differences between the CPT analogs 
in their degrees of transport by the protein. For example, different uptake rate and 
extent of CPT-11 and SN-38 have been observed in intestinal and lung cancer cells 
(van Ark-Otte et al., 1998; Chu et al., 1999b). Metabolism is also considered an 
important determinant for the cellular accumulation of CPT-11 and SN-38. CPT-11 is 
hydrolyzed by cellular CEs, whereas SN-38 is readily conjugated by UGT1A1/1A9 
which is associated with increased efflux of the drug from HT29 and HCT116 cells 
(Cummings et al., 2002a). The human colon cancer cell line HT29 also exhibited a 2-
fold intrinsic resistance to SN-38 owing to enhanced drug clearance via 
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glucuronidation, compared with A2780 ovarian cancer cells (Cummings et al., 2003). 
The determination of the Michaelis-Menten parameters will be entirely dependent on 
the experimental conditions (Rivory et al., 1996a). The kinetics reported in this study 
was limited to the examination of CPT analogs in the mixture of lactone and 
carboxylate forms found at physiological pH, mostly existing as the carboxylate form. 
The carboxylate forms of CPTs carry a full negative charge and can hardly diffuse 
across the membrane, if there is no involvement of an active organic anion transporter 
(Kobayashi et al., 1999; Gupta et al., 2000). Thus, intracellularly carboxylate form of 
CPT analogs is likely to be derived from in situ hydrolysis of the corresponding 
lactone (Kobayashi et al., 1999). 
It did not preclude the possibility that the lactone and carboxylate forms of CPTs 
compete for a single binding site and/or that there is a difference between the cleavage 
rates of the two forms. Due to the higher lipophilicity, the lactone form of CPTs is 
likely to enter the cells easier and faster than the corresponding carboxylate form. If 
the efflux rate obtained in the uptake assay is considered (Chu et al., 1997b), the 
contribution of MRP4 to the efflux of CPT-11 was approximately three times higher 
than that of SN-38. Topotecan efflux mediated by MRP4 was about two times of that 
of SN-38. MRP4 had lowest efflux activity for rubitecan. However, the sequence of 
substrate fold resistance obtained from the cytotoxicity in the 48 h drug (lactone form) 
exposure (Table 4-2 & Table 4-3) was: rubitecan (9.1) > SN-38 (8.9) > topotecan 
(6.9) > CPT-11 (5.6). There is clearly discordance in data obtained from the 
cytotoxicity and uptake assays. This discrepancy may be attributed to the difference in 
the incubation periods. The cytotoxicity effect of CPT analogs was determined after a 
continuous drug exposure for 48 h, whereas the accumulation data were determined 
after an incubation of 30 min for CPT-11, 10 min for topotecan, and 5 min for SN-38 
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and rubitecan. It appears that the effect of CPT analogs in the accumulation assays 
occurred only in an acute manner but was not sustained in chronic periods of 48 h of 
cytotoxicity assays. In longer periods of drug exposure, factors such as equilibrium of 
lactone and carboxylate inside and outside the cells, interaction of CPTs with the 
target Top 1, and interaction of CPTs with cellular proteins come into play to 
influence our results (Beretta and Zunino, 2007). We also cannot rule out rapid 
cellular metabolism of the CPTs in question leading to limited effects over longer 
periods of time. 
In this study, the accumulation of rubitecan in MRP4/HepG2 cells was increased by 
celecoxib and MK571 (Figure 4-16), which are known inhibitors of MRP4 that 
reversed drug resistance in cytotoxicity assays. Celecoxib and MK571 were able to 
directly block MRP4-mediated transport, leading to decreased efflux of rubitecan out 
of cells and consequent increase in drug accumulation. On the contrary, celecoxib and 
MK571 significantly decreased 10-OH-CPT accumulation in MRP4/HepG2 cells. 
Several reports have presented the assumption that MK571 is able to modulate MRP-
mediated drug resistance via direct interaction with transporters and serves as 
competitor with substrates in protein binding (Jedlitschky et al., 1994; Leier et al., 
1994; Renes et al., 1999). Moreover, MRP4 has been proposed to have multiple 
allosteric binding sites (Van Aubel et al., 2005). It is possibly because that celecoxib 
and MK571 might inhibit an uptake transporter on the cell membrane thereby 
inhibiting the entry of 10-OH-CPT into cells through the membrane. If the effect of 
celecoxib and MK571 is bigger on drug influx than on drug efflux, the intracellular 
concentration of drug may become lower. On the other hand, BSO showed no 
significant effect on rubitecan or 10-OH-CPT uptake in MRP4/HepG2 cells (Figure 
4-16). BSO is able to reduce MRP4-mediated efflux by lowering GSH cellular level. 
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Although GSH is needed by a number of MRP4 substrates, it is not clear if the same 
applies for rubitecan or 10-OH-CPT. If GSH is not necessary component in their 
efflux mediated by MRP4, the final effect of a decrease of GSH level by BSO would 
not be as expected.  
For other CPT analogs (CPT-11, SN-38 and topotecan), all inhibitors (celecoxib, 
MK571 and BSO) were able to increase their accumulation in MRP4/HepG2 cells. 
These findings strongly suggest that MRP4 overexpression significantly decreases the 
cellular accumulation of CPT analogs and it is involved in the resistance to CPTs. 
This is consistent with previous reports, which also showed that reduced accumulation 
and/or increased drug efflux is a component of resistance to CPT analogs, including 
CPT-11 and topotecan (Chen et al., 1991; Chen et al., 1999; Shiozawa et al., 2004).  
Moreover, the inhibitory effects of BSO indicate that GSH is an important component 
of the MRP4-mediated transport system.  
Notably, there have been some reports on such inconsistency between accumulation 
and cytotoxicity data with some CPT analogs and the implication of MRP family 
transporters (Chen et al., 1999; Cummings et al., 2002b). In MTT assays, C-A120 and 
KB/MRP cells with the overexpression of MRP1 showed 6.5- to 29.6-fold resistance 
to CPT-11 and SN-38 compared to the parental KB-3-1 cells (Chen et al., 1999). 
Consistent with the cytotoxicity results, the accumulation of CPT-11 and SN-38 in C-
A120 and KB/MRP was lower than in KB-3-1 cells at low dose exposure. However, 
when the doses of drugs were increased near to their ICB50B values, the accumulation 
levels of CPT-11 and SN-38 in C-A120 became 3- to 5-fold higher than in KB-3-1 
which did not correlate with the cytotoxicity data (Chen et al., 1999). Similarly, 
Cummings et al showed that SN-38 and CPT exhibited an unexpected cellular 
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accumulation phenomenon in HCT116 cells with the overexpression of MRP2 
(Cummings et al., 2002b). SN-38 is an established MRP2 substrate (Chu et al., 1997a; 
Chu et al., 1997b; Koike et al., 1997) and the cellular accumulation of SN-38 is 
expected to be significantly lower in the control cell line, A2780 human ovarian 
cancer cells, which do not have any expression of MRP1, MRP2, or PgP. 
Interestingly, however, the cellular accumulation profile of SN-38 over 20 h was 
similar in both HCT116 cells and A2780 cells. At the 24 h time point, the HCT116 
cells accumulated about 2 times more SN-38 than A2780 cells. It is concluded that  
the contribution of MRP2 expression to cellular accumulation of SN-38 is of less 
importance, although it is considered as a critical determinant (Cummings et al., 
2002b). 
In our context, the discrepancy between 10-OH-CPT accumulation and cytotoxicity 
may be attributed to the difference in drug incubation periods. The cytotoxic effect 
was determined after a continuous exposure for 48 h or a short exposure for 4 h with 
another 44 h of growth, whereas the accumulation data was determined after 
incubation for 2 min to 120 min. Although 10-OH-CPT accumulated to a greater 
extent in MRP4/HepG2 than V/HepG2 cells for a test period of up to 2 h, these effects 
may have occurred only in an acute manner and not sustained at more prolonged 
periods as those used for cytotoxicity assays, hence the retention of cellular resistance 
against 10-OH-CPT at 4 h and 48 h.  Moreover, intracellular accumulation is mainly 
determined by the balance between the influx and efflux of the drug, and affected by 
binding to proteins and organelles. 10-OH-CPT, especially in carboxylate form, has 
been found to be  highly bound to plasma and tissue protein (Li and Zhang, 1996). 
The higher intracellular accumulation of 10-OH-CPT in MRP4/HepG2 might partly 
be attributed to the specific binding between the carboxylate form of 10-OH-CPT and 
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MRP4 membrane protein. It is also possible that some unidentified influx-related 
factors that play a predominant role at early time points. Further experiments are 
required to fully elucidate the mechanisms responsible for these differences. 
Last but not least, we have also performed uptake assays of CPT-11 and SN-38 in 
various MRP4 mutants. As mentioned in section 4.2.4, Trp residues in different 
region of MRP1 (position 1246, 459 and 553) have been shown to affect substrate 
specificity and transport efficiency (Ito et al., 2001; Koike et al., 2002; Zhang et al., 
2006). Corresponding Trp residues in MRP4 were replaced by different amino acids 
and the resultant mutant protein evaluated for their function in drug cytotoxicity and 
accumulation. Our results showed that when cells were exposed to 1 µM SN-38 for 5 
min, the intracellular accumulation of SN-38 was significantly increased by 85-259% 
in nearly all mutant cell lines except F324W cells. This indicates that like MRP1, Trp 
residues in MRP4 are also critical in substrate transport efficiency. All replacements 
of Trp (W) by Ala (A), Cys (C) and Phe (F) at position 230, 216, and 995 showed a 
significant effect on the uptake of 1 µM SN-38 for 5 min. There is no difference for 
F324W probably because that the difference between Trp (W) and Phe (F) in polarity 
is not very substantial and the replacement at position 324 may not have significant 
effect on MRP4 protein structure. In the four amino acids tested, Cys (C) has the 
highest polarity and Ala (A) has the smallest chemical structure. MRP4 mutant with 
Ala (A) at position 230 had the lowest efflux activity for SN-38, indicating that 
stereo-structure is a crucial component in determing protein function, besides polarity.  
Interestingly, the accumulation profile for CPT-11 was entirely different from that for 
SN-38, which may be because CPT-11 has a larger chemical structure than SN-38, 
resulting in differences in their transport through cell membrane and in their 
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interactions with transporters. Only W995C showed significantly increased CPT-11 
accumulation in the time-dependent and concentration-dependent assays, which may 
be attributed to the fact that Cys is a polar amino acid, while others (Ala, Phe and Trp) 
are nonpolar amino acids. The replacement of Trp (W) at position 995 by Cys (C) 
could increase the accumulation of SN-38 to a greater degree than by Phe (F).  
In our studies, MRP4 displayed different response to CPT analogs in cytotoxicity 
assays and uptake assays. The effect of amino acid variances on MRP4-mediated 
resistance to CPT-11 and MTX in cytotoxicity assays was also studied. We found that 
variances in amino acids also displayed their effects on cytotoxicity assays by 
sensitizing cells with transfection of corresponding MRP4 mutants to  CPT-11 at 48 h 
exposure. Most mutants decreased the ICB50B of CPT-11 for 48 h exposure, which is 
different from their small effect on CPT-11 accumulation. This may be because most 
mutants were able to increase intracellular SN-38 accumulation, and the 48 h drug 
exposure afforded sufficient time for the metabolism of CPT-11 to SN-38. However, 
mutant W995C had little effect on cell sensitivity to 48 h CPT-11 exposure, although 
an increase in CPT-11 accumulation was observed. This discrepancy may be 
attributed to the difference assay system for cytotoxicity and uptake in incubation 
period, and related determining factors, such as equilibrium of lactone and 
carboxylate inside and outside cells, interaction of CPTs with the target Top 1, and 
interaction of CPTs with cellular proteins (Beretta and Zunino, 2007). The MRP4 
function for efflux of SN-38 was moderately decreased by the replacement of Phe (F) 
at position 324 by Trp (W), or the replacement of Trp (W) at position 230 by Phe (F), 
which may contribute to the lower resistance to CPT-11 at 48 h exposure in 
cytotoxicity assay. For most MRP4 mutants, they showed totally different influences 
on resistance to CPT-11 at 48 h and to MTX at 4 h in cytotoxicity assay, suggesting 
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that the variance in amino acids may affect substrate selectivity of MRP4. Mutant 
W230A with Ala at position 230 significantly increased resistance to MTX, while 
mutant F324A with Ala (A) at position 324 showed no effect on MRP4-mediated 
resistance to MTX. The replacement of Trp (W) by Ala (A), Cys (C) and Phe (F) at 
position 230, 216, and 995 significantly increased cells sensitivity to MTX 
cytotoxicity, further supporting the importance of Trp (W) in MRP4 function. 
In conclusion, MRP4 is able to mediate CPT analogs efflux. The increased resistance 
to CPT analogs in MRP4/HepG2 cells correlated with decreased accumulation, which 
can be attributable to the overexpression of MRP4. Similar to MRP1, Trp residues at 
critical positions of the MRP4 protein are important determinants of CPTs transport 
activity. MRP4-mediated resistance to CPTs and identification of CPTs as MRP4 
substrates has important clinical implications. Firstly, MRP4 enhances the ability of 
tumor cells to efflux CPTs out of cells to reduce the cellular drug concentration 
leading to drug resistance. Thus, MRP4 expression level in tumor cells may serve as 
an important determinant for the antitumor efficacy. Although caution should be taken 
when extrapolating these in vitro results of CPT resistance to the tumor in vivo, MRP4 
expression seems to be one important factor that impinges on the efficacy of CPTs in 
specific tumors. Recently, it was found that the expression level of MRP4, instead of 
MRP1-3 or PgP, was associated with poor prognosis in patients with neuroblastoma 
(Norris et al., 2005). Secondly, the inhibition studies can help to identify potential 
MRP4 inhibitors useful in clinical chemotherapy. These MRP4 modifiers may be 
combined with CPTs in tumors in which MRP4 is frequently overexpressed. Thirdly, 
modulation of MRP4 may have important pharmacokinetic implications for CPTs. 
MRP4 is expressed at moderate levels in most organs such as liver, gut, lung, and 
brain, and substantial MRP4 levels are detected in the kidneys and prostate (Kool et 
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al., 1997). MRP4 may play an important role in CPTs excretion into bile and urine. 
Finally, MRP4 seems to act as a protective barrier in the brain, MRP4 alteration may 
affect theP Pdistribution of their substrates including CPTs, thus altering therapeutics or 
toxicology. With the accumulation of information on drug resistance profile and 
physiological function of MRP4, the relationship between drug selectivity and MRP4 
level will be significant and helpful in clinical cancer management using CPTs and 
the development of novel CPT analogs that overcome MRP4-mediated resistance. 
5.1.3. Effect of CPT analogs on GSH efflux  
In our study, results of CPTs cytotoxicity assay and uptake detection suggest that 
GSH may play a significant role in the MRP4-mediated resistance to CPTs. When 
GSH level in MRP4/HepG2 cells was decreased by preincubation of cells with 200 
µM BSO for 24 h, it was found that the resistance to CPTs was significantly reduced 
in cytotoxicity assay and intracellular accumulation of CPT analogs (CPT-11, SN-38, 
and topotecan) increased. All these results suggest that the change in GSH cellular 
level is able to greatly decrease MRP4-mediated resistance to CPTs, and GSH is very 
important component of transport of CPTs by MRP4.  
The effect of GSH in the transport of substrates by MRP proteins has been well 
documented. As a GSH-S-conjugate export pump, MRP1 displayed decreased 
sensitivity to drugs that did not form GSH-S-conjugates, suggesting that MRP1 
mediate some substrates transport in both ATP-dependent and GSH-dependent 
manner (Loe et al., 1998; Renes et al., 1999). The MRP1-mediated transport of some 
natural product drugs, such as vincristine, etoposide, daunorubicin and doxorubicin or 
unconjugated aflatoxin B1 was enhanced in the presence of GSH (Loe et al., 1998; 
Evers et al., 2000; Mao et al., 2000). These compounds did not form conjugate with 
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GSH, implicating that GSH is co-transported with the drug by MRP1 as a cofactor for 
the substrate transport. Similar to MRP1 and MRP2 that co-transport compounds out 
of cells with GSH, fibroblasts with transfection of MRP4 acted as co-transporters of 
bile salts with GSH or S-methyl-GSH (Rius et al., 2003). MDCKII cells with 
overexpression of MRP4 were found to transport cAMP in the presence of GSH (Lai 
and Tan, 2002). However, GSH is not able to affect those transporters which do not 
need the presence of GSH for substrate efflux. For instance, depletion of intracellular 
GSH by BSO had no effect on the resistance of MRP3-overexpressing cells to 
etoposide, suggesting that GSH is not involved in the MRP3-mediated transport of 
etoposide (Zelcer et al., 2001).  
In view of these observations, the present study was carried out to examine whether 
CPT analogs have any effect on MRP4-mediated GSH efflux by the changes of 
bimane-GS conjugate efflux level in V/HepG2 and MRP4/HepG2 cells. CPT analogs 
tested at low concentration showed no significant effect on bimane-GS efflux in time-
dependent assays. CPT-11 at a high concentration of 10 µM, however, displayed a 
significant inhibitory effect on bimane-GS efflux in MRP4/HepG2 cells, whereas 
lower concentrations of all CPT analogs tested had no significant effect. These data 
may suggest that CPT-11 is able to inhibit MRP4-mediated GSH efflux. MRP4 has 
been proposed to have multiple allosteric substrate binding sites (Van Aubel et al., 
2005), which may explain the complex interaction patterns found with a number of 
MRP4 substrates. For example, urate was able to activate its own transport, inhibit 
MTX transport, and stimulate cGMP transport by MRP4. MRP4 was able to transport 
urate simultaneously with cAMP or cGMP, even under saturated conditions (Van 
Aubel et al., 2005). Moreover, cAMP showed inhibitory effect on MRP4-mediated 
cGMP transport (van Aubel et al., 2002). As MRP4 substrates, both GSH and CPT-11 
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are able to bind with the protein. It is possible that CPT-11 at a high concentration 
occupies most binding domains on MRP4. At low drug concentration, the GSH-
binding site remains occupied by GSH and drug-binding site becomes occupied by 
CPT-11, resulting in co-transport of both compounds. However, CPT-11 at a high 
concentration appears to be able to occupy both the GSH- and drug-binding sites, 
leading to efflux reduction of GSH by MRP4. Moreover, the size and orientation of a 
substrate in the binding site may greatly affect whether GSH could also bind with the 
protein and be transported (Ballatori et al., 2005). The steric-hindrance produced by 
the chemical structure of CPT-11 may make it more difficult for bimane-GS to bind 
with MRP4 and be effluxed by MRP4. Another MRP4 substrate, MTX, also showed 
inhibitory effect on MRP4-mediated bimane-GS efflux at a high concentration of 100 
µM (Lai and Tan, 2002). 
Furthermore, efflux of bimane-GS in MRP4/HepG2 was susceptible to inhibition by 
200 µM BSO. The nearly unchanged GSH efflux in V/HepG2 with the presence 200 
µM BSO implicates a specific influence of BSO on MRP4, which is supported by 
decreased resistance to CPTs by MRP4/HepG2 cells in our cytotoxicity assay. BSO 
has long been reported to be responsible for the increased cytotoxicity of anticancer 
drugs (Mans et al., 1992; Schneider et al., 1995; Benderra et al., 2000; Zhang et al., 
2001). The reduction of intracellular GSH levels by BSO led to decreased transport of 
MRP1 substrates in cells, such as daunorubicin, doxorubicin, etoposide and 
vincristine (Gekeler et al., 1995; Schneider et al., 1995; Versantvoort et al., 1995; 
Zaman et al., 1995; Vanhoefer et al., 1996; Rappa et al., 1997; Salerno and Garnier-
Suillerot, 2001). Exposure of V79 cells to 4 h of either 2.5 mM or 5.0 mM BSO led to 
less than 15% of control GSH depletion (Bonner et al., 1992; Sawyer and Bonner, 
1996). Short exposure to BSO for 7 h did not increase the chemosensitization of V79 
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to CPT-11. When V79 cells were exposed to 2.5 mM BSO for 28 h, the ICB50B of CPT-
11 was decreased by 3-fold. In contrast, BSO pretreatment increased 
chemosensitization of V79 cells to SN-38 in both long and short exposure (Sawyer 
and Bonner, 1996). However, BSO pretreatment showed no effect on the intracellular 
CPT-11 accumulation, conversion of CPT-11 to SN-38, and the efflux of both CPT-
11 and SN-38 in V79 cells. Incubation with BSO for 28 h could cause a GB1 B arrest and 
fewer cells were in S-phase. Since CPT-11 and SN-38 are S-phase specific, BSO 
might increase chemosensitization by redistributing cell cycle (Sawyer and Bonner, 
1996). BSO also led to the decrease in the number of stabilized DNA-Top 1 
complexes induced by CPT-11, implicating that BSO sensitized V79 cells to CPT-11 
in a manner independent of the stabilization of DNA-Top 1 complexes (Sawyer and 
Bonner, 1996). The mechanism of BSO-induced chemosensitization varies greatly 
depending on the drugs involved. Pretreatment with 10 mM BSO increased 
doxorubicin cytotoxicity to V79 cells, while BSO pretreatment had no effect on the 
cellular accumulation of doxorubicin, the rate of stabilization and dissociation of 
cleavable doxorubicin complexes, suggesting that BSO-induced doxorubicin 
sensitization might occur  by an independent mechanism (Bonner et al., 1992). 
The involvement of GSH depletion caused by BSO in the increased cytotoxicity of 
CPTs indicates the possible role of GSH in modulating cytotoxicity of CPTs (Niimi et 
al., 1992; Matsumoto et al., 1995; Sawyer and Bonner, 1996; Gamcsik et al., 2001). 
Moreover, GSH was reported to affect the activity of CPTs to influence their cellular 
target, such as Top 1, while the mechanism by which GSH acted was not known 
(Gamcsik et al., 2001). It has been found that GSH showed no effect on the opening 
rate of lactone form of CPTs or changed the equilibrium ratio of CPTs in lactone and 
carboxylate forms, and GSH was not responsible for maintaining the S-transferase in a 
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reduced form. Moreover, SN-38 and topotecan did not form covalent conjugate with 
GSH in the absence or presence of GST (Gamcsik et al., 2001). Further work should 
be done to determine whether other CPT analogs, CPT-11, rubitecan and 10-OH-CPT 
form conjugates with GSH. It would also be interesting to explore whether GSH 
depletion might involve an enhancement of the cytotoxicity following the stabilization 
of DNA-Top 1 complexes by CPTs. 
In conclusion, CPT analogs showed no significant effect on MRP4-mediated GSH 
efflux. It is suggested that CPT analogs may not affect their own transport by MRP4 
and the transport of some MRP4 substrates that is GSH-dependent. As expected, BSO 
displayed specific inhibition effect on MRP4-mediated GSH efflux, whereas only 
CPT-11 at a high concentration showed inhibitory effect on GSH efflux in 
MRP4/HepG2 cells. 
5.2. CONCLUSION & FUTURE WORK 
In this thesis, we explored the interactions between CPTs and MRP4. Our results 
indicate that CPTs are part of the MRP4 resistance profile. HepG2 cells with the 
overexpression of MRP4 conferred significant resistance to the established MRP4 
substrates, bis-POM-PMEA and MTX. The resistance capability of MRP4 to bis-
POM-PMEA and MTX was significantly inhibited by the preincubation with BSO, 
indicating that there is proper functionality of MRP4 in MRP4/HepG2 cells used in 
this study. We explored the cytotoxicity profiles of a series of CPTs including CPT, 
CPT-11, SN-38, topotecan, rubitecan and 10-OH-CPT in HepG2 cells with stably 
overexpressed human MRP4. The cytotoxicity of CPTs in V/HepG2 was much higher 
than in MRP4/HepG2 cells, and overexpression of MRP4 increased the ICB50B values 
1.8-14.2 folds for various CPTs in lactone or carboxylate forms, suggesting that 
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MRP4 overexpression conferred significant resistance to CPTs. MRP4 showed higher 
resistance to CPT and CPT-11 in lactone form than their corresponding carboxylate 
form, while displayed similar resistance to lactone and carboxylate form of SN-38. 
The resistance of MRP4 to various CPTs tested was significantly reversed in the 
presence of GSH synthesis inhibitor BSO, and MRP4 inhibitors including, MK571, 
celecoxib, and diclofenac. A panel of other anticancer agents were also screened in 
cytotoxicity assays, including vinblastine, vincristine, etoposide, carboplatin, 
cyclophosphamide, norcantharidin, 5-fluorouracil, and paclitaxel.  However, MRP4 
displayed no resistance to most of these anticancer drugs. Notably, MRP4 conferred 
resistance to cyclophosphamide, an alkylating agent, and the resistance was partially 
reversed by BSO. The accumulation of CPTs, including CPT-11, SN-38, topotecan, 
rubitecan and 10-OH-CPT, in V/HepG2 and MRP4/HepG2 cells was further 
examined to investigate the relationship with resistance to CPTs in cytotoxicity 
assays. With the exception of 10-OH-CPT, the intracellular concentrations of CPT 
analogs tested in MRP4/HepG2 cells were significantly lower than V/HepG2 cells in 
both time-dependent and concentration-dependent accumulation assays, and the 
concentrations of CPT analogs in MRP4/HepG2 cells were increased by known 
inhibitors of MRP4 that reversed drug resistance in cytotoxicity assay. The higher 
intracellular accumulation of 10-OH-CPT in MRP4/HepG2 could partly be attributed 
to the specific binding between the carboxylate form of 10-OH-CPT and MRP4, the 
particular membrane protein in MRP4/HepG2 cells. These findings strongly 
suggested that MRP4 overexpression significantly decreases the cellular accumulation 
of CPTs and is involved in the resistance to CPTs. The intracellular accumulation of 
CPT-11 and SN-38 were also examined in 7 different MRP4 mutant cell lines, and 
mutant cell lines displayed different effects on drugs cellular accumulation depending 
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on the chemical structure of drugs, the drug dose, and the incubation time. For 
cytotoxicity assay, mutant cell lines showed a different influence on resistance to 
CPT-11 at 48 h exposure and MTX at 4 h exposure, suggesting changes in amino 
acids may affect substrate selectivity of MRP4. GSH plays an important role in the 
function of MRP4, and MRP4 transports a number of its substrates in a GSH-
dependent manner. The efflux of bimane-GS from MRP4/HepG2 cells was 
significantly higher than that from V/HepG2 cells in 15 min. The effects of CPT 
analogs on GSH efflux were investigated by detecting the changes of bimane-GS 
conjugate efflux level in V/HepG2 and MRP4/HepG2. The CPT analogs tested 
showed no significant effect on bimane-GS efflux in both time-dependent and 
concentration-dependent assays, except that CPT-11 at a high concentration of 10 µM 
displayed a significant inhibitory effect on the bimane-GS efflux in MRP4/HepG2 
cells. Moreover, BSO showed inhibitory effect on the efflux of bimane-GS in 
MRP4/HepG2, while no effect was observed in V/HepG2 cells, implicating a specific 
influence of BSO on MRP4. Western blot assays showed that MRP4 was 
overexpressed in MRP4/HepG2, and was hard to be detected in V/HepG2. The 
undetectable expression of some related ABC transporters, including PgP, MRP1, 
MRP2, MRP3, MRP5 and BCRP, excluded their involvement in bimane-GS efflux, 
and their interaction with CPTs. The resistance to CPTs in cytotoxicity assays, the 
difference uptake of CPT analogs, and the GSH efflux difference in V/HepG2 and 
MRP4/HepG2 cells can be mainly attributable to high expression level of MRP4 in 
MRP4/HepG2 cells.   
Further studies are needed to explore the CPTs effects on MRP4 expression level. 
Recently, celecoxib was reported to be a MRP4 inducer in lung cancer cells. MRP4 
expression was greatly increased in terms of mRNA and protein levels by celecoxib 
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and was localized in the inner plasma membrane in human NSCLC cell line Colo 
699N (Gradilone et al., 2007). Thus, celecoxib could decrease the efflux of CPT-11 
from cells by inhibiting MRP4-mediated transport and increase the drug efflux by 
inducing MRP4 expression. The understanding of the effects of drug-induced MRP4 
expression level would be helpful in evaluating the combined drug schedules in 
chemotherapies. In addition, the transport of CPTs in both lactone and carboxylate 
forms and the effects of inhibitors could be studied in membrane vesicles from cells 
with overexpression of MRP4. This would help to clarify the influence of CPTs 
structure and inhibitors on MRP4-related efflux. While we have provided initial 
results of the effect of GSH in MRP4-mediated resistance to CPTs, several questions 
have also been raised. In particular, more experiments need to be performed to 
identifiy whether GSH is a necessary component for CPTs, or GSH has different 
influence on CPT analogs transport. Finally, studies on lactone-carboxylate 
equilibrium of CPTs and protein binding in cell culture medium would help to 
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